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Voltage-gated sodium channels initiate action potentials in excitable tissues. 
Altering these channels’ function can lead to many pathophysiological conditions. The 
family of voltage-gated sodium channel genes encodes 10 proteins (including Nav2.1) 
distributed throughout the central and peripheral nervous systems, cardiac and skeletal 
muscles. The SCN4A gene encodes the Nav1.4 channel, which is primarily responsible 
for depolarization of the skeletal muscle fibers. Many mutations in SCN4A are found and 
associated with the myotonic syndromes and periodic paralyses. These conditions are 
both considered gain-of-function and can be severely life-limiting with respect to 
performing everyday tasks. From a broader standpoint, hyperexcitability presents as a 
significant problem in other tissues besides skeletal muscles. Gain-of-function in sodium 
channels has been linked to a wide-range of pathophysiological conditions such as 
inherited erythromelalgia, epilepsy, and arrhythmias. Treating these types of pathologies 
requires an in-depth understanding of their underlying mechanisms. One way to gain this 
understanding is to investigate physiological triggers. There is also a dire need for novel 
ways of reducing the hyperexcitability associated with mutant sodium channels. One 
promising compound is the non-psychotropic component of the Cannabis sativa plant, 
cannabidiol. This compound has recently been shown to modulate some of the neuronal 
sodium channels. Although cannabidiol has shown efficacy in clinical trials, the underlying 
mechanism of action remains unknown. Sodium channels could be among the molecular 
targets for cannabidiol. 
In my doctoral research: 1) I studied how a single missense mutation, P1158S, in 
Nav1.4 causes various degrees of gain-of-function (myotonia and periodic paralysis) by 
using pH changes to probe P1158S gating modifications; 2) I studied the inhibitory effects 
of cannabidiol on voltage-dependent sodium currents; 3) I investigated the mechanism 
through which cannabidiol imparts inhibition. Overall, these data reveal novel insights into 
sodium channel hyperexcitability and pharmacologically targeting of this hyperexcitability 
using cannabidiol.  
Keywords:  sodium channel; myotonia; periodic paralysis; cannabidiol; acidosis 
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Chapter 1. Introduction 
Parts of this chapter describe the work published in (Ghovanloo et al., 2018b; 
Ghovanloo & Ruben, 2020) with minor modifications and formatting changes to suit the 
thesis style. 
1.1. Voltage-gated sodium channel: structure and function 
Ion channels orchestrate an exquisite array of physiological processes, including 
nerve impulses, muscle contraction, and signaling in all organisms. The electric current in 
signaling is generated by ion flux across the cellular membrane that is controlled by the 
opening and closing of ion channels. These channels are permeable to various types of 
ions, including sodium, potassium, calcium, and chloride (Hille, 2018). The direction of the 
ion flux is determined by the membrane potential and transmembrane ionic gradients that 
are established by ion channels and the Na+/K+ ATPase (Vassalle, 1987). For the 
generation of a specific type of signaling known as the action potential (AP) to be possible, 
it is crucial that the ion channels involved are selectively permeable to a specific type of 
ion and not to others (Hodgkin & Katz, 1949; Hodgkin & Huxley, 1952; Hille, 1975, 2001). 
A subset of these ion channels is the voltage-gated sodium (Nav) channel superfamily 
(Figure 1-1) (Catterall et al., 2005; Catterall, 2005). 
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Figure 1-1 The primary structures of the subunits of the voltage-gated sodium 
channels. 
A transmembrane folding diagram of the Nav channel. Cylinders represent a-helical segments. 
Bold lines represent the polypeptide chains of each subunit, with a length approximately 
proportional to the number of amino acid residues in the brain sodium channel subtypes. The 
extracellular domains of the β1 and β2 subunits are shown as immunoglobulin-like folds. C, sites 
of probable N-linked glycosylation; P in red, sites of demonstrated protein phosphorylation by 
protein kinase A (circles) and protein kinase C (diamonds); blue, pore-lining segments; yellow 
circles, the outer (EEEE) and inner (DEKA) rings of amino residues that form the tetrodotoxin-
binding site and ion selectivity filter; green, S1–S4 voltage sensors; h in blue circle, inactivation 
particle in the inactivation gate loop; blue circles, sites implicated in forming the inactivation gate 
receptor. ScTx, scorpion toxin (Catterall & Swanson, 2015).  
The sodium current passing through Nav channels initiates action potentials in 
neurons, skeletal muscles, and cardiac muscles (Figure 1-2). Nav channels are hetero-
multimeric proteins composed of large ion conducting α-subunits and smaller auxiliary β-
subunits (Isom et al., 1992; Patton et al., 1994; Cannon, 2006; Estacion et al., 2010; 
Catterall, 2012; Calhoun & Isom, 2014; Ghovanloo et al., 2016b; Ghovanloo & Ruben, 
2020). The α-subunit is made up of a single transcript that encodes four 6-transmembrane 
segment domains (Catterall, 2012). Each one of these four structural domains can be 
divided into two functional sub-domains known as the voltage-sensing domain (VSD) and 
the pore domain (PD) (Catterall, 2012; Ghovanloo et al., 2016b). These two functional 
sub-domains are connected through the intracellular S4-S5 linker (Yarov-Yarovoy et al., 
2012; Catterall, 2012). The VSD is formed by the first four transmembrane segments of 
3 
each domain and the pore is formed by the 5th and 6th segments along with the 
extracellular pore loop that connects them (Catterall, 2012; Ghovanloo et al., 2016b). 
 
Figure 1-2 Nav channels are predominantly expressed tissue-specifically (The 
salt-sensing Nav2.1 is not included). 
In a simplified model, the sodium channel can exist in three fundamental states: 
rest, open, and inactivated (Catterall, 2012). During depolarizations that are of sufficient 
magnitude, sodium channels open, and begin conducting ionic sodium currents. This 
process is known as activation. Upon activation, while the sodium channel is in its open 
state, it conducts sodium currents. Any disturbance to this process of sodium current 
conduction will have downstream effects on excitability. After activation, sodium channels 
may typically enter a fast-inactivated state, which is initiated by the outward movement of 
the domain IV-VSD (Figure 1-3). VSD-I-III are associated with translating changes in 
transmembrane voltage into channel activation through an electromechanical coupling 
process to a gate at the inner pore. VSD-IV is specialized in its function to control 
inactivation and is slower to activate with a different voltage dependence to VSD-I-III 
(Chanda & Bezanilla, 2002; Silva & Goldstein, 2013).  
Nav1.1- Nav1.2- Na1.3- Nav1.4- Nav1.5- Nav1.6- Nav1.7- Nav1.8- Nav1.9
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Figure 1-3 Sliding-helix model of sodium channel gating.  
(A) Transmembrane view of the ribbon representation of Rosetta models of three resting and three 
activated states of the VSD of NaChBac. Segments S1–S4 are colored individually and labeled. 
Side chain atoms of the gating charge-carrying arginines in S4 (colored dark blue), negatively 
charged residues in S1–S3 segments (colored red), polar residues in S1, S3, and S4 (colored 
purple), and key hydrophobic residues in S1–S3 (colored gray) are shown in sphere representation 
and labeled. The HCS is highlighted by orange bars. (B) Transmembrane view of the ribbon 
representation of Rosetta models of Resting State 1 and Activated State 3 of NaChBac VSD and 
pore domain. Only a single VSD is shown attached to a tetramer of the pore domain for clarity. 
Transmembrane segments S1-S6 are colored individually and labeled. The S4–S5 linker is colored 
purple. Side chains atoms of key residues in VSD are represented as in (A). The narrow region of 
focused membrane electrical field at the hydrophobic constriction site is highlighted by orange bars 
(Yarov-Yarovoy et al., 2012). 
The process of fast inactivation is mediated through the interaction of the domain 
III-IV linker with another region of the channel (West et al., 1992). Recent cryo-EM 
structures of eukaryotic sodium channels revealed that fast inactivation may proceed via 
an allosteric mechanism. This mechanism involves the IFM (isoleucine, phenylalanine, 
methionine) motif promoting pore closure by squeezing into the space between S6 and 
S4-S5 restriction ring. Indeed, the skeletal muscle sodium channel’s structure has shown 
the F residue penetrating into this space, and I and M residues to the edges around this 
space (Shen et al., 2017; Yan et al., 2017; Pan et al., 2018). The allosteric mechanism of 
fast inactivation was further elucidated using the structure of the cardiac sodium channel, 
where outward movement of the third VSD opens an interaction site for the fast inactivation 
particle. This particle in turn moves into place upon the outward shift of the fourth VSD 
5 
(Ghovanloo & Ruben, 2020; Jiang et al., 2020). This process that happens within 
milliseconds of activation, blocks the channel pore, and effectively stops current 
conduction. Therefore, this negative regulation of conductance is a way of controlling 
excitability. 
In addition to fast inactivation, which was discovered by Hodgkin and Huxley 
(Hodgkin & Katz, 1949; Hodgkin & Huxley, 1952; Hille, 2001), Nav channels have a 
second slower inactivated state (Vilin & Ruben, 2001). Repetitive or prolonged stimulation 
can result in slow inactivation. In a physiological setting, this slow inactivation process is 
vital to limit the frequency of firing and define the length of trains of action potentials to 
protect cells against excitotoxic injury (Vilin & Ruben, 2001). It is thought that during slow 
inactivation, two of the opposite S6 segments move towards the pore axis with the other 
two pointing outwards. This asymmetry causes a structural collapse leading to a slowly 
reversible inactivation (Gamal El-Din et al., 2013a).  
1.1.1. Types of Nav currents 
Upon the presence of a sufficiently strong depolarizing stimulus, Nav channels 
activate. Once activated, a macroscopic transient sodium current is generated, which can 
be divided into two components: peak and persistent currents. The peak current is known 
as the large-amplitude inward segment of the sodium transient. The overall sodium current 
tends to incompletely inactivate in both muscle and nerve cells. This incomplete 
inactivation results in a small, persistent current component which is only a small 
percentage (<5%) of the peak current amplitude (Crill, 1996). The persistent current plays 
a vital role in excitatory cell bodies and dendrites where it increases the size of 
postsynaptic potentials and boosts the cell threshold during trains of action potentials (Liu 
& Shipley, 2008).  
Some classes of neurons may also generate resurgent currents (Raman & Bean, 
1997; Raman et al., 1997; Cannon & Bean, 2010). These currents appear as a rebound 
inward current that may appear following a voltage pulse or an action potential. Resurgent 
currents are caused by reopening Nav channels and is dependent on the presence of the 
β4 subunit, which competes with the inactivation particle at more depolarized potential. At 
more depolarized potentials, when the fast inactivation particle is in its non-conductive 
state, the population of channels that have the β4 in its bound state may serve as a 
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reservoir for subsequent firing. Thus, the unbinding of β4 causes a surge of inward sodium 
current that depolarizes the membrane. The interactions between Nav1.6 and β4 were 
studied extensively by (Cannon & Bean, 2010; Patel et al., 2016). Overall, persistent and 
resurgent currents work together with slow inactivation to generate complex patterns of 
action potentials firing.  
1.1.2. Structural segments of the Nav pore and pharmacological 
modulation 
The general Nav pore structure includes a large external vestibule, a narrow 
selectivity filter, a large central cavity that is lined by S6 segments that is filled with water, 
and an intracellular activation gate that is formed by the crossing of S6 segments at the 
intracellular side of the membrane (Payandeh et al., 2011; Yan et al., 2017; Pan et al., 
2018; Jiang et al., 2020).  
The first ion channel crystal structures described the architecture of potassium 
channels (Doyle et al., 1998). The emergence of a multitude of crystal and cryo-EM 
structures revealed that the overall structure of the pore between Nav and Kv is similar. 
However, the structure of the ion selectivity filters, and mechanisms of ion conductance 
are different between the two channels. Potassium channels select potassium by direct 
interactions between the backbone carbonyls of residues that comprise the selectivity 
filter. These interactions create 4 ion coordination sites (Catterall, 2012). In potassium 
channels, no amino acid charged functional groups or water molecules are involved in the 
selectivity process. However, in Nav channels, the selectivity filter has a high field strength 
on the extracellular side which is composed of amino acid side chains. This outer vestibule 
is followed by 2 ion coordination sites that are formed by backbone carbonyls (Figure 1-
4) (Payandeh et al., 2011; Yan et al., 2017). These sites allow for passage of sodium ions 
with 4 water molecules (hydration). These sites would be too large for a dry sodium ion to 
go through, which would be energetically unfavorable. This indicates that sodium 
conductance and selectivity are different to that of potassium ions.   
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Figure 1-4 The pore domain of EeNav1.4 is kept Open at the intracellular gate.  
(A) The intracellular gate is kept open. The permeation path, calculated by HOLE, is illustrated by 
brown dots in the left panel. The pore radii of EeNav1.4 (brown) and NavPaS (purple) are tabulated 
in the right panel. The side chains of Asp/Glu/Lys/Ala (DEKA) in EeNav1.4 are not well resolved. 
Therefore, the corresponding radii are shown as a gray dashed line. (B) Conformational changes 
between the pore domains of EeNav1.4 and NavPaS. For visual clarity, the pore domain segments 
from the two diagonal repeats of the superimposed structures of EeNav1.4 and NavPaS are shown 
in each panel. (C) The Gly hinge that demarcates the conformational shifts of S6. The structures 
of EeNav1.4 and NavPaS are superimposed as in (B). The Cα atoms of the indicated residues are 
shown as spheres. The labels for EeNav1.4 residues are domain colored. The corresponding 
NavPaS residues are labeled below in purple. (D) Shifts of the conserved Asn residues on each 
S6 segment between EeNav1.4, NavPaS, and Cav1.1. Intracellular views are shown. (left) The 
pronounced conformational shifts of the conserved S6-Asn residues between EeNav1.4 and 
NavPaS. (right) The corresponding Asn residues in EeNav1.4 and Cav1.1 exhibit similar 
orientations. (E) The pore domain has four fenestrations. The structure of the pore domain is shown 
in four perpendicular side views. The fenestrations are highlighted by orange circles. Upper inset: 
the residues that were characterized to be involved in anesthetic binding are shown as spheres 
(Yan et al., 2017).  
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From a functional perspective, both the outer and inner segments of the PD are 
interaction sites for pharmacological agents. The most selective and well-known Nav 
blocker is tetrodotoxin (TTX), which comes from symbiotic bacteria in the pufferfish (and 
some other animals) diet (Hille, 2001; Chau et al., 2011). The sensitivity of sodium channel 
subtypes to TTX has been used to divide the family into two classes: TTX-sensitive and 
TTX-resistant. The IC50 of TTX-sensitive (Nav1.1-4, Nav1.6-7) channels to TTX is less 
than 30 nM (Catterall et al., 2005; Gamal El-Din et al., 2013b). The molecular reason 
underlying differential affinity for TTX in Nav has been attributed predominantly to a single 
homologous residue difference in the Nav pore-loop. The TTX-resistant channels have a 
cysteine or serine in this position, instead of a tyrosine or phenylalanine residue in TTX-
sensitive channels. A recent study determined that this substitution does not alter the local 
conformation of the channel. However, lacking an aromatic side chain in this position may 
cause steric constraints that reduce the TTX affinity (Ghovanloo & Ruben, 2020; Jiang et 
al., 2020).  
TTX is considered a state-independent Nav blocker, a function of its binding-site 
residing on the outer selectivity filter, which is a more rigid part of the Nav pore-domain. 
In contrast, most local-anesthetics (LA) are highly state-dependent Nav blockers (may 
also have high affinity for open state); their binding site is located below the selectivity 
filter, a more flexible region of the pore-domain. This part of the channel is highly 
conserved among Navs (Ragsdale et al., 1996). Therefore, it is not surprising that most 
Nav pore blockers that interact at the LA site impart little subtype selectivity. The flexibility 
difference between the outer and inner PD has important pharmacological implications.  
Because the proportion of channels populating different states is controlled by the 
membrane potential, the state-dependence of such compounds is often termed voltage-
dependence. Many of these compounds also display a phenomenon known as use-
dependence, which occurs when the compound apparent potency increases upon higher 
sodium channel firing frequency stimulations (Gamal El-Din et al., 2018).  
Many Nav modulating compounds are used to treat various clinical conditions 
caused by changes to excitability. In particular they are used as anticonvulsants (ex. 
Carbamazepine, Phenytoin), as local anesthetics (ex. Lidocaine), and as antiarrhythmics 
(ex. Mexiletine) (Nuss et al., 1995; Mantegazza et al., 2010; Pless et al., 2013; Ghovanloo 
et al., 2016a). Because these compounds largely lack selectivity across the sodium 
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channel superfamily, they may lead to potentially undesirable side-effects. All of these 
compounds are either neutral or weakly basic. In addition to the two general sites in the 
PD, recent efforts have culminated in the development of highly selective sodium channel 
blockers that target DIV-VSD (Ahuja et al., 2015). 
1.1.3. Nav distribution and tissue-specific channelopathies 
There are multiple sodium channel isoforms expressed in tissues throughout the 
body. Nav1.1-Nav1.3 are found in the central nervous system (Figure 1-2). Nav1.4 and 
Nav1.5 are expressed in skeletal and cardiac muscles, respectively (Figure 1-2). Nav1.6 
is expressed in both the central and peripheral nervous systems (Figure 1-2). Nav1.7-
Nav1.9 are primarily found in the peripheral nervous system (Figure 1-2). The expression 
pattern of the neuronal Nav channels depends on both the developmental stage, brain 
region, and cell type. Nav1.3 is expressed predominantly in neonatal brain cells; thus, it is 
thought to be a key contributor to brain development. In contrast, Nav1.1, Nav1.2, and 
Nav1.6 are highly expressed in adult brains. Furthermore, Nav1.6 displays greatest 
expression in unmyelinated axons, whereas Nav1.2 is found in the cell soma (Whitaker et 
al., 2001; Hu et al., 2009). Although the different isoforms share a similar structure, their 
gating and response to physiological and pathophysiological modulators can vary widely. 
Changes to the gating properties of sodium channels, and subsequently the 
current passing through them during an action potential can cause potentially fatal 
abnormalities in electrical signaling. Both gain-of-function (GOF) and loss-of-function 
(LOF) in sodium channels disrupt electrical signaling. Interestingly, several mutants 
display both GOF and LOF, leading to multiple disease phenotypes (Makita et al., 2008; 
Webb & Cannon, 2008).  
In the primary sodium channel isoforms of the CNS, namely Nav1.1, 1.2, 1.3, and 
1.6, both GOF and LOF elicit epilepsy syndromes (Catterall, 2010; Estacion et al., 2010; 
Veeramah et al., 2012). These include relatively mild epilepsies, like benign familial 
neonatal-infantile seizures, or more severe forms, such as Dravet syndrome (Heron et al., 
2002; Scalmani et al., 2006; Dravet, 2011) and early-infantile epileptic encephalopathy-13 
(O’Brien & Meisler, 2013). In skeletal muscle, Nav1.4, GOF mutants elicit myotonic and 
paralytic syndromes (e.g. hypokalemic periodic paralysis, hypoPP), causing an inability to 
relax or contract the muscle, respectively (Cannon, 1996; Ghovanloo et al., 2018a). Long 
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QT-3 syndrome is due to an increase in the fraction of Nav1.5 cardiac sodium channels 
that fail to inactivate and, consequently, an increased persistent sodium current 
throughout the action potential plateau that delays repolarization (Wang et al., 1995). 
Conversely, mutants that decrease peak Nav1.5 current cause Brugada syndrome and 
other diseases of conduction (Antzelevitch et al., 2005; Ghovanloo et al., 2020a). Lastly, 
certain GOF mutations in Nav1.7 cause inherited erythromelalgia (Cheng et al., 2010a; 
Shields et al., 2012; Tham et al., 2017; Bankar et al., 2018).  
1.2. Clinical phenotypes involved with Nav1.4 
Mutations in Nav1.4 are associated with several pathogenic skeletal muscle 
phenotypes (Figure 1-5). The pathogenicity associated with these mutations can manifest 
in increased or reduced muscle excitability (Cannon, 2015).  
Muscular hyperexcitability typically presents with a distinctive stiffness, known as 
myotonia. Myotonia results from an involuntary contraction that persists for several 
seconds after voluntary movement. This after-contraction is caused by a burst of muscle 
action potentials that lasts for many seconds and is not dependent on motor neuron 
excitation (Brown & Harvey, 1939; Rudel & Lehmann-Horn, 1985). The severity of 
myotonic attacks in patients fluctuates with the levels of muscle activity. Myotonia-induced 
stiffness is often more pronounced after the first forceful movement after long periods of 
rest, and usually decreases over seconds with continued voluntary movement. This is 
known as the warm-up phenomenon. In some cases, the myotonic stiffness may 
paradoxically worsen with repeated muscle contraction. This is known as paramyotonia. 
Myotonia may be aggravated by external triggers such as cooler temperatures or ingestion 
of high-potassium food. Muscular myotonia is caused by either a LOF in the muscle 
chloride channel, ClC-1, or a GOF in Nav1.4 (Cannon, 2015).  
A reduction in skeletal muscle contractility can arise from defects in Nav1.4. This 
is perceived as transient attacks of weakness or a chronic state of permanent myopathic 
weakness. The most prevalent manifestation of these attacks is a state of periodic 
paralysis, which happens with episodes of moderate to severe weakness from a sustained 
depolarization from rest, activating and inactivating Nav1.4. The prolonged Nav1.4 
inactivation prevents additional excitability of the muscle fiber (Cannon, 2015).  
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Similar to myotonia, periodic paralyses-induced attacks of weakness are also 
usually triggered by external factors, including post-exercise rest. Another factor that could 
trigger weakness attacks is a diet that is high in carbohydrates, salt, or fasting. Increased 
levels of emotional stress is also suggested to trigger attacks (Lehmann-Horn et al., 2008; 
Cannon, 2015).  
Periodic paralysis attacks usually onsets over the span of minutes, lasting for 
several hours, and may go as long as a day or longer. The attacks are followed by a 
spontaneous recovery. In severe cases, paralytic attacks may hinder the patient’s ability 
to move any limbs, or even breathe. The onset of symptoms typically begins after the age 
of forty and worsens with time (Cannon, 2015).  
In contrast to the GOF conditions described, LOF in Nav1.4 can result myasthenia 
or congenital myopathy (Figure 1-5). Myasthenia is characterized by rapid muscle fatigue 
that lasts from seconds to minutes. Recovery is also rapid. Congenital myopathy is 
associated with reduced muscle tone that is accompanied by various degrees of 
weakness (Tsujino et al., 2003; Zaharieva et al., 2016).  
 
Figure 1-5 Spectrum of clinical phenotypes, muscle diseases, and functional 
deficits for Nav1.4 channelopathies.  
Paramyotonia congenita and hyperkalemic periodic paralysis have considerable overlap in clinical 
features and Nav1.4 deficits. Sustained fluctuations in muscle strength may occur with myasthenia 
(dashed line), but the relation to periodic paralysis is uncertain (Cannon, 2018).  
The channelopathies associated with Nav1.4 are considered rare disorders with a 
prevalence of ~1:100,000 (Horga et al., 2013). The majority of these channelopathies are 
autosomal dominant and are highly penetrant (Lehmann-Horn & Jurkat-Rott, 1999; Huang 
et al., 2017). Years of functional studies on SCN4A mutations established the association 
of particular genotypes to phenotypes (Miller et al., 2004b; Cannon, 2015). These studies 
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suggest that specific mutations in SCN4A are consistently found to underlie a particular 
skeletal muscle disorder. Furthermore, most of these mutations are found to be missense 
changes, although several frameshift, nonsense, and splice-site mutations have also been 
identified (Zaharieva et al., 2016).   
1.2.1. GOF mutations in SCN4A cause myotonic and paralytic 
syndromes 
Missense GOF mutations in SCN4A are associated with three overlapping 
syndromes. At one end of the spectrum is myotonia, which is manifested in patients 
showing characteristic symptoms, but without any periodic paralyses. The mutations that 
cause pure myotonia often do so by altering the kinetics of Nav1.4 (Figure 1-6) (Cannon, 
2010a, 2015).  
The next syndromes on the spectrum are paramyotonia and hyperPP (triggered 
by >5 mM plasma [K+]), which can manifest in overlapping symptoms (Figure 1-5). The 
mutations causing these two conditions usually alter both Nav1.4 kinetics,  steady-state, 
and slow inactivation (Figure 1-6) (Cannon, 2010a, 2015).  
The last GOF syndrome caused by SCN4A mutations is hypoPP (triggered by <3 
mM [K+]) (Figure 1-6) (Fontaine, 2008; Ghovanloo et al., 2018a). Unlike the previous 
conditions that generally increase the ionic sodium current into the cell, hypoPP mutations 
result in pathogenetic gating pore currents through the VSD. This pathogenic gating 
current depolarized the membrane potential and renders Nav channels from recovery, and 
hence prevent further AP firing.  
1.2.2. P1158S profile  
P1158S is a unique mixed hypoPP and myotonia causing mutation that is located 
on the intracellular side of Nav1.4 (Sugiura et al., 2000, 2003; Webb & Cannon, 2008; 
Ghovanloo et al., 2018a). P1158S in Nav1.4 is a missense mutation in the S4-S5 linker of 
domain (D) III that is the result of a C to T mutation at position 3549 in SCN4A (Sugiura et 
al., 2003). P1158S is described to cause both myotonia and hypoPP. This mutation was 
first reported in a Japanese family. The first case report described a 33 year old man who 
started experiencing paralysis attacks at the age of 13 and myotonia since the age of 25 
(Sugiura et al., 2000). The ability of P1158S to give rise to severe GOF (hypoPP) and 
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more moderate GOF (myotonia) make it a unique clinical SCN4A mutation (Cannon, 
2018). 
 
Figure 1-6 Model simulation of myotonia and periodic paralysis. 
Simulated Nav1.4 mutant currents. A two-compartment model for skeletal muscle (Cannon et al., 
1993), to simulate the sarcolemma and the t-tubule including K+ accumulation, was used to 
simulate the response to current injection (Cannon, 2015). 
1.2.3. Therapeutic approaches against myotonia and periodic 
paralyses 
Treatment for myotonia is focused on reducing the involuntary action potential 
bursts. It is vital that myotonic patients modify their lifestyles to avoid some triggers 
including potassium ingestion or cold temperatures. However, there are some commonly 
used therapeutics to relieve and prevent muscle stiffness (Figure 1-7). These drugs are 
often anticonvulsants, antiarrhythmics, and local anesthetics (Alfonsi et al., 2007; Trip et 
al., 2008).  
Treating hypoPP is usually achieved using oral potassium ingestion and by 
avoiding dietary carbohydrates and sodium. During hypokalemia increasing 
potassium levels could help in reducing membrane depolarization and shifting the resting 
potential to more negative potentials (in contrast to the hyperpolarization predicted by the 
Nernst equation, a higher [K+] gradient obtained by low external potassium may cause 
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paradoxical RMP depolarization (Jurkat-Rott et al., 2009); therefore, extracellular 
potassium reduction reduces currents that hyperpolarize the RMP, such as the outward 
component of the inwardly rectifying (Kir) channels). Administrating acetazolamide or 
dichlorphenamide is sometimes useful; however, in some cases these compounds can 
exacerbate symptoms (Figure 1-7) (Torres et al., 1981; Tawil et al., 2000; Sternberg et 
al., 2001; Venance et al., 2004). Despite these agents there is still a need for other 
compounds that would alleviate the hyperexcitability associated with both myotonia and 
hypoPP. 
 
Figure 1-7 Medication in the different forms of Nav myotonia and paralyses.  
Potassium-aggravated myotonia (PAM), paramyotonia congenita (PMC), hyperkalemic periodic 
paralysis (HyperPP), hypokalemic periodic paralysis (HypoPP) (Simkin & Bendahhou, 2011). 
1.3. Sodium channel modulation by pH 
Maintaining the physiological pH balance is vitally important to human body 
function. Under normal physiological conditions, the extracellular pH is maintained at 
approximately 7.4, with the intracellular pH ranging between 7.2 and 7.4. Under hypoxic 
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and ischemic conditions, the extracellular pH decreases significantly. During focal 
ischemia, rabbit brain pH could drop to 6.0 (brain intracellular pH is 7.0) (Meyer, 1990). 
Similarly, intense physical exercise results in a decrease of muscle extracellular pH to 6.4 
(Hermansen & Osnes, 1972; Maruki et al., 1993). In cardiac tissue, myocardial ischemia, 
including regional and global ischemia, extracellular pH can lower to 6.1 (Cobbe & Poole-
Wilson, 1980). The presence of extracellular protons can modulate both the VSD and the 
PD, depolarizing the voltage-dependence of activation and blocking ionic current, 
respectively (Khan et al., 2002; Jones et al., 2013b). Acidification decreases peak sodium 
conductance by protonating the outer vestibule carboxylates (Khan et al., 2002, 2006), 
and likely by binding to negative charges in the VSDs, which destabilizes the outward 
conformation of the voltage-sensors (Shi et al., 2014; Peters et al., 2017).   
1.3.1. Mechanisms of proton block 
We demonstrated additional mechanisms by which neuronal excitability is altered 
by extracellular acidosis (Ghovanloo et al., 2018b). For instance, in neurons expressing 
Nav1.1 or Nav1.3, excitability could be decreased during extracellular acidification. 
 Previous studies in sodium channels determined that mutations in the conserved 
DEKA and EEDD motifs cause a shift in the pKa of proton block in the acidic direction 
(Terlau et al., 1991; Sun et al., 1997; Khan et al., 2002). Mutating these carboxylates into 
alanine residues results in an approximately 25% decrease in proton block. This suggests 
that the interactions between the positively charged H+ and pore carboxylates blocks the 
ion conductance pathway, which subsequently reduces sodium current (Sun et al., 1997). 
As DEKA and EEDD are conserved across the sodium channel family, it is not surprising 
that, in all of the sodium channels studied thus far, proton block exists albeit with varying 
degrees (Vilin et al., 2012a; Peters et al., 2018; Ghovanloo et al., 2018b). This is 
particularly evident in Nav1.4 where previous studies have shown a reduction in current 
density that is neither statistically significant nor negligible (Vilin et al., 2012a; Ghovanloo 
et al., 2018a).  
 Proton block is not limited to the protonation of carboxylates in the selectivity filter. 
Previous studies in Nav1.5 identified a cysteine (C373) residue on the outer vestibule of 
domain I that imparts pH-sensitivity (Khan et al., 2002, 2006). In Nav1.1-1.4 this cysteine 
is replaced with either phenylalanine or tyrosine residues. During acidosis, C373 gets 
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protonated, creating a positive charge outside the pore that causes proton block. The 
presence of this cysteine can in part explain the increased pH-sensitivity observed in 
Nav1.5 compared to other sodium channels (Jones et al., 2013b).  
In addition to C373, two other residues involved in pH response were identified in 
Nav1.4 and Nav1.5. H880 in Nav1.5 is located in the pore loop of domain II, and P1158 in 
Nav1.4 is located on the hinge of the intracellular S4-S5 linker of domain III. Both these 
residues are conserved in Nav1.1-Nav1.5 (Jones et al., 2013b; Ghovanloo et al., 2018a) 
and are important to the biophysical properties of the respective channels in which they 
were described. Mutating H880 into a glutamine (Q) residue reduces the pH-sensitive 
current and shifts the voltage-dependence of activation in Nav1.5. Unlike C373 and H880, 
both of which directly contribute to proton block in Nav1.5 (Jones et al., 2013b), P1158 in 
Nav1.4 indirectly contributes to a reduced proton-insensitivity. P1158 is located on the 
intracellular side of the channel, and we previously showed that mutating this proline to a 
serine (S) residue increases proton block in Nav1.4 at low pH (Ghovanloo et al., 2018a). 
This effect may occur by altering the voltage-dependence of gating in domain III.  
1.3.2. Mechanisms by which protons modulate gating 
 In addition to proton block, low pH alters channel gating. The effects of protons on 
gating were studied in Nav1.5 (Peters et al., 2018). Although the identity of the residues 
involved in pH-dependent changes in gating are not fully determined, structural studies in 
bacterial sodium channels and potassium channels suggest that acidic residues play a 
role (Payandeh et al., 2012; Shi et al., 2014). Interactions of protons at the individual 
domains typically depolarizes the voltage-dependence, presumably via electrostatic 
interactions which hinder the outward movement of S4 voltage-sensors. This electrostatic 
hindrance at domains I-III primarily affects activation, and at domain IV affects fast 
inactivation. However, the effects of protons on sodium channel gating is strongly subtype-





Table 1-1 Response to acidosis among sodium channels 
Subtype Activation Relative to pH7.4 
Inactivation Relative 
to pH7.4 Reference 
Nav1.1 Depolarized Unchanged (Ghovanloo et al., 2018b) 
Nav1.2 Depolarized Unchanged (Vilin et al., 2012a; Peters et al., 2013) 
Nav1.3 Depolarized Unchanged (Ghovanloo et al., 2018b) 
Nav1.4 Unchanged Unchanged (Vilin et al., 2012a; Ghovanloo et al., 2018a) 
Nav1.5 Depolarized Depolarized (Vilin et al., 2012b) 
 
1.3.3. pH response comparison among the Nav subtypes 
 We characterized the effects of protons on Nav1.1 and Nav1.3. Our findings 
suggest that the magnitude of the proton-dependent changes in the biophysical properties 
of these channels is nearly identical (Ghovanloo et al., 2018b). This similarity is consistent 
with the shared localization of Nav1.1 and Nav1.3 in the cell bodies of neurons, which may 
suggest similar roles in neuronal excitability, as the expression of these channels are 
inversely correlated during neonatal development and postnatal weeks (Gordon et al., 
1987; Scheinman et al., 1989; Beckh et al., 1989; Whitaker et al., 2001; Yu et al., 2006). 
We also found that at low pH, both channel subtypes display a depolarized conductance-
voltage relationship, but no effects on steady-state fast inactivation. These results are 
consistent with the pH-sensitivity reported for rat pyramidal neurons (Tombaugh & 
Somjen, 1996).  
 The comparison of proton-sensitivity across Nav1.1-Nav1.5 reveals that activation 
is more susceptible to pH modulation than inactivation (Table 1.1). There are two potential 
explanations for this observation that are not mutually exclusive: 1) there is more exposure 
to extracellular protonation of sites involved in activation, and 2) having one domain 
controlling fast inactivation instead of three controlling activation decreases the number of 
protonatable sites and therefore decreases the probability that protons modulate fast 
inactivation. Testing the first hypothesis requires extensive mutation-based 
experimentation that should be investigated in future studies. The second hypothesis is 
based on the classic Hodgkin-Huxley model that describes the sodium conductance in 
terms of three activation components and a single fast inactivation component (gNa = m3h) 
(Hodgkin & Huxley, 1952). Thus, it is conceivable that having more domains controlling 
activation may increase the likelihood of carboxylate-proton interactions in domains I-III, 
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which is in part due to having a larger net number of carboxylate-containing residues to 
protonate (Ghovanloo et al., 2018b). 
1.4. Cannabinoids 
The cannabis plant, Cannabis sativa, contains over 120 active constituents, which 
are collectively called phytocannabinoids (Morales et al., 2017). Cannabis originated in 
the Himalayas and was first cultivated in China for seed and fiber production. Early records 
of using cannabis medicinally can be traced to Sumerians records around 1800 B.C.E., 
which mention using this plant against a variety of diseases, including convulsions. There 
are more recent records of cannabis use against epilepsy in Islamic literature (Elsohly, 
2007; Russo et al., 2008b).  
1.4.1. THC 
Over the last century, cannabis consumption became illegal in many parts of the 
world due to its psychotropic effects; and these legal constraints also disrupted cannabis 
research. In the 1960s, however, some progress was made on the research front and, 
several years later, (Devane et al., 1988) determined how ∆9-tetrahydrocannabinol (THC), 
the key psychotropic phytocannabinoid, imparts psycho-activity. THC discovery led to 
identifying two cannabinoid receptors, CB1 and CB2. These receptors play many 
physiological roles in our bodies, including pain response, mood, and memory, among 
others (Pertwee, 2008; Billakota et al., 2019).  
THC has a high affinity for the human CB receptors; its modulation of these 
receptors trigger psychoactivity. THC serves as an agonist at sub-micromolar 
concentrations. CB1 receptors are primarily found in the presynaptic terminals of CNS 
neurons. These receptors are predominantly expressed in cerebral cortex, basal ganglia, 
limbic structures, and some areas of the midbrain and medulla. CB1 is a G-protein coupled 
receptor that modulates neurotransmitter release. Endogenous ligands bind to the CB-
receptors in the postsynaptic terminals and mediate several forms of long- and short-term 
synaptic plasticity. CB2 receptors are expressed in the CNS neurons of the brainstem and 
hippocampus. THC binding to CB2 in these areas can affect neuronal excitability. In 
addition to CB1 and CB2, THC also interacts with some TRP, calcium, and potassium 
channels (Lupica et al., 2004; Ross et al., 2008; De Petrocellis et al., 2011). The functional 
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consequences of modulation of the non-CB receptor targets by THC are not fully 
understood. However, THC is reported to also be an analgesic, a muscle relaxant, and an 
anti-inflammatory agent (Russo, 2008; Russo et al., 2008a).  
1.4.2. CBD 
Cannabidiol (CBD) is another key phytocannabinoid that shares a similar structure 
and many of the physiological effects of THC without psycho-activity. This major difference 
is because CBD has little to no affinity for the CB receptors with which THC interacts 
(Devane et al., 1988). The lack of CBD activity at CB receptors and diversity of reports of 
efficacy (both anecdotal and clinical trials) in various disorders have resulted in many 
proteins being proposed as CBD targets, including Navs, Kvs, Cavs, TRP channels, GPR 
receptors, etc. (Ross et al., 2008; De Petrocellis et al., 2011; Patel et al., 2016; Kaplan et 
al., 2017; Ghovanloo et al., 2018c).  
Among these CBD targets, the Nav family is particularly interesting, as 
abnormalities in the functions of Nav channels are suggested or shown to be associated 
with many of the conditions for which CBD has therapeutic value, such as Dravet 
Syndrome (DS) (Dravet, 2011; Devinsky et al., 2017). This condition affects almost every 
aspect of development in children who suffer from it by causing hundreds of seizures a 
week. The shear frequency and intensity of these seizure attacks prevents the child from 
performing some of the most basic activities, including the ability to talk or walk. 
Unfortunately, each seizure also has the potential to be lethal (Dravet, 2011; Devinsky et 
al., 2017).  
The first step in understanding the molecular interactions between CBD and Navs 
suggested that CBD preferentially blocks resurgent currents (Patel et al., 2016). 
Therefore, if Navs are among the physiological targets for CBD in efficacy against epileptic 
disorders (specifically Dravet syndrome), then this efficacy might be due to the CBD block 
of Nav1.6 resurgent currents over peak currents. Nav1.2 and Nav1.6 are presumed to be 
the predominant Nav isoforms in excitatory neurons; however, the Nav1.2 isoform gets 
partially replaced by Nav1.6 within the first year of life (Spratt et al., 2019). As Dravet 
syndrome is a LOF in Nav1.1 (the predominant Nav channel subtype in inhibitory 
neurons), the inhibition of Nav1.6 resurgent currents would reduce the overall 
hyperexcitability associated with epilepsy (Patel et al., 2016). Nav1.1 and Nav1.6 exist in 
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a balance to maintain proper nerve conduction. Therefore, reducing the activity of Nav1.6 
excitability would implicate a reduction in Nav1.1 LOF.  
1.4.3. Other potential cannabinoid uses 
Cannabis constituents are suggested to possess therapeutic effects in a range of 
other disorders. For instance, in patients with muscular dystrophy, cannabis helps to 
manage pain and involuntary muscle tightness. In patients that suffer from neuropathic 
pain, cannabis significantly reduces the intensity of chronic pain and also improve sleep. 
Cannabis also helps with involuntary muscle tightness and reduces muscle tremors and 
spasticity (Baker et al., 2000; Pertwee, 2008; Ware et al., 2010; Wilsey et al., 2013; Borgelt 
et al., 2013; Woodhams et al., 2015; Iannotti et al., 2019).  
In addition to the plant-based phytocannabinoids, much effort has gone into 
studying the endogenous cannabinoids, 2-arachidonoyl glycerol (2-AG) and arachidonoyl 
ethanolamide (anandamide) which have important physiological implications. Since this 
dissertation focuses on phytocannabinoids, detailed discussions of endogenous 
cannabinoids can be found elsewhere (De Petrocellis et al., 2011; Iannotti et al., 2019).  
1.5. Conclusion 
Many mutations in SCN4A are associated with the myotonic syndromes and 
periodic paralyses. These conditions can be severely life-limiting with respect to 
performing everyday tasks. Currently, there is a lack of mechanistic insight on many 
mutants underlying these conditions. There is little known about how physiological triggers 
affect the mutants causing these conditions.  
From a broader standpoint, hyperexcitability presents as a significant problem in 
other tissues besides skeletal muscles. GOF in Navs has been linked to a wide range of 
conditions such as inherited erythromelalgia, epilepsy, and arrhythmias. Treating these 
types of conditions requires an in-depth understanding of their underlying mechanisms. 
One way to gain this understanding is to investigate physiological triggers. There is also 
a dire need for novel ways to reduce the hyperexcitability associated with Navs. One 
promising compound is CBD.  
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For my doctoral research I first studied how a single missense mutation (P1158S) 
in Nav1.4 causes various degrees of GOF (myotonia and periodic paralysis). In aim 1 
(Chapter 2), I began by investigating pH-sensitivity in P1158S, as changes in extracellular 
pH that are associated with physical activity, are a common trigger for both myotonia and 
periodic paralysis. The results from this project provided new information about additional 
ways protons interact with Navs. This project also laid the foundation for developing a new 
in-vitro/in-silico assay of Nav1.4 hyperexcitability.  
In aim 2 (Chapter 3), I studied the inhibitory effects of the FDA-approved 
cannabidiol on Nav currents. Although CBD (commercial name: Epidiolex) has shown 
efficacy in clinical trials, the underlying mechanism for the efficacy was unknown. The 
findings from project 2 provided important information on how the presence of CBD 
modulates voltage-dependent sodium currents. These findings laid the foundation of a 
series of hypotheses about the molecular mechanism of CBD-Nav interactions.  
In aim 3 (Chapters 4-5), I investigated the in-depth biophysical (along with other 
computational and structural means through collaborations) mechanism through which 
CBD inhibits Nav currents. I also measured CBD effects in the in-vitro/in-silico assay 
developed in aim 1 to model potential therapeutic value against myotonia and periodic 
paralysis.  
These three aims provide a deeper understanding of the mechanism underlying 
certain aspects of Nav GOF and also unveil the ways through which this GOF could be 
suppressed by a superhydrophobic compound like CBD.  
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Chapter 2. A mixed periodic paralysis & myotonia 
mutant, P1158S, imparts pH-sensitivity in skeletal 
muscle voltage-gated sodium channels 
This chapter describes the work published in (Ghovanloo et al., 2018a) with minor 
modifications and formatting changes to suit the thesis style. 
2.1. Abstract 
Skeletal muscle channelopathies, many of which are inherited as autosomal 
dominant mutations, include myotonia and periodic paralysis. Myotonia is defined by a 
delayed relaxation after muscular contraction, whereas periodic paralysis is defined by 
episodic attacks of weakness. One sub-type of periodic paralysis, known as hypokalemic 
periodic paralysis (hypoPP), is associated with low potassium levels. Interestingly, the 
P1158S missense mutant, located in the third domain S4-S5 linker of the ‘‘skeletal 
muscle’’, Nav1.4, has been implicated in causing both myotonia and hypoPP. A common 
trigger for these conditions is physical activity. We previously reported that Nav1.4 is 
relatively insensitive to changes in extracellular pH compared to Nav1.2 and Nav1.5. 
Given that intense exercise is often accompanied by blood acidosis, we decided to test 
whether changes in pH would push gating in P1158S towards either phenotype. Our 
results suggest that, unlike in WT-Nav1.4, low pH depolarizes the voltage-dependence of 
activation and steady-state fast inactivation, decreases current density, and increases late 
currents in P1185S. Thus, P1185S turns the normally pH-insensitive Nav1.4 into a proton-
sensitive channel. Using action potential modeling we predict a pH-to-phenotype 
correlation in patients with P1158S. We conclude that activities which alter blood pH may 
trigger the noted phenotypes in P1158S patients. 
2.2. Introduction 
Electrical signaling is an integral part of many processes including the heartbeat 
and voluntary movement. This kind of signaling depends on a group of transmembrane 
proteins called voltage-gated ion channels (Hodgkin & Huxley, 1952). Voltage-gated 
sodium channels are responsible for the initiation and propagation of action potentials in 
most excitable cells. These channels are hetero-multimeric proteins composed of a large 
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voltage-sensing and pore-forming a-subunit, and smaller b-subunits (Calhoun & Isom, 
2014). The a-subunit family is composed of 9 subtypes, which are expressed in different 
parts of the body (Catterall, 2012). Nav1.4, highly expressed in skeletal muscle, is 
encoded by the SCN4A gene. Mutations in SCN4A often lead to either gain-of-function or 
loss-of-function phenotypes (Ghovanloo et al., 2016b).  
Although most Nav1.4-mutants depolarize the sarcolemma, this depolarization can 
result in either hyper- or hypo-excitability (Cannon, 2006). The manifestation of Nav-
channelopathies occurs through changes in membrane excitability, and these changes 
underlie various clinical syndromes. Traditionally, muscular channelopathies are classified 
as either non-dystrophic myotonias or periodic paralysis (Ryan et al., 2007; Lehmann-
Horn et al., 2008). Most of these channelopathies are either sporadic de novo or inherited 
autosomal dominant mutations (George, 2005).  
The phenotypic expression of most muscle channelopathies takes place within the 
first two decades of life, and many afflicted individuals suffer from life-long symptoms such 
as muscle stiffness, weakness, or pain (Tan et al., 2011). Despite their high penetrance, 
these mutations can show clinical variability within different familial groups or even a single 
family (Tan et al., 2011). 
Most gain-of-function mutations in SCN4A result in myotonic syndromes. Myotonia 
is defined by a delayed relaxation after muscle contraction (Lehmann-Horn & Rudel, 1995; 
Tan et al., 2011). In myotonia, there is an increase in muscle membrane excitability in 
which even a brief voluntary contraction can lead to a series of action potentials that can 
persist for several seconds following the termination of motor neuron activity. This 
phenomenon is perceived as muscle stiffness (Tan et al., 2011). The global prevalence of 
non-dystrophic myotonias is estimated at 1: 100,000 (Emery, 1991). Although this 
condition is not considered lethal, it can be extremely life-limiting due to the multitude of 
muscle contractility problems it can cause. Given the characteristic hyper-excitability of 
myotonia, most therapeutics are targeted against membrane excitability (Desaphy et al., 
2004; Vicart et al., 2005; George, 2012). 
Until recently, loss-of-function Nav1.4-mutants were thought to cause periodic 
paralysis. This was due to most periodic paralysis-causing mutations neutralizing 
positively charged residues in voltage sensors. Newer studies described a cation leak with 
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characteristics similar to the ω-current in Shaker potassium channels. These findings 
indicate a form of gain-of-function resulting in periodic paralysis (Lehmann-Horn & Jurkat-
Rott, 1999; Tombola et al., 2005; Sokolov et al., 2007; Wu et al., 2011). Some 
channelopathies are triggered by low serum potassium levels and manifest in episodes of 
extreme muscle weakness. These are known as hypo-kalemic periodic paralyses 
(hypoPP) (Miller et al., 2004a). The onset of hypoPP occurs between the ages of 15 and 
35, and the prevalence of hypoPP is also estimated to be 1: 100,000. HypoPP can be 
triggered by external factors such as stress, high-sugar diet, and exercise (Miller et al., 
2004a). A serum potassium concentration less than 3 mM may trigger hypoPP (Fontaine, 
2008). 
P1158S in Nav1.4 is a missense mutant in the S4-S5 linker of domain (D) III that 
is the result of a C to T mutation at position 3549 in SCN4A (Sugiura et al., 2003). P1158S 
is described to cause both myotonia and hypoPP. The ability to cause two seemingly 
contrasting syndromes is shared between P1158S and some mutants of the cardiac 
sodium channel, Nav1.5, which cause both the Brugada and long QT syndromes (Makita 
et al., 2008). Our group recently showed that physiological triggers may be important in 
modulating disease phenotype in the E1784K mutant in Nav1.5 (Peters et al., 2016), 
leading us to hypothesize a possible role of similar triggers in P1158S.  
Exercise is a common trigger for both myotonia and hypoPP (Lehmann-Horn & 
Rudel, 1995; Miller et al., 2004a; Tan et al., 2011). Physical activity results in delayed 
relaxation in myotonic patients and extreme weakness in hypoPP patients. Exercise is 
normally accompanied by changes in extracellular pH, which can modulate sodium 
channel function (Vilin et al., 2012a; Jones et al., 2013b; Peters et al., 2016). We therefore 
hypothesized that pH alterations may push P1158S towards either myotonia or hypoPP.  
Changes in extracellular pH levels modulate the activities of Nav1.2 and Nav1.5; 
however, Nav1.4 is relatively pH-insensitive (Vilin et al., 2012a). One theory behind the 
pH-sensitivity of Nav1.5 is the presence of a cysteine (C373) residue on the outer vestibule 
of DI (Khan et al., 2006; Jones et al., 2013b). The increase in H+ concentration results in 
the protonation of this cysteine, which creates a positive charge outside the pore. This 
positive charge causes an electrostatic repulsion, blocking sodium ions from going through 
the pore. This cysteine is missing in Nav1.4 (Khan et al., 2006). However, there are other 
residues on the extracellular side of Nav1.4 that may get protonated (Khan et al., 2002, 
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2006). We postulated that one reason for the apparent pH-insensitivity of Nav1.4 relative 
to other sodium channels might be due to hydrophobic amino acids protecting the 
protonate-able functional groups from becoming protonated at low pH.  
The serine functional group is floppier than the highly restrained proline functional 
group. Furthermore, previous studies suggest that in Nav1.4, DIII activates before DI and 
DII (Gosselin-Badaroudine et al., 2012). Also, it is suggested that SCN4A-mutations that 
disrupt the movement of DIII S4 during recovery can result in hypoPP (Groome et al., 
2014). Given the location of P1158S on the DIII S4-S5 linker, along with the nature of the 
mutation, and because DIII activates first, we predicted that this mutation might lead to the 
exposure of residues, protected in WT-Nav1.4, to protonation. Here we report the results 
of homology modeling, patch-clamp experiments, and action potential modeling. These 
results support our hypothesis and show P1158S imparts pH-sensitivity to Nav1.4 that 
underlies the dual myotonia/hypoPP phenotype. 
2.3. Methods 
2.3.1. Cell culture 
 Chinese Hamster Ovary (CHO) cells were transiently co-transfected with cDNA 
encoding eGFP and the β1-subunit and either WT-Nav1.4 (GenBank accession number: 
NM_000334) or P1158S α-subunit. Transfection was done according to the PolyFect 
transfection protocol. After each set of transfections, a minimum of 8-hour incubation was 
allowed before plating on sterile coverslips.   
2.3.2. Homology modeling 
 Homology modeling was performed using the Swiss-Model server (Bordoli et al., 
2008). The sodium channel structure developed by Ahuja et al., (2015) was used as a 
template against which the Nav1.4 sequence with and without P1158S were modeled 
(Arnold et al., 2006; Bordoli et al., 2008). Modeling was done according to the protocol 
established by Bordoli et al., (2008). PyMOL-pdb viewer was used for optimization and 
structure visualization.  
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2.3.3. Electrophysiology  
 Whole-cell patch-clamp recordings were performed in an extracellular solution 
containing (in mM): 140 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES or MES (pH6.4). 
Solutions were adjusted to pH (6.4, 7.0, 7.4, 8.0) with CsOH. Pipettes were filled with 
intracellular solution, containing (in mM): 120 CsF, 20 CsCl, 10 NaCl, 10 HEPES or MES 
(pH6.4). All recordings were made using an EPC-9 patch-clamp amplifier (HEKA 
Elektronik, Lambrecht, Germany) digitized at 20 kHz via an ITC-16 interface (Instrutech, 
Great Neck, NY, USA). Voltage-clamping and data acquisition were controlled using 
PatchMaster/FitMaster software (HEKA Elektronik, Lambrecht, Germany) running on an 
Apple iMac. Current was low-pass-filtered at 10 kHz. Leak subtraction was performed 
automatically by software using a P/4 procedure following the test pulse. Gigaohm seals 
were allowed to stabilize in the on-cell configuration for 1 min prior to establishing the 
whole-cell configuration. Series resistance was less than 5 MΩ for all recordings. Series 
resistance compensation up to 80% was used when necessary. All data were acquired at 
least 1 min after attaining the whole-cell configuration. Before each protocol, the 
membrane potential was hyperpolarized to −130 mV to ensure complete removal of both 
fast inactivation and slow inactivation. All experiments were conducted at 22 ˚C. 
2.3.4. Activation protocols 
To determine the voltage-dependence of activation, we measured the peak current 
amplitude at test pulse potentials ranging from −100 mV to +80 mV in increments of +10 
mV for 20 ms. Channel conductance (G) was calculated from peak INa: 
GNa=INa/V−ENa  (Eq. 1) 
where GNa is conductance, INa is peak sodium current in response to the command 
potential V, and ENa is the Nernst equilibrium potential. Calculated values for conductance 
were fit with the Boltzmann equation: 
G/Gmax=1/(1+exp[−ze0[Vm−V1/2]/kT])  (Eq. 2) 
where G/Gmax is normalized conductance amplitude, Vm is the command potential, z is the 
apparent valence, e0 is the elementary charge, V1/2 is the midpoint voltage, k is the 
Boltzmann constant, and T is temperature in K. 
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2.3.5. Steady-state fast inactivation protocols 
 The voltage-dependence of fast inactivation was measured by preconditioning the 
channels to a hyperpolarizing potential of −130 mV and then eliciting pre-pulse potentials 
that ranged from −170 to +10 mV in increments of 10 mV for 500 ms, followed by a 10 ms 
test pulse during which the voltage was stepped to 0 mV. Normalized current amplitudes 
from the test pulse were fit as a function of voltage using the Boltzmann equation: 
I/Imax=1/(1+exp(−ze0(VM−V1/2)/kT)  (Eq. 3) 
where Imax is the maximum test pulse current amplitude. 
2.3.6. Late current protocols 
 Late current was measured between 145 and 150 ms during a 200 ms depolarizing 
pulse to 0 mV from a holding potential of -130 mV. Pulses were averaged to increase 
signal-to-noise ratio. 
2.3.7. Use-dependent inactivation protocols 
 Cells were held at -60 mV and repetitively stimulated with 2000, 20 ms test pulses 
to 0 mV. Peak currents from test pulses were normalized to the amplitude of the first 
current in the series and values were plotted versus the time of each pulse in seconds.   
2.3.8. Immunocytochemistry  
 CHO cells co-transfected with the β1-subunit and wild-type Nav1.4 or P1158S  -
subunits were incubated for 24 hours. The transfections were done on glass coverslips. 
Non-transfected cells were also incubated and were used as negative control. After this 
incubation period, cells were fixed in 4% paraformaldehyde for 10 minutes while being 
incubated on a shaker. Then, cells were incubated in 0.1% Triton X-100 for another 10 
minutes. Cells were blocked in 10% goat serum for 30 to 45 minutes. Following this step, 
the cells were kept on Parafilm on top of a wet filter paper. Diluted primary anti-Nav1.4 
(1:100, Rabbit polyclonal IgG, commercially available via Alomone) antibodies were 
added. The next day, cells were incubated in PBS for 10 minutes. Lastly, secondary IgG2a 
(1:500) was added. Stained cells were studied using a Zeiss confocal microscope.  
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2.3.9. Action potential modeling 
 Skeletal action potential modeling was based on a model developed by Cannon et 
al., (1993). All action potentials were programmed and run using Python. The modified 
parameters were based on electrophysiological results obtained from whole-cell patch-
clamp experiments (Cannon et al., 1993). The model accounted for activation voltage-
dependence, steady-state fast inactivation voltage-dependence, and late sodium currents. 
The WT pH7.4 model uses the original parameters from the model. As the WT-Nav1.4 
was not sensitive to changes in pH, the WT models are identical for all pH values. P1158S 
models were programmed by shifting the midpoints of activation and fast inactivation from 
the original Cannon model by the difference between the values in P1158S experiments 
at a given pH and the average value in WT at all pH values. As persistent current was 
increased by the P1158S mutant, but was not significantly impacted by changes in pH, 
the simulated P1158S persistent current was the same at all pH values. 
2.3.10. Analysis  
Analysis and graphing were done using FitMaster software (HEKA Elektronik) and 
Igor Pro (Wavemetrics, Lake Oswego, OR, USA). All data acquisition and analysis 
programs were run on an Apple iMac (Apple Computer). Statistical analysis was 
performed in JMP version 13. Confocal images were analyzed in ImageJ.   
2.3.11. Statistics 
A two-factor analysis of variance (ANOVA) was used to compare the mean 
responses [activation, current density, steady-state fast inactivation, late currents, fast 
inactivation kinetics, use-dependent inactivation] between the channel variants and pH 
points. Channel variant, pH, and the way interaction involving the two were considered to 
be fixed effects in the model. Channel variant had two levels (WT, P1158S) and pH had 
four levels (pH6.4, 7.0, 7.4, 8.0). A one-factor ANOVA was used to compare the means 
membrane fluorescence intensities of the two channels and a negative control. Post hoc 
tests using the Tukey Kramer adjustment compared the mean responses between 
channel variants across conditions. A level of significance α = 0.05 was used in all overall 
post hoc tests, and effects with p-values less than 0.05 were considered to be statistically 
significant. All values are reported as means ± standard error of means for n cells. 
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2.4. Results 
2.4.1. P1158S alters the hinge angle of the DIII S4-S5 linker  
In the sliding-helix model of voltage-sensor movement during activation, when the 
potential across the cell membrane becomes depolarized, the voltage-sensor domain 
(VSD) undergoes an outward movement. This movement pulls on the S4-S5 linker and 
drags open the pore-domain (PD), leading to an influx of sodium ions (Yarov-Yarovoy et 
al., 2012). Based on this model we sought to determine whether P1158S alters the S4-S5 
topology. We predicted that any topological change might alter the mobility of this linker 
and impart pH-sensitivity during acidosis.  
To test our hypothesis, we performed homology modeling using the Swiss-Model 
server, accessible via the ExPASy web server, to model the sequence of both WT and 
P1158S against the Nav1.7 structure (Ahuja et al., 2015). The Nav1.7 structure was used 
as a skeleton on which the WT and mutant-Nav1.4 sequences were placed (Bordoli et al., 
2008). Our results show the critical position of P1158 in Nav1.4 on the hinge of DIII S4-
S5 linker (Figure 2-1A-C).  
Gain- and loss-of-function mutations may alter the atomic structure of sodium 
channels by causing connectivity rearrangements and changing interatomic bonds and 
topological angles (Kapetis et al., 2017). Therefore, we ran the model with the P1158S 
mutant to test whether there was an effect on the hinge angle of the S4-S5 linker. The 
hinge angle with proline was 84.9˚; however, this angle was increased to 87.2˚ with the 
serine mutation (Figure 2-1D-E). This suggests there is less angle strain on the S4-S5 
linker when serine is present as opposed to proline. P1158 is conserved across all Nav 
subtypes, further suggesting its structural importance (Figure 2-1F).   
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Figure 2-1 Homology model of sodium channel.  
(A-C) Show the views of the location of P1158 from the side, intracellular, and extracellular sides. 
The structure is colored by domain. P1158 is highlighted in red. (D-E) Show the hinge angle 
difference between having proline (84.9˚) or serine (87.2˚) at position 1158. (F) Show the location 
of the P1158S mutation on a generic sodium channel schematic (highlighted in red), and the 
conservation of this part of Nav1.4, aligned with the rest of sodium channels.  
2.4.2. P1158S makes Nav1.4 sensitive to changes in extracellular, but 
not intracellular pH 
We conducted whole-cell patch-clamp experiments to investigate whether the 
P1158S mutant in the S4-S5 linker increases the sensitivity of Nav1.4 to protons. We 
examined the effects of pH changes on channel activation in WT and P1158S by 
measuring peak channel conductance at membrane potentials between -100 and +80 mV 
(Figure 2-2H). Neither decreasing nor increasing extracellular pH causes significant 
effects on the midpoint (V1/2) or apparent valence (z) of activation in WT channels (p > 
0.05). In the P1158S mutant, however, there are significant shifts in the depolarized 
direction in the V1/2 of activation when extracellular pH is changed from pH8.0 to 6.4 (p = 
0.0011) (Figure 2-2A-E). We fitted the conductance V1/2 of P1158S using the Hill equation 
and WT using a flat line (Figure 2-2G; Table 2.1). The P1158S mutant has a pKa of 7.27 





















Figure 2-2 Normalized conductance plotted against membrane potential.  
(A-D) Show overlaps of WT (blue squares) and P1158S (grey circles) conductance at pH6.4, 7.0, 













dependence of activation as a function of pH and fitted with Hill equation (P1158S) or a flat line 
(WT). (H) Shows pulse protocol.  
 
Table 2-1 Conductance comparison across pH6.4 to 8.0 between WT and 
P1158S 
Channel Type-pH Mean V1/2 ± SE (mV) Mean z ± SE (slope) n 
P1158S-pH6.4 -19.48 ± 2.22A 2.76 ± 0.32 9 
P1158S-pH7.0 -22.11 ± 2.52A 2.68 ± 0.36 7 
P1158S-pH7.4 -29.95 ± 2.35B 4.71 ± 0.34 8 
P1158S-pH8.0 -34.77 ± 2.35B 3.02 ± 0.34 8 
WT-pH6.4 -25.86 ± 2.72 3.15 ± 0.39 6 
WT-pH7.0 -24.87 ± 2.52 3.56 ± 0.36 7 
WT-pH7.4 -24.84 ± 2.52 3.14 ± 0.36 7 
WT-pH8.0 -21.92 ± 2.98 3.16 ± 0.43 5 
Letter codes and asterisk indicate statistical significance. Numbers with different letter codes and/or matching 
asterisks are significantly different.  
Maximal conductance density could relate to membrane channel expression and 
trafficking. We calculated the peak conductance density from the conductance at +20 mV 
measured by a test pulse and dividing this value by the cell membrane capacitance 
(nS/pF). We also measured current density from the ratio of peak current amplitude to the 
cell membrane capacitance (pA/pF). Representative current traces are shown in (Figure 
2-3A-H). Although the conductance and current densities of WT channels were decreased 
at lower pH, these decreases were not significant (p > 0.05); however, the P1158S 
conductance (p = 0.0014) and current (p < 0.0001) densities were significantly decreased 
at lower extracellular pH’s of 6.4 and 7.0 compared to 7.4 and 8.0 (Figure 2-3I; Table 
2.2). To study the effects of proton block in WT and P1158S, we measured peak current 
amplitudes over a series of depolarizing pulses while perfusing extracellular solutions with 
pH8.0 to pH6.4 (Figure 2-3J). Peak current reduction at low pH was larger in P1158S 
than WT (Figure 2-3K).   
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Figure 2-3 Current and conductance densities measured in pA/pF and nS/pF, 
respectively.  
(A-H) Sample macroscopic sodium currents elicited by depolarizations between -100 and +80 mV. 
(I) Average current (left Y-axis) and conductance (right Y-axis) densities of P1158S and WT at 
extracellular pH between 6.4 and 8.0. The solid bars represent current density and patterned bars 
represent conductance density. ** indicate p < 0.01, * indicate p < 0.05 (P1158S at pH6.4 and 7.0 
are significantly different from pH7.4 and 8.0; P1158S at physiological pH of 7.4 is significantly 
different from WT at pH7.4). (J) Sample proton block trace. Maximal current amplitude is plotted 
over a series of depolarizing pulses. External solution pH is 8.0 at the start of the trace. pH6.4 gets 
perfused at the pulses indicated by arrows. (K) Sample current amplitude at pH8.0 and 6.4 in WT 
and P1158S. 
Table 2-2 Peak conductance and current densities  
Channel Type-pH Mean density ± SE (pA/pF) n 
Mean Conductance ± SE 
(nS/pF) n 
P1158S-pH6.4 45.7 ± 19.5A 9 1.06 ± 0.45A 9 
P1158S-pH7.0 70.4 ± 20.7A
 
 8 1.68 ± 0.48A
 
 8 
P1158S-pH7.4 192.0 ± 20.7B* 8 3.40 ± 0.48B* 8 
P1158S-pH8.0 167.6 ± 22.1B
 
 7 3.86 ± 0.51B 7 
WT-pH6.4 77.2 ± 26.1 5 1.69 ± 0.57 5 
WT-pH7.0 88.0 ± 26.1 5 1.90 ± 0.57 5 
WT-pH7.4 110.2± 18.5* 10 2.22 ± 0.40* 10 
WT-pH8.0 94.0 ± 23.9 6 1.78 ± 0.52 6 
Letter codes and asterisk indicate statistical significance. Numbers with different letter codes and/or matching 
asterisks are significantly different.  
After activation, the DIII-DIV linker, known to be the fast inactivation gate, binds to 
the inside of the channel within milliseconds and blocks the flow of sodium through the 
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pore (West et al., 1992). We measured the voltage-dependence of fast inactivation using 
a standard pre-pulse voltage protocol (Figure 2-4H). Normalized current amplitudes were 
plotted as a function of pre-pulse voltage (Figure 2-4A-F). Like activation, the voltage-
dependence of steady-state fast inactivation was depolarized by low extracellular pH in 
P1158S (p = 0.0027). Also, similar to activation, the WT V1/2 of fast inactivation was not 
significantly affected by changes in extracellular pH (p > 0.05) (Table 2.3). We fit fast 
inactivation V1/2 as a function of pH with either a Hill curve (P1158S) or a flat line (WT) 
(Figure 2-4G). The P1158S V1/2 of fast inactivation has a pKa of 7.63.  
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Figure 2-4 Voltage-dependence of steady-state fast inactivation as normalized 
current plotted against membrane potential. 
(A-D) Show the voltage-dependence of fast inactivation of WT (blue squares) and P1158S (grey 














and P1158S. (G) Shows the voltage-dependence of steady-state fast inactivation as a function of 
pH and fitted with a Hill equation (P1158S) or a flat line (WT). (H) Shows voltage protocol. 
Table 2-3 Steady-state fast inactivation comparison across pH6.4 to 8.0 
between WT and P1158S 
Channel Type-pH Mean V1/2 ± SE (mV) Mean z ± SE (slope) n 
P1158S-pH6.4 -70.18 ± 3.16A -2.96 ± 0.25 6 
P1158S-pH7.0 -70.95 ± 2.74A -2.53 ± 0.21 8 
P1158S-pH7.4 -74.52 ± 2.58B -2.63 ± 0.20 9 
P1158S-pH8.0 -84.54 ± 3.16B -2.41 ± 0.25 6 
WT-pH6.4 -68.41 ± 3.16 -3.74 ± 0.25 6 
WT-pH7.0 -67.65 ± 2.74 -3.32 ± 0.21 8 
WT-pH7.4 -67.77 ± 2.58 -2.49 ± 0.20 9 
WT-pH8.0 -67.44 ± 2.74 -3.27 ± 0.21 8 
Letter codes indicate statistical significance. Numbers with different letter codes are significantly different. 
We also measured the open-state fast inactivation time constant, which did not 
differ significantly between channels or pH points (p > 0.05) (Figure 2-5; Table 2.4).  
 
Figure 2-5 Open-state fast inactivation time constants.  
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Table 2-4 Open-state fast inactivation time constants across four voltages 
Channel Type-pH -30 mV 𝞽 ± SE (ms) 
-10 mV 𝞽 ± SE (ms) 0 mV 𝞽 ± SE (ms) +10 mV 𝞽 ± SE (ms) n 
P1158S-pH6.4 1.85 ± 0.27 0.95 ± 0.20 0.66 ± 0.09 0.59 ± 0.13 7 
P1158S-pH7.0 2.26 ± 0.41 0.96 ± 0.11 0.80 ± 0.05 0.69 ± 0.06 4 
P1158S-pH7.4 1.48 ± 0.14 0.78 ± 0.05 0.63 ± 0.04 0.56 ± 0.04 13 
P1158S-pH8.0 1.26 ± 0.10 0.67 ± 0.05 0.56 ± 0.06 0.54 ± 0.08 7 
WT-pH6.4 2.06 ± 0.40 0.98 ± 0.17 0.72 ± 0.06 0.60 ± 0.05 6 
WT-pH7.0 1.62 ± 0.34 0.77 ± 0.10 0.62 ± 0.06 0.52 ± 0.04 6 
WT-pH7.4 2.41 ± 0.37 1.22 ± 0.21 0.89 ± 0.20 0.77 ± 0.17 8 
WT-pH8.0 2.00 ± 0.20 1.05 ± 0.15 0.76 ± 0.07 0.68 ± 0.10 7 
 
Total sodium current can be divided into two components: peak (INaP) and late 
(INaL) currents. Whereas INaP refers to the maximum amount of sodium ions going 
through the channels during the open state, the smaller INaL is a manifestation of 
destabilized fast inactivation. We show representative normalized current traces for both 
channels across all conditions (Figure 2-6A-D). We measured the percentage of INaL by 
dividing the maximum INaL between 145 ms and 150 ms by INaP. Our results indicated 
that WT INaL is not significantly sensitive to changes in pH (p > 0.05). In contrast, P1158S 
showed a channel effect with a greater fraction of late current compared to WT (p = 
0.0041) (Figure 2-6E; Table 2.5). This is an important result because previous studies 
suggested that late sodium current may be the basis of repetitive action potential firing 




Figure 2-6 Late sodium current.  
(A-D) Representative normalized current traces of late currents in WT and P1158S at extracellular 
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sodium current as a percentage of peak sodium current for WT and P1158S at extracellular pH 
between 6.4 and 8.0. ** indicate p < 0.01 (P1158S is significantly different from WT). 
Table 2-5 Late sodium current percentage across pH6.4 to 8.0 
Channel Type-pH Mean %INaL ± SE (%INaL) n 
P1158S-pH6.4 7.67 ± 1.42A 9 
P1158S-pH7.0 8.96 ± 1.81A 4 
P1158S-pH7.4 4.13 ± 1.21A 6 
P1158S-pH8.0 5.18 ± 1.46A 6 
WT-pH6.4 2.66 ± 1.03B 4 
WT-pH7.0 3.33 ± 1.03B 5 
WT-pH7.4 4.34 ± 0.67B 5 
WT-pH8.0 2.57 ± 0.95B 4 
Letter codes indicate statistical significance. Numbers with different letter codes are significantly different. 
To investigate the effects of pH on inactivation in WT and P1158S, we compared 
use-dependent current reduction at all four pH points. The maximal voluntary contraction 
frequencies in the soleus muscle, biceps branchii, and deltoid muscle are: ~11, ~23, and 
~29 Hz, respectively (Hermansen & Osnes, 1972; Kukulka & Clamann, 1981; Bellemare 
et al., 1983; St Clair Gibson, 2004). We chose a 45 Hz pulse stimulation frequency to 
emulate physical activity. This frequency was chosen as some studies have shown that 
artificial stimulation rates can increase firing rates in muscles (St Clair Gibson, 2004). Our 
results suggest that, although WT current decay does not significantly differ with changes 
in extracellular pH (p > 0.05), P1158S shows a significant acceleration of use-dependent 




Figure 2-7 Use-dependent inactivation.  
(A-D) Show normalized current decay plotted as a function of time. The inset in panel (A) shows 
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Table 2-6 Use-dependent inactivation comparison between WT and P1158S 
Channel Type-pH Mean 𝞽 ± SE (s) n 
P1158S-pH6.4 0.132 ± 0.057A 4 
P1158S-pH7.0 0.725 ± 0.238 8 
P1158S-pH7.4 1.643 ± 0.309 3 
P1158S-pH8.0 1.753 ± 0.539B 5 
WT-pH6.4 0.416 ± 0.128 3 
WT-pH7.0 0.849 ± 0.090 6 
WT-pH7.4 0.639 ± 0.290 4 
WT-pH8.0 0.711 ± 0.290 4 
Letter codes indicate statistical significance. Numbers with different letter codes are significantly different. 
During physical activity, accumulation of lactate and CO2 reduces extracellular pH 
because of acid efflux from muscle cells (Aalkjaer & Peng, 1997). These changes in blood 
acidity play a vital role in blood flow homeostasis (Aalkjaer & Peng, 1997). However, this 
acidosis begins on the intracellular side of muscle cells. To test whether the P1158S 
responses to pH changes are due to protonation on the intracellular side of the channel, 
we performed whole-cell voltage-clamp experiments in which the pipette solution pH was 
lowered to 6.4, while buffering the extracellular bath pH at 7.4. The results of these 
experiments were compared to the experiments with both intra- and extracellular solutions 
at pH7.4. We found that intracellular acidosis does not significantly alter activation, steady-
state fast inactivation, current density, or late current levels in P1158S (p > 0.05) (Figure 
2-8; Table 2.7). Thus, the observed pH-dependence in the previous experiments are due 
to extracellular modifications. 
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Figure 2-8 Effects of changing intracellular pH to 6.4.  
(A-B) Representative current traces of P1158S with both intra- and extracellular pH at 7.4, and 
intracellular pH6.4 and extracellular pH7.4, respectively. (C) Shows the voltage-dependence of 
activation for P1158S at intracellular pH7.4 (blue squares) and intracellular pH6.4 (grey circles). 
(D) Shows the voltage-dependence of steady-state fast inactivation for P1158S at intracellular 
pH7.4 (blue squares) and intracellular pH6.4 (grey circles). Insets show voltage protocols. (E) 
Shows average current density for P1158S channels at intracellular pH7.4 and 6.4. (F) Shows late 
sodium current as a percentage of peak sodium current for WT and P1158S channels.   
Table 2-7 Intracellular acidosis biophysical parameters 
Parameter P1158S IpH7.4 n P1158S IpH6.4 n 
Conductance V1/2 ± SE (mV) -29.95 ± 2.41 8 -31.67 ± 2.58 7 
Conductance z ± SE (slope) 4.71 ± 0.56 8 3.34 ± 0.60 7 
SSFI V1/2 ± SE (mV) -74.52 ± 2.43 9 -77.78 ± 2.75 7 
SSFI z ± SE (slope) -2.63 ± 0.24 9 -3.10 ± 0.27 7 
Current density ± SE (pA/pF) 282.7 ± 45.3 10 222.3 ± 50.7 8 
%INaL ± SE (%INaL) 4.91 ± 1.72 6 6.92 ± 2.43 3 
 
2.4.3. P1158S does not alter channel trafficking or expression 
Our patch-clamp results indicated the average conductance (p = 0.0395) and 
current (p = 0.0092) densities of P1158S mutants were significantly greater than that of 
WT at physiological pH (Table 2-2). Therefore, we sought to determine whether there are 
any differences in the trafficking and expression between WT and P1158S. We performed 
immunocytochemistry and used confocal microscopy to visualize and quantify channel 
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distribution and, thus, channel trafficking (Figure 2-9A-C). The non-specific fluorescence 
in negative control was subtracted from the WT and P1158S conditions in all analyses. 
Pixel intensity grey value was used as a function of the length of cells (distance) from the 
middle confocal plane image.  
For a typical CHO cell with a length of about 14 µm, both WT and P1158S were 
localized within the 0 to 4 µm and 9 to 14 µm ranges. These two ranges correspond to the 
outer cellular edges, indicating that most of the channels seem to be concentrated in the 
proximity of cell membranes (Figure 2-9D-E). To quantify expression, we measured the 
average pixel intensity across all confocal planes per cell area, for all cells in all conditions. 
We found no significant difference between WT and P1158S channel expression (p > 
0.05) (Figure 2-9F).  
 
Figure 2-9 Immunocytochemistry measurements of channel trafficking and 
expression.  
(A-C) Representative images of WT, P1158S, and negative control cells taken from the middle 
confocal plane. (D-E) Show the distribution of channels, measured by using pixel grey value, across 
the cell. Both WT and P1158S channels are localized around the edges of cells, in proximity to cell 
membrane (distances 0-4 µm, and 9-14 µm). (F) Average pixel intensity across all confocal images 
per cell area (n = 3 per condition).  
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2.4.4. pH Alterations Can Push P1158S into Periodic Paralysis or 
Myotonia 
We used an action potential model to simulate how the pH-dependent 
electrophysiological shifts in P1158S may affect phenotype (Cannon et al., 1993). We ran 
the simulations at a stimulus of 50 µA/cm2. A single action potential at physiological pH7.4 
required a shorter stimulus duration in P1158S (1.2 ms) than WT (2.0 ms) (Figure 2-10A). 
The repolarization of P1158S was slightly prolonged compared to WT due to the presence 
of larger late sodium current. This late current also led to an increase in the T-Tubule 
potassium concentrations in P1158S (Figure 2-10B). The long duration simulation pulse 
started at 50 ms and stopped at 350 ms. During this pulse, the WT channels activated at 
50 ms. WT channels fired only a single action potential. The channels remained 
inactivated until the stimulus was removed at 350 ms (Figure 2-10C). Unlike the WT 
channels, the action potential morphology changed as a function of pH in P1158S. At the 
beginning of the stimulus, in pH8.0 models, P1158S mutants displayed an action potential 
spike, followed by a period during which the membrane potential remained depolarized at 
-30 mV even after the stimulus was removed (Figure 2-10D). This inability to repolarize 
holds the sodium channels in an inactivated state, and is consistent with the periodic 
paralysis phenotype (Cannon, 2015). As with pH8.0, P1158S also displayed a periodic 
paralysis-like action potential at pH7.4 (Figure 2-10D). At pH7.0, P1158S showed a 
continuous train of action potentials for most of the stimulus duration. After the stimulus 
was removed, there was an after-discharge consistent with myotonic action potentials, 
which then degenerated into periodic paralysis (Cannon, 2012, 2015) (Figure 2-10D). At 
pH6.4, the P1158S-mutants showed a continuous train of action potentials for the entire 
stimulation period. After the stimulus was removed, P1158S displayed a progressive 
repolarization of the membrane potential during a myotonic burst (Cannon, 2012, 2015) 
(Figure 2-10D). Overall, during extreme acidosis, at pH6.4, P1158S only displayed the 
myotonic phenotype (Figure 2-10E); however, at the less extreme pH of 7.0, P1158S 
displayed both myotonia and periodic paralysis (Figure 2-10F). At pH7.4 and pH8.0, 
P1158S only showed periodic paralysis (Figure 2-10G-H). 
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Figure 2-10 Skeletal muscle action potential modeling.  
(A) Shows single action potential simulations of WT and P1158S channels at the physiological pH 
of 7.4. The stimulation pulse of 50 µA/cm2 was applied for 2.0 ms (WT) and 1.2 ms (P1158S). (B) 
Shows the T-Tubule potassium concentration in WT and P1158S. The potassium concentration is 
proportional to amount of sodium late currents. (C-D) Show long stimulation pulse from 50-350 ms 
in WT, and P1158S at all four pH points. (E-H) Show P1158S at pH6.4, 7.0, 7.4, and 8.0. 
2.5. Discussion  
Periodic paralysis and myotonia represent two life-limiting conditions. Interestingly, 
they fall at the opposite extremes of the disease-spectrum caused by Nav1.4-related 






sought to understand how replacing one amino acid might cause both myotonia and 
hypoPP. Our investigations began with a quest to find common ground between myotonia 
and periodic paralysis. Because exercise is a common trigger for both conditions, we 
focused on physiological changes caused by exercise. These changes include variations 
in cytosolic calcium levels, blood sugar, pH, body temperature, etc. Previous studies 
characterized P1158S with respect to its temperature sensitivity. A study by Sugiura et al. 
(2003) suggested that the voltage-dependence of activation in P1158S hyperpolarizes 
upon cooling (Sugiura et al., 2003). Furthermore, P1158S can also disrupt slow 
inactivation at cold temperatures (Webb & Cannon, 2008). 
P1158 is fully-conserved in all mammalian Nav subtypes, the eukaryotic cockroach 
sodium channel (NavPaS), and the electric eel sodium channel (EeNav1.4) (Shen et al., 
2017; Yan et al., 2017). The mutation of this vital proline to leucine (P1308L) in Nav1.7 
has been implicated in causing inherited erythromelalgia (IEM). IEM is characterized by 
intermittent burning pain and skin redness in hands and feet. This condition is usually 
triggered by warmth or exercise (Cheng et al., 2010b). Therefore, P1308L in the neuronal 
Nav1.7 shares some of the triggers with P1158S in skeletal muscles. 
We examined whether exercise-induced acidosis can modulate P1158S. Although 
it is reported that during exercise the skeletal muscle tissue pH may drop to as low as 
pH6.4, our previous study found that Nav1.4 is relatively unaffected by extracellular 
acidosis compared to Nav1.2 and Nav1.5 (Hermansen & Osnes, 1972; Vilin et al., 2012a). 
The pH-independent current was suggested to protect skeletal muscle activity during 
exercise-induced acidosis (Khan et al., 2006).  
 We hypothesized that the mutation of P1158 to a serine could lead to exposure of 
protonate-able residues to protons. To test this hypothesis, we took a bottom-up approach. 
We started with a homology model to understand where the conserved P1158 is located 
on a molecular level. The model also enabled us to determine that there is a hinge-angle 
difference in the S4-S5 linker with serine instead of proline. Our next step was to find out 
how much this angle difference would affect the electrophysiology of Nav1.4. The patch-
clamp experiments indicated that P1158S causes Nav1.4 to become a pH-sensitive 
sodium channel, with similar pH-sensitivity to Nav1.5 (Vilin et al., 2012a). During 
extracellular acidosis, the voltage-dependence of activation and steady-state fast 
inactivation depolarized, current density decreased, and late currents were larger. 
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Previous studies on Nav1.5-mutants, S1787N and S1103Y, have shown that 
intracellular acidosis can modulate channel gating leading to arrhythmias (Plant et al., 
2006; Hu et al., 2015). To determine whether intracellular pH changes can also modify the 
gating characteristics of P1158S in Nav1.4, we repeated experiments under acidic 
intracellular conditions. We found intracellular acidosis to have minimal effects. This 
suggests the pH-dependence in P1158S is due to the unmasking of protonate-able 
extracellular residues by the mutation.  
Changes in the sodium channel expression in NG108-15 cells can alter current 
and conductance densities, leading to downstream changes in action potential generation 
(Liu et al., 2012). We observed a difference in current and conductance densities between 
WT and P1158S, raising the possibility that the mutant might alter channel trafficking and 
expression. Our confocal microscopy results eliminated this possibility, leaving the mutant 
effect on channel gating as the most parsimonious explanation for differences in current 
and conductance densities.  
Lastly, to understand how the pH-dependent changes in P1158S can cause the 
described phenotypes, we ran action potential simulations. These simulations predict that 
during alkalosis, such as while hyperventilating (Johnson, 2017), P1158S can cause 
periodic paralysis. However, in the presence of a long stimulus, extreme acidosis can 
trigger myotonia in P1158S. This is interesting because it is suggested that a pH decrease 
in muscle cells could alleviate paralytic attacks in some patients (Kuzmenkin et al., 2002). 
Furthermore, P1158S requires a shorter stimulation period to activate compared to WT-
Nav1.4. The simulated action potential patterns in P1158S are consistent with the 
phenotypes associated with periodic paralysis- and myotonia-specific mutants (Cannon, 
2012, 2015).  
The molecular mechanism of Nav1.5-proton interactions suggest two mechanisms 
of proton block. The first mechanism involves the selectivity filter. There are four residues 
in the P-loop that compose the selectivity filter (DEKA), which along with another four 
carboxylate residues (EEDD) cause sodium permeation (Terlau et al., 1991; Favre et al., 
1996; Balser et al., 1996). These residues are fully conserved across the sodium channel 
superfamily. The carboxylates of these residues can get protonated during acidosis. The 
second mechanism involves the protonation of C373. The pH-insensitivity of Nav1.4 has 
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been attributed to the absence of C373, and the presence of the homologous Y401 in its 
place (Khan et al., 2006; Jones et al., 2013b).  
In addition to the two modes of proton block, a third mode of action exists where 
protons interact with channel voltage-sensors (Jones et al., 2013a). We propose that the 
interaction of protons with the channel voltage-sensors can occur in Nav1.4. Based on the 
sliding-helix model (Yarov-Yarovoy et al., 2012), our results suggest that the mechanism 
through which P1158S imparts pH-sensitivity in Nav1.4 might involve a change in mobility 
of the DIII S4-S5 linker. Indeed, gating current studies indicate that in Nav1.4, DIII 
activates prior to DI and DII, suggesting that changes in this linker’s structure could have 
downstream effects on the mobility of the rest of the channel (Gosselin-Badaroudine et 
al., 2012). As a result, the outer vestibule residues that are normally hidden from protons 
during acidosis, could become exposed, and thus mediate pH-sensitivity. This idea is at 
least partly supported by the upward conformation of VSDIII in the EeNav1.4 cryo-EM 
structure (Yan et al., 2017). Future experiments should test this idea using fluorescently 
labeled residues within the voltage-sensors (Chanda & Bezanilla, 2002; Peters et al., 
2017). 
Cations at the extracellular side of the sodium channel VSD modulate gating 
charges and fast inactivation, hence the presence of protons impedes the immobilization 
of gating charges (Jones et al., 2013a). Previous studies on Nav1.5 indicate a destabilized 
fast inactivation at low pH. This suggests that protons disrupt charge immobilization 
through a direct interaction with the extracellular carboxylates of DIII and DIV VSDs (Jones 
et al., 2013b, 2013a). Interestingly, unlike cardiac tissue, the skeletal muscle pH changes 
more frequently, which may have contributed to the evolution of the pH-insensitive current 
in Nav1.4 (Hermansen & Osnes, 1972; Khan et al., 2002, 2006). We suggest that the 
P1158S mutant likely exposes the carboxylates of the DIII VSD, pushing the Nav1.4 gating 
properties towards Nav1.5. The identity and exact location of these carboxylates need to 
be determined in future studies. 
In conclusion, we characterized a naturally occurring mutation that increases pH-
sensitivity in Nav1.4. From a clinical perspective, we identified pH as a potential trigger for 
periodic paralysis and myotonia in patients with P1158S. Any activity that alters the blood 
pH balance in P1158S patients could trigger the mutant phenotypes.   
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Chapter 3. Inhibitory effects of cannabidiol on 
voltage-dependent sodium currents 
This chapter describes the work published in (Ghovanloo et al., 2018c) with minor 
modifications and formatting changes to suit the thesis style. 
3.1. Abstract 
Cannabis sativa contains many related compounds known as phytocannabinoids. 
The main psychoactive and non-psychoactive compounds are Δ9-tetrahydrocannabidiol 
(THC) and cannabidiol (CBD), respectively. Much of the evidence for clinical efficacy of 
CBD-mediated anti-epileptic effects has been from case reports or smaller surveys. The 
mechanisms for CBD’s anticonvulsant effects are unclear and likely involve non-
cannabinoid receptor pathways. CBD is reported to modulate several ion channels, 
including sodium channels (Nav). Evaluating therapeutic mechanisms and safety of CBD 
demands a richer understanding of its interactions with central nervous system targets. 
Here, we used voltage-clamp electrophysiology of HEK-293 cells and iPSC neurons to 
characterize the effects of CBD on Nav channels. Our results show that CBD inhibits 
hNav1.1-1.7 currents, with an IC50 of 1.9–3.8 μM, suggesting that this inhibition could 
occur at therapeutically relevant concentrations. A steep Hill slope of ~3 suggested 
multiple interactions of CBD with Nav channels. CBD exhibited resting-state blockade, 
became more potent at depolarized potentials, and also slowed recovery from inactivation, 
supporting the idea that CBD binding preferentially stabilizes inactivated Nav channel 
states. We also found that CBD inhibits other voltage-dependent currents from diverse 
channels, including bacterial homomeric Nav channel (NaChBac) and voltage-gated 
potassium channel subunit Kv2.1. Lastly, the CBD block of Nav was temperature-
dependent, with potency increasing at lower temperatures. We conclude that CBD’s mode 
of action likely involves (1) compound partitioning in lipid membranes, which alters 
membrane fluidity affecting gating, and (2) undetermined direct interactions with sodium 
and potassium channels, whose combined effects are loss of channel excitability. 
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3.2. Introduction 
The cannabis plant is composed of over 100 compounds known as 
phytocannabinoids (Lerner, 1963). Among these phytocannabinoids, CBD, is of great 
interest due to its lack of potency on CB1 and CB2 receptors that are thought to mediate 
psychotropic activity. Interactions with these receptors by yet another cannabinoid, THC, 
at sub-micromolar concentrations cause the well-known ‘cannabis’ effects (Pertwee, 
2008). Recently, reports of the use of CBD as an anticonvulsant agent have been rapidly 
increasing (Devinsky et al., 2017); however, to date, there is no consensus on a well-
defined mode of action for the CBD-mediated anti-epileptic effects. 
As CBD has a lower affinity for the endocannabinoid receptors than THC (Straiker 
et al., 2018), several studies suggest that the anticonvulsant effects of THC and CBD in 
maximal electroshock (ED50 ~120 mg/kg, brain concentration ~ 22 µM) and pilocarpine 
models occur via different mechanisms (Deiana et al., 2012; Devinsky et al., 2014). 
Whereas the THC activity is mostly on the CB1 receptor, the anticonvulsant effects of CBD 
are not. These findings have inspired the growth of CB1- and CB2-independent-focused 
research. Many mechanisms have been proposed for the action of CBD on different 
systems. CBD acts as an agonist on human TRP channels (3-30 µM), and specifically on 
TRPV1 (Ledgerwood et al., 2011; Ibeas Bih et al., 2015), which is in part responsible for 
calcium channel modulation (Blumenfeld et al., 2009). CBD also inhibits heterologously 
expressed Cav3.1, Cav3.2, and native neuronal T-type voltage-gated calcium channels 
(Ross et al., 2008). These low-voltage activated channels also can be blocked by other 
anti-epileptic drugs such as zonisamide (Porter & Jacobson, 2013). In addition to Cav 
channels, CBD inhibits persistent and resurgent sodium currents generated by WT-Nav1.6 
channels, and the exacerbated versions of these currents in GOF epilepsy-causing 
Nav1.6-mutants (Patel et al., 2016). A recent human clinical trial has indicated that CBD 
(dosed at 20 mg/kg) is efficacious against drug-resistant seizures in Dravet syndrome 
(Devinsky et al., 2017). Previous investigations of the cannabis-mediated blockade of Nav 
channels have determined that CBD (10 µM) significantly decreases action potential 
frequency in rat CA1 hippocampal neurons and Nav current density in human 
neuroblastoma cells and mouse cortical neurons (Hill et al., 2014). Other studies have 
used dissociated hippocampal cultures derived from embryonic day 18 rats to measure 
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toxicity and neuroprotective responses to CBD. These studies indicate that the EC50 of 
CBD is within the 1-4 µM range, while causing neurotoxicity at 33 µM (Kinney et al., 2016). 
The transient sodium current through Nav channels initiates action potentials in 
neurons, skeletal muscles, and cardiac muscles. Any changes to the gating properties of 
these channels, and subsequently the current passed through them during an action 
potential can cause extremely life-limiting conditions that can sometimes be lethal. Both 
GOF and LOF in sodium channels disrupt electrical signaling (Catterall, 2012; Ghovanloo 
et al., 2016b, 2016a, 2018a).  
In the primary sodium channel isoforms of the CNS, Nav1.1, 1.2, 1.3, and 1.6, both 
GOF and LOF elicit epilepsy syndromes (Catterall, 2010; Estacion et al., 2010; Veeramah 
et al., 2012; Ghovanloo et al., 2016b). These include relatively mild epilepsies, like benign 
familial neonatal-infantile seizures, and more severe forms, such as Dravet syndrome 
(Heron et al., 2002; Scalmani et al., 2006; Dravet, 2011) and early-infantile epileptic 
encephalopathy-13 (O’Brien & Meisler, 2013).  
Compounds that inhibit Nav current have been used extensively for clinical 
treatment of all of the above hyperexcitability disorders (George, 2005). In this study, we 
sought to characterize, in detail, the biophysical effects of CBD on peripheral and CNS 
sodium channel isoforms. 
3.3. Methods 
3.3.1. Cell culture 
Suspension Human Embryonic Kidney (HEK-293) cells were used for automated 
patch-clamp experiments. HEK-293 cells were either stably transfected using inducible 
protein expression - T-REx™ system, or transiently transfected using Lipofectamine 2000 
with sodium α-subunit cDNA constructs. The human SCN1B cDNA construct was co-
transfected into each cell line. The stable cell lines were maintained under Zeocin (5 µg/ml) 
and G418 (1 mg/ml) selection in DMEM (Dulbecco's Modified Eagle's Medium), 10% FBS 
(Fetal Bovine Serum) and 2mM L-Glutamine media. The hNav1.1 F1763A and the 
hNav1.6 N1768D mutations were generated using the QuickChange site-directed 
mutagenesis kit (Agilent Technologies). GABAergic iPSC neurons were purchased from 
Cellular Dynamics International, (Madison, WI, USA). The cells were seeded at 20-40% 
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confluency onto glass cover slips and cultured up to 4 weeks according to user’s guide 
provided by the vendor. All cells were incubated at 37 ˚C/5% CO2. All cell culture reagents 
were purchased from ThermoFisher Scientific, Waltham, MA, unless otherwise noted. 
3.3.2. Automated patch-clamp 
Automated patch-clamp recording was used for all experiments unless otherwise 
noted. HEK cell lines stably expressing the full-length cDNAs coding each Nav α-subunit 
were generated. The human β1-subunit was co-expressed in each of internally generated 
cell lines. GenBank accession numbers for α-subunits were: Human Nav1.1 
(NM_006920), hNav1.2 (NM_021007), hNav1.3 (AF225987), hNav1.4 (NM_000334), 
hNav1.5 (AC137587; SCN5A), hNav1.6 (NM_014191), mNav1.6 (NM_ 001077499) and 
hNav1.7 (NM_002977). Sodium currents were measured in the whole-cell configuration 
using a Qube-384 (Sophion A/S, Copenhagen, Denmark) automated voltage-clamp 
system. To determine inhibition of the inactivated-state, the membrane potential was 
maintained at a holding-potential (HP) where inactivation of the channel subtype is 
complete. Membrane holding voltages used for subtype selectivity experiments were: -60 
mV (hNav1.5 and hNav1.7), -45 mV (hNav1.1, hNav1.2, hNav1.3, hNav1.4, hNav1.6, and 
mNav1.6). In the protocol used to assess inhibition for hNav1.5 and hNav1.7 a brief 
hyperpolarization to a negative (Vhold = -150 mV) voltage for 20 ms was applied at 1 Hz to 
recover fast inactivated channels but not compound bound channels and then a 20 ms 
test pulse to 0 mV was applied to quantify the fractional availability of channels. For 
hNav1.1, hNav1.2, hNav1.3, hNav1.4, and hNav1.6 the recovery period was 60 ms 
applied at a frequency of 0.05 Hz. Intracellular solution contained (in mM): 120 CsF, 10 
NaCl, 2 MgCl2, 10 HEPES, adjusted to pH7.2 with CsOH. The extracellular recording 
solution contained (in mM): 145 NaCl, 3 KCl, 1 MgCl2, 1.5 CaCl2, 10 HEPES, adjusted to 
pH7.4 with NaOH. For some studies, a flipped Na+ gradient was used where the 
extracellular solution contained (in mM): 125 choline chloride, 1 NaCl, 5 KCl, 2 CaCl2, 1 
MgCl2, 10 HEPES/NaOH, pH7.4, and the intracellular solution contained (in mM): 115 
NaF, 15 CsCl2, 5 CsF, 3 Na2ATP, 0.3 Na2GTP, 2 MgCl2, 0.1 CaCl2, 10 EGTA, 10 
HEPES/CsOH, pH7.2. Liquid junction potentials calculated to be ~7 mV were not adjusted 
for. Currents were low pass filtered at 5 kHz and recorded at 25 kHz sampling frequency. 
Series resistance compensation was applied at 100% and leak subtraction enabled. The 
Qube-384 temperature controller was used to manipulate recording chamber temperature 
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for certain experiments. The rest of the measurements were obtained at room temperature 
which corresponds to 27 ± 2 ˚C at the recording chamber. Appropriate filters for cell 
membrane resistance (typically >500 MΩ), Series resistance (<10 MΩ) and Nav current 
magnitude (>500 pA at a test pulse from a resting HP of -120 mV) were routinely applied 
to exclude poor quality cells. Vehicle (0.5% DMSO) controls were run on each plate to 
enable correction for any compound independent decrease of currents over time. 
Baselines were established after 20 minutes in vehicle. Fractional inhibition was measured 
as current amplitude from baseline to maximal inhibition after 20-minute exposure to test 
compound unless otherwise noted. Maximal inhibition was established by application of 
300 nM tetrodotoxin (TTX) to each well at the end of the experiment apart from for Nav1.5 
for which 30 uM tetracaine was used. Normalized mean inhibition data were fit to the Hill-
Langmuir equation: 
Y = [C]h/(IC50h+[C]h)   (Eq. 1) 
to estimate the half maximal inhibitory concentration (IC50 value); where Y is the 
normalized inhibition, C the compound concentration, IC50 the concentration of test 
compound to inhibit the currents 50%, and h the Hill coefficient. Data analysis was 
performed using Analyzer (Sophion A/S, Copenhagen, Denmark) and Prism (GraphPad 
Software Inc., La Jolla, CA, USA) software. IC50 values on the Qube-384 automated 
voltage-clamp platform were generated from Hill equation fits to pooled data at each 
concentration so do not have standard errors. 
3.3.3. Manual patch-clamp 
Whole-cell patch-clamp recordings were obtained using an Axopatch 200B patch-
clamp amplifier (Molecular Devices, Sunnyvale, CA) controlled and recorded using 
pClamp8 (Molecular Devices, Sunnyvale, CA). The recording pipette intracellular solution 
contained (in mM): 120 CsF, 10 NaCl, 2 MgCl2, 10 HEPES, adjusted to pH7.2 with CsOH. 
Pipette resistances were 2-5 MOhm. The extracellular recording solution contained (in 
mM): 145 NaCl, 3 KCl, 1 MgCl2, 1.5 CaCl2, 10 HEPES, adjusted to pH7.4 with NaOH. 
Currents were low-pass-filtered at 5 kHz and recorded at 25 kHz sampling frequency using 
a Digidata1440 (Molecular Devices, Sunnyvale, CA). Series resistance compensation was 
applied at 60-80%. Experiments were performed at room temperature 19-20 ˚C. Liquid 
junction potentials calculated to be ~7 mV were not adjusted for. 
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3.3.4. Compound preparation 
CBD was purchased from Cayman Chemicals and THC was purchased from 
Toronto Research Chemicals in powder form. Powdered CBD and THC were dissolved in 
100% DMSO to create stock. The stock was used to prepare drug solutions in extracellular 
solutions at various concentrations with no more than 0.5% total DMSO content.  
3.3.5. Manual patch-clamp IC50 measurements 
IC50 measurements were made while holding the membrane voltage at -45 mV. To 
activate sodium channels, a 60 ms pre-pulse to -150 mV was used to recover channels 
from fast-inactivation, followed by a 10 ms pulse to -20 mV to open the channel. Using this 
protocol at a 1 Hz pulse rate, the membrane voltage is maintained at -45 mV 97% of the 
time. The peak of the inward sodium current at -20 mV was measured and a stable 
baseline was established prior to perfusion with compound, after which increasing 
concentrations of compound were perfused and resulting currents measured after 
equilibrium was obtained.  
3.3.6. Activation protocols 
To determine the voltage-dependence of activation, we measured the peak current 
amplitude at test pulse potentials ranging from −100 mV to +80 mV in increments of +5 
mV for 100 ms. Channel conductance (G) was calculated from peak INa: 
GNa=INa/V−ENa   (Eq. 2) 
where GNa is conductance, INa is peak sodium current in response to the command 
potential V, and ENa is the Nernst equilibrium potential. Calculated values for conductance 
were fit with the Boltzmann equation: 
G/Gmax=1/(1+exp[[V1/2−Vm]/k)   (Eq. 3) 
where G/Gmax is normalized conductance amplitude, Vm is the command potential, V1/2 is 
the midpoint voltage and k is the slope. 
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3.3.7. Steady-state fast-inactivation protocols 
The voltage-dependence of fast-inactivation was measured by preconditioning the 
channels from −120 to +10 mV in increments of 5 mV for 100 ms, followed by a 10 ms test 
pulse during which the voltage was stepped to -20 mV. Normalized current amplitudes 
from the test pulse were fit as a function of voltage using the Boltzmann equation: 
I/Imax=1/(1+exp[[V1/2−Vm]/k)   (Eq. 4) 
where Imax is the maximum test pulse current amplitude. 
3.3.8. State-Dependence protocols 
To determine state-dependence, potency was measured from four different 
holding-potentials (-100, -90, -80, -70 mV). The protocol started with a holding-potential of 
-100 mV followed by 180 x 20 ms depolarizing pulses to 0 mV at 1 Hz. Then, the holding-
potential was depolarized by 10 mV, and the 180-pulse protocol was repeated until -70 
mV was reached.  
3.3.9. Recovery from inactivation protocols 
Recovery from inactivation was measured by holding the channels at -120 mV, 
followed by a depolarizing pulse to 0 mV, then the potential was returned to -120 mV. This 
was followed by a depolarizing 10 ms test pulse to 0 mV to measure availability. Recovery 
from inactivation was measured after pre-pulse durations of 300 ms and 10 s and fit with 
a bi-exponential function of the form: 
SpanFast = (Y0-Plateau) * PercentFast * 0.01   (Eq. 5) 
SpanSlow = (Y0-Plateau) * (100-PercentFast) * 0.01    (Eq. 6) 
Y = Plateau + SpanFast * exp(-KFast * t) + SpanSlow * exp(-KSlow * t)  (Eq. 7) 
where t is time in seconds, Y0 is the Y intercept at t=0, KFast and KSlow are rate constants 
in units the reciprocal of t, PercentFast the fraction of the Y signal attributed to the fast 
decaying component of the fit. 
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3.3.10. Kinetics at varying temperatures 
 The kinetics of CBD block were measured at three temperatures: 20, 28, and 33 
˚C. The channels were held at -45 mV followed by a recovery pulse to -150 mV for 60 ms. 
The blocked sodium current was normalized to vehicle and subsequently fit with a single 
exponential function: 
Y = (Y0 - Plateau) * exp(-K * t) + Plateau    (Eq. 8) 
3.3.11. Action potential modeling 
Neuronal action potential modeling was based on a modified Hodgkin-Huxley 
model (Hodgkin & Huxley, 1952). The model was modified to match the properties of 
cortical pyramidal cells (Yi et al., 2017). The modified parameters were based on 
electrophysiological results obtained from whole-cell patch-clamp experiments in this 
study. The model accounted for activation voltage-dependence, steady-state fast-
inactivation voltage-dependence, and peak sodium currents. 
3.3.12.  Homology modeling 
Homology modeling was performed using the Swiss-Model server. The cryo-EM 
sodium channel structure of Navpas was used as a template against which the hNav1.1 
sequence was modeled (Bordoli et al., 2008; Shen et al., 2017). Modeling was done 
according to the protocol established by Bordeli et al., (2008). 
3.3.13. Molecular docking 
The homology model of hNav1.1 and SMILES structure of CBD were imported into 
Chimera. The structures were energetically minimized, and the lowest energy structure 
was determined as the most likely molecular interaction. 
3.3.14. Immunocytochemistry 
HEK cells stably transfected with the β1-subunit and hNav1.1 α-subunits were 
incubated for 24 hours with 0 (vehicle) and 5 µM CBD. After this incubation period, cells 
were fixed in 4% paraformaldehyde for 10 minutes while being incubated on a shaker. 
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Then, cells were incubated in 0.1% Triton X-100 for a further 10 minutes. Cells were 
blocked in 10% goat serum for 30 to 45 minutes. Following this step, diluted primary anti-
hNav1.1 (1:100, Mouse monoclonal IgG, commercially available via UC Davis/NIH 
NeuroMab Facility) antibodies were added. The next day, cells were incubated in PBS for 
10 minutes. Lastly, secondary Alexa Fluor 546 IgG (1:500) and Hoe33342 (nuclear stain) 
were added. Stained cells were studied using a Nikon confocal microscope. Images were 
analyzed using ImageJ. 
3.3.15. Lipid binding assessment 
Made using the TRANSILXL Brain Absorption Kit (ADME Cell) as per 
manufacturer's instructions. 
3.3.16. Statistics 
A one-factor analysis of variance (ANOVA) was used to compare the mean 
responses. Post hoc tests using the Tukey Kramer adjustment compared the mean 
responses between channel variants across conditions. A level of significance α = 0.05 
was used in all overall post hoc tests, and effects with p-values less than 0.05 were 
considered to be statistically significant. All values are reported as means ± standard error 
of means (SEM) for n cells.  
3.4. Results 
3.4.1. CBD is an inhibitor of human sodium currents 
Previous reports suggested that Nav currents are inhibited by micromolar 
concentrations of CBD but lacked detailed concentration-response data and defined 
potencies. We sought to determine whether CBD has any selectivity across the sodium 
channel superfamily. Thus, we measured the concentration-dependence of inhibition of 
inactivated-state sodium channels by CBD. Our results demonstrate that CBD inhibits 
hNav1.1-1.7 with low micromolar potency (Figure 3-1A, D). To construct the 
concentration-response, individual cells were exposed to single concentrations of CBD, 
then normalized inhibition at each concentration was pooled and fit with a Hill Langmuir 
equation, providing IC50 and Hill-slopes (Figure 3-1A). Representative current traces at 
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approximately IC50 concentrations for each subtype tested are shown in (Figure 3-1C). 
Interestingly, the sodium current inhibition has very steep Hill-slopes of >2 across all 
subtypes (Figure 3-1A, D). This indicates that CBD does not likely inhibit the channel 
currents through a 1:1 binding mechanism, but instead suggests multiple interactions 
contribute to this inhibition. Although there is some variation in the IC50 values obtained 
on each subtype, the steep Hill-slopes make IC50 values extremely sensitive to small 
changes in concentration, which could account in part for this variation of ~2-fold in IC50. 
Similar to the hNav channels, CBD also inhibited the mouse Nav1.6 (mNav1.6) current 
suggesting these human IC50 values hold in rodent isoforms (Figure 3-1A, D).  
 
Figure 3-1 CBD & THC inhibits Nav currents. 
(A) The IC50 curves of CBD block on hNav1.1-1.7 and mNav1.6. The chemical structure of CBD is 
shown on the top left corner. (B) THC IC50 of hNav1.2 compared with CBD. The pulse protocols 
used, and chemical structure of THC are shown on the bottom right. Channels were exposed to 
each compound for 20 min. (C) Representative current traces at IC50 in each sodium channel. 
Traces are taken from the concentrations that are closest to IC50. (D) Table of IC50 and Hill-slope 
fitted parameters (n = 3-15 cells exposed at each concentration, SE quoted are errors of the fit). 
3.4.2. THC inhibition of Nav currents 
The chemical structures of CBD and THC are very similar, with the sole difference 









hNav1.1 - CBD 2.0 ± 0.1 3.1 ± 0.2 1.9
hNav1.2 - CBD 2.9 ± 0.1 3.4 ± 0.3 1.7
hNav1.3 - CBD 3.3 ± 0.1 3.0 ± 0.3 3.7
hNav1.4 - CBD 1.9 ± 0.1 2.0 ± 0.2 1.9
hNav1.5 - CBD 3.8 ± 0.2 3.2 ± 0.6 3.3
hNav1.6 - CBD 3.0 ± 0.1 3.1 ± 0.2 1.9
hNav1.7 - CBD 2.9 ± 0.1 2.6 ± 0.4 3.3
hNav1.2 - THC 2.4 ± 0.1 1.4 ± 0.1 3.1
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that this difference is the structural basis for the functional differences between CBD and 
THC, we tested THC against hNav1.2. Our results suggest that although the potency of 
the sodium current inhibition between THC and CBD is similar, the Hill-slope associated 
with THC is less steep (Figure 3-1B, D). This may indicate that THC has some differences 
in the mechanism of sodium current inhibition than CBD.  
3.4.3. CBD prevents Nav channels from opening   
We next examined the effects of CBD on Nav channel activation by measuring 
peak channel conductance at membrane potentials between -120 and +30 mV. We show 
the effects of 3.3 µM CBD on peak sodium current densities (Figure 3-2A) and a plot of 
conductance (Figure 3-2B). About ~90% of the sodium conductance was inhibited. The 
normalized conductance is plotted against membrane potential, showing that CBD does 
not induce large changes in either the midpoint (V1/2) or apparent valence (slope, k) of 
activation of the available sodium channels (p>0.05) (Figure 3-2C). Therefore, exposure 
to CBD at this concentration prevents channels from conducting; however, this exposure 
does not alter the voltage-dependence of activation.  
We next measured the voltage-dependence of fast-inactivation. The normalized 
current amplitudes at the test-pulse is shown as a function of pre-pulse voltages (Figure 
3-2D). The current at the test-pulse was inhibited by over 90%; however, unlike activation, 
the voltage-dependence of steady-state fast-inactivation of the remaining current was 
hyperpolarized by 8.1 mV (p=0.0002). This indicates CBD increased the propensity for 
channels to inactivate over the 500 ms pre-pulse in channels that were not inhibited from 
opening from rest, suggesting that CBD stabilizes the inactivated-state of sodium 
channels.  
It was previously shown that 1 µM CBD inhibits the persistent and resurgent 
sodium currents in form of epilepsy caused by hNav1.6 GOF mutation, N1768D, which 
displays a non-inactivating component (Patel et al., 2016). We also found that CBD inhibits 
the resurgent current induced by including 200 µM ß4-peptide to the intracellular solution. 
Figure 3-2E shows that 5 µM CBD inhibits the majority of resurgent currents, which is 
consistent with CBD preventing channels from opening (Figure 3-2A). Next, we sought to 
establish the concentration-dependence of CBD inhibition of the persistent current of the 
inactivation-deficient N1768D mutant. We found that persistent currents were inhibited at 
61 
slightly lower concentrations than the peak currents, suggesting there may be interactions 
between CBD and the open or inactivated-states over the course of a 100 ms 
depolarization (Figure 3-2F).  
 
Figure 3-2 CBD effects on activation, steady-state fast-inactivation (SSFI), 
resurgent, & persistent currents. 
(A) Conductance difference in hNav1.1 in vehicle and 3.3 µM CBD concentration (Veh: V1/2 = -42.5 
± 0.8, slope = 3.1 ± 0.7, n = 11; CBD: V1/2 = -39.6 ± 1.8, slope = 4.6 ± 1.5, n = 5). (B) Average 
current density of hNav1.1 in vehicle and CBD (Veh: current density = -75.3 ± 8.9 pA/pF, n = 11; 
CBD: current density = -6.8 ± 3.0 pA/pF, n = 5). (C) Voltage-dependence of activation as normalized 
conductance plotted against membrane potential (Vehicle: V1/2 = -41.9 ± 0.4 mV, Slope = 3.6 ± 0.4, 
n = 7; CBD: V1/2 = -40.3 ± 1.0 mV, Slope = 7.2 ± 0.9, n = 5). (D) Voltage-dependence of SSFI as 
normalized current plotted against membrane potential (Vehicle: V1/2 = -69.7 ± 0.2 mV, Slope = 5.0 
± 0.2, n = 12; CBD: V1/2 = -77.8 ± 0.3 mV, Slope = 5.8 ± 0.3, n = 5). (E) Resurgent current block in 
hNav1.6 (Veh: resurgent density = -33.9 ± 4.8 pA/pF, n = 11; CBD: resurgent density = -7.3 ± 1.2 
pA/pF, n = 23; TTX: resurgent density = -3.3 ± 0.7 pA/pF, n = 31). (F) IC50 of CBD block of peak 
and persistent currents in hNav1.6 mutant (N1768D) (Peak: IC50 = 10.0 ± 0.7 µM, slope = 2.0 ± 0.4, 
n = 3-11; Persistent: IC50 = 6.4 ± 1.0 µM, slope = 1.3 ± 0.2, n = 3-9).  
3.4.4. CBD stabilizes inactivated-states of Nav channels  
We used a protocol to examine state-dependent inhibition across a range of 
holding-potentials where channel inactivation varies (Kuo & Bean, 1994). We first held 
channels at a holding-potential of -100 mV where channels are almost all in the resting-
state, while pulsing the channels 180 times at 1 Hz to allow CBD to reach equilibrium. 
Then, we depolarized the holding-potential by 10 mV three more times and repeated the 
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pulse train at each voltage (Figure 3-3A). We show the fractional block of sodium currents 
from the last pulse (180th) from each holding-potential (Figure 3-3B). Figure 3-3C shows 
a plot of the inverse of the apparent IC50 fit with a 4-state binding model that used 
parameters obtained from the Boltzmann fit of the voltage-dependence of steady-state 
fast-inactivation. This established that the apparent potency is directly related to the 
proportion of inactivated channels at different holding-potentials. Our results demonstrate 
that CBD inhibits the sodium current from both rest and inactivated-states; however, the 
potency of CBD is about 10-fold greater for inhibiting inactivated compared to resting-
states (Figure 3-3C). 
To assess the time-dependence and degree of stabilization of the inactivated-state 
we then measured the recovery from inactivation of hNav1.6 in the presence of 3.7 µM 
CBD (Figure 3-1A). This was done after depolarizing pre-pulse durations of 300 ms and 
10 s, from a holding-potential of -120 mV. These pre-pulse durations correspond to 
inactivation recovery from fast and slow inactivated-states, respectively. The mean 
normalized recovery following the pre-pulse in CBD and control conditions were plotted 
and fit with a bi-exponential function (Figure 3-3D-E). The 𝞃Slow and fraction of the recovery 
fit with 𝞃Slow are plotted in (Figure 3-3F), which shows that CBD increases the fraction of 
recovery that is slow and the time constant of the slow component of recovery from 
inactivation from 300 ms to 10 s. This indicates that CBD slows the recovery from 




Figure 3-3 State-dependent inhibition of Nav current by CBD & effects on 
recovery from inactivation. 
(A) Pulse protocol showing 180 pulses run at 1 Hz at each holding-potential and representative 
current traces. (B) CBD potency at four holding-potentials at pulse 180 (3 min) (IC50 (µM): -100 mV 
= 12.7 ± 1.0, -90 mV = 10.3 ± 0.5, -80 mV = 6.7 ± 0.4, -70 mV = 2.9 ± 0.6; n = 2-6). (C) Apparent 
Kd at different voltages was well fit with a 4-state model invoking different potencies for resting and 
inactivated-state block. (D-E) Recovery from inactivation in 3.7 µM CBD at: 300 ms (Veh: 𝞃Fast = 
0.00173 s, 𝞃Slow = 0.0688 s, n = 35; CBD: 𝞃Fast = 0.00654 s; 𝞃Slow = 0.516 s; n = 3) and 10 s (Veh: 
𝞃Fast = 0.0715 s, 𝞃Slow = 0.696 s, n = 33; CBD: 𝞃Fast = 0.272 s; 𝞃Slow = 8.72 s; n = 3). (F) The slow 
components of recovery from inactivation in vehicle and CBD at 300 ms and 3 s are shown on the 
left Y-axis, and the fraction of slow to fast component of recovery from inactivation is shown on the 
right Y-axis.  
3.4.5. CBD potency is increased at lower temperatures 
Binding kinetics are typically responsive to changes in temperature, with higher 
temperatures increasing the rates of compound equilibration. To further investigate the 
mode of CBD interaction with sodium channels, we measured the observed rates of 
equilibration (time constant observed, 𝞃obs) of inhibition by fitting single exponential decays 
to inhibition of currents at three different temperatures. We examined the kinetics at 
concentrations above the IC50 to ensure a clear inhibition signal window to define the 𝞃obs 
(Figure 3-4A-C). Channels were held at -45 mV and pulsed at 1 Hz following a recovery 
pulse to -150 mV for 60 ms and CBD was rapidly applied to the cells at different 
concentrations (Figure 3-4A). The fraction of inhibition was normalized against the 
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response in vehicle and plotted against the time elapsed after CBD addition which was 
set at t = 0. The inhibition was then fit with a single exponential function to obtain 𝞃obs and 
plotted against concentration. We show 𝞃obs saturated at a minimum with increasing 
concentrations, counter to the prediction of a single 2-state ligand binding reaction, which 
predicts a continually increasing 𝞃obs with increasing compound concentrations (Figure 3-
4D). This suggests a rate-limiting step in the inhibitory pathway that is not dependent on 
the concentration of CBD in bulk solution as would be expected for binding to a specific 
inhibitory site on the channel. Interestingly, the kinetics of CBD inhibition were also found 
to be more rapid at cooler temperatures (Figure 3-4D). This is the opposite of what is 
expected for a classic inhibitor in a 2-state binding model, where the binding and unbinding 
rate constants, kon and koff, are intrinsically temperature-dependent. These results further 
suggest that CBD does not inhibit conductance through a direct interaction with a single 
specific binding-site on the channel. We also found that the potency of CBD is increased 
at the lower temperatures (Figure 3-4E-F). 
 
Figure 3-4 Lower temperatures increase kinetics & potency of CBD inhibitory 
effects. 
(A-C) The kinetics of CBD block at 20, 28, and 33 ˚C at 50.0, 25.0, 12.5, and 6.3 µM (20 ˚C: 6.3 
µM = 51.0 ± 0.6 s, 12.5 µM = 42.2 ± 0.3 s, 25.0 µM = 21.6 ± 0.4 s, 50.0 µM = 23.3 ± 0.3 s; 28 ˚C: 
6.3 µM = 162.6 ± 0.9 s, 12.5 µM = 87.7 ± 0.2 s, 25.0 µM = 42.8 ± 0.1 s, 50.0 µM = 30.4 ± 0.4 s; 33 
˚C: 6.3 µM = 299.0 ± 9.5 s, 12.5 µM = 137.0 ± 0.5 s, 25.0 µM = 79.2 ± 0.3 s, 50.0 µM = 84.1 ± 0.3 
s, n = 10-14). The variability at the lower concentration of 6.3 µM at 33 ˚C is larger due to the 
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slowing of CBD effect. (D) Time constants associated with the plots at (A-C). (E) IC50 at the noted 
temperatures (IC50 (µM): 20 ˚C = 2.1 ± 0.1, 28 ˚C = 3.4 ± 0.1, 33 ˚C = 4.7 ± 0.2, n = 2-11), the slope 
factor is fixed at 3. (F) Relationship of CBD potency as a function of temperature. 
3.4.6. CBD does not inhibit via interactions at the classic local-
anesthetic pore binding-site 
As CBD inhibition shares a characteristic of classic pore blockers (preference for 
the inactivated-state), we created a pore mutation in the local-anesthetic receptor site in 
hNav1.1 (F1763A) to determine whether the CBD potency was affected. The F1763 
residue is part of a well-established binding-site for many of the most common local-
anesthetics, including Tetracaine (TTC) (Ragsdale et al., 1994). To avoid any impacts on 
potency being caused by the shifts in stability of inactivation in this mutant (WT-hNav1.1 
inactivation V1/2 = -62.0 ± 0.4 mV, Slope = 7.2 ± 0.4, n = 3; F1763A inactivation V1/2 = -
49.3 ± 0.1 mV, Slope = 6.4 ± 0.1, n = 17), we measured inhibition from a holding potential 
of -45 mV where both channels were >50% inactivated. To validate the F1763A-mutant 
channels, we also measured the potency of TTC, and compared the results against WT-
hNav1.1, which showed a drop in potency (Figure 3-5A). For CBD, the F1763A-mutant 
channels only caused a slight drop in potency of approximately 2-fold (Figure 3-5B). 
Molecular docking using a homology model of hNav1.1 based on the eukaryotic cockroach 
cryo-EM structure (Navpas) (Figure 3-6) suggested that CBD may in fact bind close to 
F1763. This suggests that F1763 is not a primary determinant of CBD inhibition, but does 
not rule out the possibility that CBD may interact with other pore residues. 
To determine if CBD could also inhibit other non-human Nav channels, we tested 
it on the bacterial homomeric Nav channel (NaChBac) (Figure 3-5C). Interestingly, we 
found that NaChBac is also blocked by CBD, though with a slightly greater potency 
(Figure 3-5C). Unlike mammalian Nav channels, NaChBac does not fast inactivate (Ren 
et al., 2001). We hypothesized that if the previously observed state-dependence of CBD 
block in hNav channels is dependent upon the fast-inactivation process, then NaChBac 
should not show such a state-dependence. The potency measured at -100 and -55 mV 
suggest that state-dependence also exists in NaChBac; moreover, this effect may be even 
more pronounced than in hNav channels (Figure 3-5D). This may implicate that CBD is 
not dependent upon, or selective amongst, different modes of Nav inactivation.  
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Our findings in the homo-tetrameric NaChBac raises the question of whether CBD 
might also inhibit voltage-gated potassium channels, which are also homo-tetrameric. Our 
results indicate that CBD also inhibits the Kv2.1 current. Current traces are shown (Figure 
3-5E). These findings, along with the previous reports of CBD modulation of calcium 
channel currents support the idea that CBD is a poly-pharmacological inhibitor of voltage-
dependent ionic currents (Ross et al., 2008). 
 
Figure 3-5 CBD block of F1763A-mutant, NaChBac, and Kv2.1. 
(A) TTC block of hNav1.1 (hNav1.1, IC50 = 1.6 ± 0.1 µM, slope = 0.7 ± 0.03; F1763, IC50 ~ 44.1 
µM) with and without the F1763A mutation. (B) F1763A causes a slight decrease in CBD potency 
in hNav1.1 (hNav1.1: IC50= 2.5 ± 0.2 µM, slope = 2.0 ± 0.2, n = 2-6; F1763A: IC50 = 4.8 ± 0.2 µM, 
slope = 4.1 ± 0.6, n = 3-811 cells exposed at each concentration). (C) Shows a comparison of the 
CBD inhibition of hNav1.6, NaChBac, and Kv2.1 (hNav1.6: IC50 = 3.0 ± 0.1 µM, slope = 3.1 ± 0.2, 
n = 2-6; NaChBac: IC50 = 1.5 ± 0.2 µM, slope = 2.8 ± 0.9, n = 1-4; Kv2.1: IC50 = 3.7 ± 0.8 µM, slope 
= 1.1 ± 0.2, n = 1-5 11 cells exposed at each concentration). (D) Shows the state-dependent block 
of NaChBac tested at -55 and -100 mV (-100 mV: IC50= 1.5 ± 0.2 µM, slope = 2.8 ± 0.9, n = 1-4; -
55 mV: IC50 = 0.24 ± 0.05 µM, slope = 2.8 ± 0.9, n = 1-311 cells exposed at each concentration). 
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Figure 3-6 Molecular docking of CBD interaction with F1763 in hNav1.1. 
Molecular docking prediction of at least one of the CBD binding locations inside the Nav pore. This 
is a homology model of hNav1.1 based on eukaryotic Navpas. F1763 is highlighted in orange and 
CBD is indicated in magenta. 
3.4.7. CBD Does Not Alter Trafficking  
 As CBD non-specifically inhibits voltage-dependent currents, we sought to 
establish whether incubation of CBD could affect the channel trafficking to the cell surface 
over the time scale of our voltage-clamp experiments. To address this question, we 
assessed membrane channel distribution in cells incubated overnight with CBD. The 
results indicate that overnight incubation in 5 µM CBD does not alter sodium channel 
trafficking and therefore would not affect trafficking on timescales of the voltage-clamp 
































































Figure 3-7 Analysis of overnight CBD incubation. 
(A) Confocal images of stained HEK cells from the middle confocal plane. The nuclei are stained 
with Hoe33342 (blue) and hNav1.1 is stained with Alexa Fluor-546 (red) (n = 3). (B) Pixel intensity 
grey value was used as a function of the length of cells (distance) from the middle confocal plane 
image. For a typical HEK cell with a diameter of about 13 µm, the majority of both vehicle and CBD 
incubated hNav1.1 channels were localized within the 0 to 3 µm and 11 to 13 µm ranges.  These 
two ranges correspond to the outer cellular edges, indicating that most of the channels seem to be 
concentrated in the proximity of cell membranes. (C) We functionally tested both conditions using 
whole-cell voltage-clamp. The sodium currents of the CBD-incubated channels were inhibited. In 































































shown (Veh: current density = 280.1 ± 67.5 pA/pF, n = 5; CBD: current density = 18.2 ± 3.5 pA/pF, 
n = 6). The comparison is between vehicle and 5 µM CBD following overnight incubation. 
Representative current traces are shown. 
3.4.8. CBD inhibits nav currents in h-iPSC neurons 
To determine whether our observations in HEK cells translate to native neuronal 
voltage-dependent currents, we measured the effects of CBD on human iPSC neurons. 
First, we established that potency established with manual patch-clamp methodology, 
using continuous perfusion of compound, correlated with Qube data by measuring the 
potency of sodium current inhibition of HEK cells expressing hNav1.2. Figure 3-8A shows 
the mean normalized concentration response plot which gave an IC50 value similar to the 
Qube value for hNav1.2. The slightly increased potency in the manual assay can be 
explained by the temperature-dependence data (Figure 3-4), as manual voltage-clamp 
was performed at around 20 ˚C (room temperature) and the Qube IC50 values were 
established at 28 ̊ C (Figure 3-1A). Consistent with our previous results in HEK cells, both 
the neuronal sodium and potassium currents were blocked ~50 % by 1 µM CBD as shown 
by the representative families of current traces in (Figure 3-8D-E). CBD also caused a 
hyperpolarization of ~16 mV in the steady-state inactivation in the remaining available Nav 
channels in iPSCs (p=0.0031), which was similar to the shifts observed in hNav1.1 in HEK 
cells (Figure 3-2D; Figure 3-8B). We also measured the rate time constant of open-state 
fast inactivation at -20 mV, which did not differ significantly before and after CBD perfusion 
(p>0.05) (Figure 3-8C). 
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Figure 3-8 CBD inhibits human iPSC neuronal Nav, & Kv currents. 
(A) Concentration-response relationship for CBD inhibition of hNav1.2 channels obtained using 
manual patch clamp (IC50 = 1.3 ± 0.1 µM, slope = 2.1 ± 0.4, n = 3-6). (B) Plot of normalized SSFI 
after a 100 ms pre-pulse before (V1/2 = -50.0 ± 0.4 mV, slope = 6.4 ± 0.4, n = 3) and after (V1/2 = -
66.1 ± 0.7 mV, slope = 8.1 ± 0.6, n = 3) perfusion. (C) Open-state fast-inactivation time constants 
shown on log scale on the Y-axis at -20 mV for vehicle (-20 mV: 1.3 ± 0.1 ms, n = 3) and CBD (-20 
mV: 1.3 ± 0.4 ms, n = 3) in iPSC neurons. (D) Representative current-voltage relationship recorded 
from iPSC neurons with a KF based internal solution before 1 µM perfusion of CBD and (E) after 
perfusion. Inset in the panel are zoomed-in view of currents at the test-pulse used to assess 
availability. 
3.4.9. CBD reduces neuronal excitability in a Hodgkin-Huxley model of 
cortical neuron 
To test the effect of IC50 concentrations of CBD on neuronal excitability, we used 
a modified version of the Hodgkin-Huxley model to simulate a cortical neuron’s excitability 
(Hodgkin & Huxley, 1952; Yi et al., 2017). In the CBD condition, the sodium and potassium 
conductances were reduced by 50%. The activation and inactivation V1/2 and slopes were 
taken from the results shown in (Figure 3-2C-D). In our simulations, the channels were 
given a series of stepwise current injections with increasing intensities at each step for 
100 ms. Each 100 ms step was followed by a 50 ms recovery period in which no current 
injection was applied (Figure 3-9A). Our results suggest that the peak amplitude of the 
first action potential (AP) in CBD is smaller than vehicle. This is consistent with the 
reduction of peak sodium conductance caused by CBD. Furthermore, in the CBD condition 
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we observed that threshold for the first AP after depolarization was reduced (Figure 3-
9B). The overall effect of CBD on the action potential morphology is that at all current 
injection intensities, CBD reduces the number of action potentials, leading to a net loss of 
excitability. These results are consistent with previous studies using current clamp 
recordings, and may in part theoretically explain the reported efficacy of CBD in treating 
conditions including epilepsy and pain (Khan et al., 2018). 
 
Figure 3-9 CBD reduces excitability in an action potential model & schematic 
representation of CBD’s mode of action. 
(A) Simulation of the effects of CBD on action potential morphology over a series of increasing 
current injection intensities. (B) Zoomed-in simulation of action potentials from the first interval 
shown in (A). (C) Proposed mode of action of CBD involving interactions with both the membrane, 
resting and inactivated sodium channels. 
3.5. Discussion 
 CBD has a weak affinity for CB receptors thus its anticonvulsant properties are 
attributed to modulations of other targets, including ion channels. Our study suggests that 
the Nav channel family is amongst the possible ion channel targets of CBD.  
 Our results in this study suggest that CBD as a sodium channel inhibitor is non-
selective; therefore, we performed some of our experiments on single sodium channel 
subtypes, including the temperature-dependence and channel trafficking assays. We 
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believe that due to the non-specific nature of the interactions, the results obtained from 
single subtypes will be generalizable to the whole sodium channel superfamily. This idea 
is supported by the consistencies we observed between HEK cells that express only a 
single sodium channel subtype, and iPSC neurons, which host several sodium channel 
subtypes in a native environment.  
3.5.1. Mechanisms of sodium current inhibition 
The initial results obtained from the selectivity experiments on hNav channels 
suggested that CBD is indeed a sodium current inhibitor. However, this inhibition is 
relatively non-selective in nature and has a steep average Hill-slope, suggesting multiple 
interactions. Like CBD, we found that THC also inhibits hNav1.2, albeit with a less steep 
Hill-slope. Our results indicated that CBD prevents the activation of sodium channels from 
rest, while also stabilizing the inactivated-states of these channels without altering the 
voltage-dependence of activation. This inhibition has similarities to that reported for 
amphiphilic compounds (Lundbæk et al., 2004; Lundbæk, 2005). It is suggested that 
amphiphilic compounds tend to localize at the solution-bilayer interface. This occurrence 
is made possible by having the polar group of the amphiphile residing at the interface with 
the hydrophobic region, which then gets inserted into the core of the bilayer. This 
partitioning into the lipid bilayer alters the biophysical properties of the membrane by 
reducing stiffness, changing phase preference and curvature. The net effect of these 
alterations to the membrane is an increased preference for the bilayer-embedded Nav 
channel in its inactivated-state (Lundbæk, 2005).  
The similarity of CBD to amphiphiles, along with the multi-modal interaction 
relationship between this compound and the voltage-dependent sodium currents 
suggested three potential mechanisms culminating in inhibition: 1) multiple direct 
interactions between CBD and Nav channels, 2) CBD alteration of membrane biophysical 
properties, or 3) a combination of direct interactions with Nav channels and changes in 
the membrane fluidity.  
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3.5.2. Evidence for CBD effects on sodium channels through altering 
membrane fluidity 
Contrary to what is expected for classic pseudo-second order bimolecular blocking 
scheme, CBD inhibition curves displayed a Hill-slope ~3 and compound was fastest to 
equilibrate and most potent at lower temperatures, indicating that CBD does not follow a 
classic blocking scheme (Figure 3-4). One potential explanation for the decreased 
potency at 33 ˚C is that higher temperatures increase the thermal fluctuations of the 
sodium channels, which become faster, and consequently, it becomes harder for CBD to 
find interaction sites that may reside in thermally volatile regions of the structure. A second 
potential explanation is that because the fluidity of the membrane changes as a function 
of temperature (Otto et al., 1984), higher CBD concentrations are required to have the 
same reduction of stiffness at 33 ˚C where the membrane is more fluid than at lower 
temperatures, and the relative reduction in stiffness is more pronounced.  
3.5.3.  Evidence for direct binding of CBD to the channels to cause 
inhibition  
The observation of an inactivated-state preference, which is a characteristic of Nav 
pore blocking local-anesthetics, led us to investigate the CBD block of a hNav1.1-mutant 
(F1763A) with a mutation in the local-anesthetic pore binding-site. We found that CBD’s 
inhibitory effects were minimally affected in the F1763A mutants. This suggests that 
binding at this site is not via similar interactions to local-anesthetics (Ragsdale et al., 1994; 
Pless et al., 2013), although molecular docking supports the possibility that CBD could 
interact in the pore of hNav1.1.  
We found that CBD also inhibits a non-mammalian sodium channel, NaChBac, 
and the voltage-gated potassium channel, Kv2.1. Interestingly, the CBD block of NaChBac 
was slightly more potent than the mammalian orthologs. This increased potency might be 
due to the presence of 4-fold symmetry in these channels and thus, the 4-time repeating 
of a domain that may be involved in inhibition. Indeed, the equivalent F residue in the pore 
of homo-tetrameric NaChBac that contributes to local-anesthetic binding (Lee et al., 2012) 
(F200) is repeated 4-times, as opposed to the single F1763 in the monomeric hNav1.1, 
where the F1763A mutation in Nav1.1 induced a small drop in potency. These results offer 
some support to the hypothesis that, in addition to altering membrane properties, CBD 
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might also have direct interactions with Nav channels that alter conductance. Additionally, 
our observation that membrane Nav channel distribution was unchanged in cells after a 
24-hour incubation with CBD suggested there were no effects on trafficking.   
3.5.4.  CBD inhibits heterologously expressed and native hNav 
currents 
To assess whether the observed CBD inhibitory effects on voltage-dependent 
currents in HEK cells could be replicated in the native neuronal environment, we assessed 
inhibition of currents in iPSC neurons and saw significant inhibition of both Nav and Kv 
currents (Figure 3-8). The potency was comparable to the effects seen in HEK cells stably 
expressing Nav channels indicating the HEK cell is a valid expression system to 
characterize Nav inhibition by CBD. 
3.5.5.  Mechanism of sodium current inhibition by CBD 
We found CBD to be highly lipid bound in a TRANSIL brain lipid binding assay 
(Table 3.1). This supported the possibility that the observed effects might be due to 
alterations to the biophysical properties of the membrane. However, consistent with 
previous studies (Longhi et al., 2011), we found that phenytoin, a well-established non-
selective Nav blocker also had high lipid binding (98.5%, Table 3-1), and it is assumed 
that phenytoin’s efficacy against seizures is via direct Nav channel pore block (Ragsdale 
et al., 1996; Remy et al., 2003; Mantegazza et al., 2010). The reported brain exposure 
levels required for efficacy in rodent maximal electroshock seizure models was also 
comparable between CBD and phenytoin supporting the possibility that CBD could at least 
in part mediate its efficacy through sodium channel inhibition (Table 3-1) (Consroe & 
Wolkin, 1977; Demonaco & Lawless, 1983; Ragsdale et al., 1996; Grotenhermen, 2003; 
Beyreuther et al., 2007; Mantegazza et al., 2010; Deiana et al., 2012; Shandra et al., 
2013). This similarity in lipid binding however raises the question of why the two 
compounds inhibit through different mechanisms. When comparing other physico-
chemical properties between the compounds it is striking that the calculated LogD of CBD 
and phenytoin are 6.6 and -0.7, respectively (ChEMBL database). In contrast to TRANSIL 
which measures lipid binding, the LogD is derived by measuring the partitioning of small 
molecules between octanol and water at pH7.4, and depends on a variety of structural 
interactions, including hydrogen bonds and Van der Waals interactions. However, since 
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octanol is structurally different from membrane phospholipid bilayers, which contain both 
polar and non-polar moieties, it cannot model these interactions well. Consequently, it is 
possible for compounds to have similar TRANSIL (lipid binding) numbers and different 
LogD, as found for these compounds. This may suggest that despite having similar lipid 
binding percentages (Table 3-1), the much lower LogD of phenytoin underlies its action 
as a classic sodium channel blocker that can enter the pore. In contrast, CBD’s very high 
LogD could result in its accumulation deeper inside the bilayer hydrophobic regions that 
leads to a greater effective change in the membrane stiffness than phenytoin and 
underlies CBD’s different mode of current inhibition compared with phenytoin. This 
disconnect between LogD and lipid binding fractions is further supported by considering 
another anti-epileptic sodium channel pore blocker, carbamazepine, that has a lower lipid 
binding percentage (83.7%) than phenytoin, while having a higher LogD (2.0) than 
phenytoin (Table 3-1). We therefore suggest that high lipid binding alone is not a sufficient 
property for a compound to alter membrane stiffness, which results from a combination of 
lipid binding with other physico-chemical properties unique to CBD over phenytoin and 
carbamazepine. Overall, our results suggest that CBD has a non-selective inhibitory effect 
on voltage-dependent sodium currents. The results presented in this study suggest that 
this mechanism likely involves a combination of: direct interactions with channel 
hydrophobic regions, possibly the pore, and changing the membrane bilayer flexibility 
through lipid accumulation, as illustrated by the cartoon in (Figure 3-9C).  
Table 3-1 The comparison of CBD to phenytoin and carbamazepine. 
Parameter Cannabidiol Phenytoin Carbamazepine 
Brain Lipid Binding - TRANSIL (%) 99.6 98.5 83.7 
Plasma Protein Binding (%) ~95-99* 95* ~70* 
IC50 on Nav Channels (µM) 1-4 ~10* ~25* 
ED50 MES (mg/kg) ~120* 8.2-17.5* 7.5* 
Efficacious Plasma Level (µM) 6.4-8.3* 4-10* 5-12* 
Brain Concentration (µM) 21.9* 86* 9.7* 
Brain / IC50 (Ratio) 5.5-21.9 8.6 0.4 
Parameters with asterisk were taken from literature (Hooper et al., 1975; Consroe & Wolkin, 1977; 
Demonaco & Lawless, 1983; Ragsdale et al., 1996; Kuo et al., 1997; Sun et al., 2002; Grotenhermen, 2003; 
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Luszczki JJ et al., 2006; Beyreuther et al., 2007; Sheets et al., 2008; Mantegazza et al., 2010; Deiana et al., 
2012; Shandra et al., 2013; Devinsky et al., 2014). 
Results from previous studies along with our findings in this study leads us to 
conclude that the underlying mechanism for the reported efficacy of CBD against seizures 
likely involves many systems beyond just CB receptors (Ledgerwood et al., 2011), GPR 
receptors (Kaplan et al., 2017), or ion channels (Ross et al., 2008; Patel et al., 2016). 
Dravet syndrome is primarily caused by a heterozygous LOF of Nav1.1 in the brain 
(Parihar & Ganesh, 2013). As such, clinically used sodium channel blockers are often 
considered pro-convulsant in Dravet syndrome (Brunklaus et al., 2012; Nabbout et al., 
2013), presumably because they inhibit the reduced Nav1.1 current even further. This 
raises the question of why CBD, as a non-selective Nav inhibitor, would act as an anti-
convulsant in Dravet syndrome. A recent study, however, unexpectedly demonstrated 
efficacy with a non-selective sodium channel blocker in a Dravet mouse model, suggesting 
that Nav inhibition can be protective (Anderson et al., 2017). In addition, another study in 
a Dravet mouse model suggested that the efficacy of CBD against Dravet syndrome may 
be mediated through antagonism at GPR55 receptors independently of Nav channels 
(Kaplan et al., 2017).  
The promiscuity of CBD interactions that have been reported with multiple targets 
suggests that this compound, like many natural products, is a pleiotropic compound with 
a complex poly-pharmacology. It is therefore unlikely that any efficacy against epilepsy is 
related solely to inhibitory effects on Nav channels; however, our study suggests that 
inhibition of Nav currents could occur at therapeutically relevant concentrations, and thus 
might contribute to efficacy against seizures. 
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Chapter 4. Mechanism and effects of the skeletal 
muscle Nav1.4 inhibition by cannabidiol 
This chapter describes the work submitted for publication and posted as a pre-print 
(Ghovanloo et al., 2020b) with minor modifications and formatting changes to suit the 
thesis style.  
4.1. Abstract 
Cannabis sativa contains active constituents called phytocannabinoids. Some 
phytocannabinoids are psychotropic and others are not. The primary non-psychotropic 
phytocannabinoid is cannabidiol (CBD), which is proposed to be therapeutic against many 
conditions, including muscle spasms. Mechanisms have been proposed for the action of 
CBD on different systems, involving multiple targets, including the voltage-gated sodium 
channel (Nav) family, which are heavily implicated in many of the conditions CBD has 
been reported to relieve. In this study, we investigated the modulatory mechanism of CBD 
on Nav1.4. Based on previous results, we tested the hypothesis that CBD mechanism of 
action involves: 1) modulation of membrane elasticity, which indirectly contributes to Nav 
inhibition; and 2) physical block of the Nav pore. We first performed molecular dynamic 
(MD) simulations to visualize CBD effects and localization inside the membrane, and then 
performed NMR to verify the MD results, showing CBD localizes below membrane 
headgroups. Then, we performed a gramicidin-based fluorescence (GFA) assay that 
showed CBD alters membrane elasticity. Next, we used site-directed mutagenesis in 
(F1586A) and around (WWWW) the Nav1.4 pore. Removing the local anesthetic binding 
site with F1586A reduced CBD block of INa. Occluding the fenestrations with WWWW 
blocked CBD access from the membrane into the Nav1.4 pore. However, stabilization of 
inactivation, via CBD-induced changes in membrane elasticity persisted, in WWWW. To 
investigate the potential therapeutic value of CBD against some Nav1.4 channelopathies, 
we used a pathogenic variant of Nav1.4, P1158S, known to cause myotonia and periodic 
paralysis. We found CBD reduces excitability in both wild-type and the mixed 
myotonia/periodic paralysis variant. Our in-vitro/in-silico results suggest that CBD may 
have therapeutic value against myotonia. Because Nav1.4 is crucial to skeletal muscle 
contraction, we used rat diaphragm myography and found the presence of saturating 
levels of CBD reduces skeletal muscle contraction. 
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4.2. Introduction 
The cannabis plant, Cannabis sativa, contains over 120 active constituents, 
collectively known as phytocannabinoids (Morales et al., 2017). Some phytocannabinoids 
mediate psychotropic effects, whereas others do not (Morales et al., 2017). The primary 
non-psychotropic phytocannabinoid is cannabidiol (CBD). The structure of CBD is nearly 
identical to the main psychotropic compound isolated from cannabis, ∆9-
tetrahydracannabinol (THC) (Morales et al., 2017). The only structural difference between 
the two compounds is the presence of a free hydroxyl in CBD in place of a closed ring in 
THC. This structural difference underlies THC’s high affinity for the human cannabinoid 
receptors, CB1 and CB2, thought to mediate the euphoria associated with using cannabis 
(Devinsky et al., 2017). In contrast to THC, CBD has little to no affinity for CB receptors 
(Pertwee, 2008). However, CBD has been suggested to be a potentially therapeutic 
compound against a variety of different conditions, including muscle spasms, pain, and 
seizures. Some reports of CBD efficacy are anecdotal, whereas others have been 
experimentally and clinically substantiated (Devinsky et al., 2017). CBD showed 
therapeutic efficacy in a recent phase III human clinical trial against Dravet syndrome 
(Devinsky et al., 2017), a severe form of childhood epilepsy and received FDA approval 
for its treatment.  
Reports of CBD efficacy, along with its low affinity for CB receptors, have inspired 
studies on its CB-independent actions. Many mechanisms and targets have been 
proposed for the action of CBD (Ross et al., 2008; De Petrocellis et al., 2011; Patel et al., 
2016; Kaplan et al., 2017; Ghovanloo et al., 2018c). The voltage-gated sodium channel 
(Nav) family is among these suggested targets (Patel et al., 2016; Ghovanloo et al., 
2018c), in part because Nav underpin many of the conditions for which CBD is, or is 
suggested, to be efficacious.  
Sodium currents through Nav initiates action potentials (AP) in neurons, 
myocardium, and skeletal muscles. Nav are hetero-multimeric proteins composed of a 
large ion conducting and voltage-sensing α-subunit and smaller β-subunits (Cannon, 
2006; Ghovanloo et al., 2016b; Ghovanloo & Ruben, 2020). The α-subunit is a single 
transcript that includes four 6-transmembrane segment domains. Each structural domain 
can be divided into two functional sub-domains: the voltage-sensing domain (VSD) and 
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the pore-domain (PD) (Ghovanloo et al., 2016b). These functional sub-domains are 
connected through the intracellular S4-S5 linker (Yarov-Yarovoy et al., 2012). The Nav 
pore is the site of interaction for many pharmacological blockers (Lee et al., 2012; Gamal 
El-Din et al., 2018). The pore is surrounded by four intra-bilayer fenestrations whose 
functional roles remain speculative (Pan et al., 2018).  
Variants of the Nav subtype predominantly expressed in skeletal muscles, Nav1.4, 
are associated with contractility dysfunction. Most Nav1.4 variants depolarize the 
sarcolemma; this depolarization can result in either hyper- or hypo-excitability in 
phenotypes (Cannon, 2006). Hyperexcitable muscle channelopathies are classified as 
either non-dystrophic myotonias or periodic paralyses (Lehmann-Horn et al., 2008). Most 
of these channelopathies arise from sporadic de-novo or autosomal dominant mutations 
in SCN4A (Ghovanloo et al., 2018a).  
The majority of gain-of-function (GOF) Nav1.4 variants result in myotonic 
syndromes, which are defined by a delayed relaxation after muscle contraction (Lehmann-
Horn & Rudel, 1995; Tan et al., 2011). In myotonia, there is an increase in muscle 
membrane excitability in which even a brief voluntary contraction can lead to a series of 
APs that can persist for several seconds after motor neuron activity is terminated, a 
condition that is perceived as muscle stiffness (Tan et al., 2011). The global prevalence 
of non-dystrophic myotonias is ~1/100,000 (Emery, 1991). This condition is not considered 
lethal, but it can be life-limiting due to the multitude of problems it can cause, including 
stiffness and pain (Vicart et al., 2005).  
A cationic leak (gating-pore current in the VSD), with characteristics similar to the 
ω-current in Shaker potassium channels, causes periodic paralyses (Jiang et al., 2018). 
This mechanism indicates that periodic paralyses can be caused by a severe form of GOF 
in Nav1.4 (Tombola et al., 2005; Wu et al., 2011). A subset of periodic paralyses is 
triggered by low serum [K+] and results in episodes of extreme muscle weakness. These 
are known as hypo-kalemic periodic paralyses (hypoPP) (Miller et al., 2004a). hypoPP 
onsets between the ages of 15–35. The prevalence of hypoPP is also ~1/100,000. A 
serum [K+] less than 3 mM (normal concentration=3.5–5.0) may trigger hypoPP (Fontaine, 
2008). 
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There are few therapeutics for these skeletal muscle dysfunctions, and treating 
myotonias and periodic paralyses mostly relies on drugs developed for other conditions, 
including local-anesthetics (LA). Myotonia treatment is focused on reducing the 
involuntary AP bursts (Desaphy et al., 2004; Vicart et al., 2005); hypoPP treatment is 
mostly focused on restoring serum [K+] (Torres et al., 1981; Tawil et al., 2000; Sternberg 
et al., 2001; Venance et al., 2004). Thus, there remains a need for compounds that 
alleviate the hyperexcitability associated with both myotonia and hypoPP. Interestingly, 
non-euphoric plant cannabinoids enhance muscle quality and performance of dystrophic 
mdx mice (Iannotti et al., 2019). 
In this study, we first sought to delineate the mechanisms by which CBD may affect 
Nav1.4. We previously described the inhibitory effects of CBD on some neuronal Nav 
subtypes, which prompted us to predict a possible mechanism in which CBD both directly 
(direct interaction with channel) and indirectly (modulating membrane elasticity) inhibits 
Nav (Ghovanloo et al., 2018c). In the present study, we explored whether CBD 
accumulates in the membrane, which could alter membrane elasticity, and, while residing 
inside the membrane, enters the Nav1.4 fenestrations and blocks the channel pore(Gamal 
El-Din et al., 2018). Next, we explored the effects of CBD on a mixed periodic paralysis 
and myotonia Nav1.4 mutation (P1158S) (Webb & Cannon, 2008; Ghovanloo et al., 
2018a) to determine whether it could alleviate the mutant phenotypes. Finally, we sought 
to survey whether saturating levels of CBD can reduce skeletal muscle contractility, which 
it does. 
4.3. Methods 
4.3.1. Rat diaphragm preparation 
Four 4-week old male Sprague Dawley rats (Charles River, Raleigh site) were 
euthanized. The rat phrenic hemi-diaphragm preparation was isolated according to the 
method described by Bulbring (1946) (BULBRING, 1946). A fan-shaped muscle with an 
intact phrenic nerve was isolated from the left side and transferred to a container with 
Krebs’ solution (NaCl 95.5, KCl 4.69, CaCl2 2.6, MgSO4.7H2O 1.18, KH2PO4 2.2, NaHCO3 
24.9, and glucose 10.6 mM) and aerated with carbogen (95% oxygen and 5% carbon 
dioxide). All experimental protocols were approved by the Animal Care and Use 
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Committees (Xenon Pharmaceuticals). Contraction experiment was performed using a 
Radnoti Myograph system. 
4.3.2. Molecular docking 
Docking of CBD into the cryo-EM structure of hNav1.4 (PDB ID: 6AGF was carried 
out using Autodock Vina (Trott & Olson, 2010). CBD was downloaded in PDB format from 
Drugbank (Wishart et al., 2018). To dock CBD into Nav1.4 a large search volume of 32 Å 
x 44 Å x 26 Å was considered, that enclosed nearly the whole of the pore domain and 
parts of VSD. This yielded the top 9 best binding poses of CBD ranked by mean energy 
score. 
4.3.3. MD simulations system preparation 
We ran two different sets of MD simulations, a first consisting of CBD interacting 
with model POPC membranes, and a second consisting of CBD interacting with the 
hNav1.4 channel embedded in its POPC/solution environment. 
First, a homogenous lipid bilayer consisting of 188 POPC molecules was prepared 
using the CHARMM-GUI Membrane builder (Jo et al., 2008; Wu et al., 2014; Lee et al., 
2016). Three different systems were created: one with two CBD molecules, each one 
placed in each leaflet of the bilayer (System 1), one with three CBDs, all of them placed 
in the upper leaflet (System 2) and one with six CBDs, of which three were placed in the 
upper leaflet and three in the lower leaflet (System 3). CBD was placed manually into the 
bilayer, with the polar headgroup of CBD facing the lipid headgroups. Lipid molecules with 
at least one atom within 2 Å of a CBD were manually deleted. A control simulation without 
any CBD was also prepared (System 0). The system was hydrated by adding two ~25 Å 
layers of water to both sides of the membrane. Lastly, 150 mM NaCl was added (30 Na+ 
and 30 Cl–). The simulation systems are summarized in Table 4-1. This system was 
defined as the lipid-CBD  
Second, hNav1.4 and the best docked position of CBD obtained from Autodock 
Vina was used as a starting structure. The starting system was embedded into POPC lipid 
bilayer. The system was hydrated by adding two ~25 Å layers of water to both sides of the 
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membrane. Lastly, the system was ionized with 150 mM NaCl. This system is defined as 
the Nav1.4-CBD-lipid system. 
Table 4-1 Details of the simulation systems. 












#0 0 188 11377 30/30 59383 
#1 2 (symmetric) 178 11348 30/30 58062 
#2 3 (asymmetric) 171 11377 30/30 57264 
#3 6 (symmetric) 171 11377 30/30 57423 
 
4.3.4. MD simulations 
The CHARMM36 forcefield was used to describe the protein, lipid bilayer, and the 
ions (Klauda et al., 2010). CBD was parameterised using the SWISS-PARAM software 
(Zoete et al., 2011). The TIP3P water model was used to describe the water molecules. 
The systems were minimised for 5000 steps using steepest descent and equilibrated with 
constant number of particles, pressure and temperature (NPT) for at least 450 ps for the 
lipid-CBD system and 36 ns for the Nav1.4-CBD-lipid system, during which the position 
restraints were gradually released according to the default CHARMM-GUI protocol. During 
equilibration and production, a time step of 2 fs was used, pressure was maintained at 1 
bar through Berendsen pressure coupling, temperature was maintained at 300 K through 
Berendsen temperature coupling with the protein, membrane and solvent coupled and 
LINCs algorithm (Hess et al., 1997) was used to constrain the bonds containing hydrogen. 
For long range interactions, periodic boundary conditions and particle mesh Ewald (PME) 
were used. For short range interactions, a cut-off of 12 Å was used. Finally, unrestrained 
production simulations were run for 150 ns for each of the lipid-CBD system and 10 ns for 
the Nav1.4-CBD-lipid system, using Parinello-Rahaman pressure coupling (Parrinello & 
Rahman, 1981) and Nose-Hoover temperature coupling (Nosé, 1984). Simulations were 
performed using GROMACS 2018.4 (Abraham et al., 2015). 
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4.3.5. ABMD simulations 
Adiabatic biased molecular dynamics (ABMD) (Marchi & Ballone, 1999) 
simulations were performed using GROMACS 2018.4 (Abraham et al., 2015) patched with 
Plumed-2.5.1 (Tribello et al., 2014) to study the entrance pathway of CBD into its docking 
site in hNav1.4. ABMD is a simulation method in which a time dependent biasing harmonic 
potential is applied to drive the system towards a target system along a predefined 
collective variable. Whenever the system moves closer towards the target system along 
the collective variable, the harmonic potential is moved to this new position, resulting in 
pushing the system towards the final state. The bias potential was applied along the 
distance between the center of masses of CBD and F1586. Two types of biasing potentials 
were considered: one along the y-component of distance and other along all 
components of distance. 
4.3.6. 2H NMR lipid analysis 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC-d31, sn-1 chain 
perdeuterated) was obtained from Avanti Polar Lipids (Alabaster, AL). The POPC-
d31:CBD sample was prepared with ~50 mg lipid and 3.4 mg of CBD for a ratio of 
POPC/CBD 8:2. The two samples, pure POPC-d31 and POPC-d31:CBD (8:2), were 
dissolved in Bz/MeOH 4:1 (v/v) and freeze-dried. After hydration with excess amounts of 
deuterium-depleted water (ddw), five freeze-thaw-vortex cycles were done between liquid 
nitrogen (−196°C) and 60°C to create multilamellar dispersions (MLDs).  
Deuterium 2H NMR experiments were performed on a TacMag Scout spectrometer 
at 46.8 MHz using the quadrupolar echo technique1. The spectra were produced from 
~20,000 two-pulse sequences. 90° pulse lengths were set to 3.1 μs, inter-pulse spacing 
was 50 μs, dwell time was 2 μs, and acquisition delays were 300 ms. Data were collected 
using quadrature with Cyclops eight-cycle phase cycling. The spectra were dePaked to 
extract the smoothed order parameter profiles of the POPC sn-1 chain in the presence or 
absence of CBD. Samples were run at 20, 30, and 40°C, left to equilibrate at each 
temperature for 20 mins before measurements were taken. 
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4.3.7. Cell culture 
Chinese Hamster Ovary (CHOK1) cells were transiently co-transfected with cDNA 
encoding eGFP and the β1-subunit and either WT-Nav1.4 (GenBank accession number: 
NM_000334) or any of our mutant a-subunits. Transfection was done according to the 
PolyFect transfection protocol. After each set of transfections, a minimum of 8-hour 
incubation was allowed before plating on sterile coverslips. 
4.3.8. Gramicidin-fluorescence membrane elasticity assay 
1,2-dierucoyl-sn-glycero-3-phosphocholine (DC22:1PC) were from Avanti Polar 
Lipids (Alabaster, AL). CBD was from Sigma-Aldrich (St. Louis, MO). 8-
Aminonaphthalene-1,3,6-trisulfonate (ANTS) was from Invitrogen Life Technologies 
(Grand Island, NY). Gramicidin D was from (Sigma Aldrich). 
GFA: Large unilamellar vesicles (LUVs) were made from DC22:1PC as described 
previously (Rusinova et al., 2015). Briefly, phospholipids in chloroform and gA in methanol 
(1000:1 lipid:gA weight ratio) were mixed. Quench rates were obtained by fitting the 
quench time course from each mixing reaction with a stretched exponential (Ingólfsson et 
al., 2010): 
  (Eq. 1) 
and evaluating the quench rate at 2 ms (the instrumental dead time is ~1.5 ms): 
  (Eq. 2) 
To test drug effects on the lipid bilayer CBD was equilibrated with the LUVs for 10 
min at 25 °C before acquiring quench time courses. Each measurement consisted of (4 – 
8) individual mixing reactions, and the rates for each mixing reaction were averaged and 
normalized to the control rate in the absence of drug. 
 
F(t) = F(∞)+ F(0)− F(∞)( ) ⋅exp −(t / τ0 )β{ }
 




Whole-cell patch-clamp recordings were performed in an extracellular solution 
containing (in mM): 140 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES or MES (pH6.4). 
Solutions were adjusted to pH6.4 and 7.4 with CsOH. Pipettes were filled with intracellular 
solution, containing (in mM): 120 CsF, 20 CsCl, 10 NaCl, 10 HEPES. In some experiments 
lower sodium concentration of 1 mM (intracellular) was used to boost driving force, and 
hence current size. All recordings were made using an EPC-9 patch-clamp amplifier 
(HEKA Elektronik, Lambrecht, Germany) digitized at 20 kHz via an ITC-16 interface 
(Instrutech, Great Neck, NY, USA). Voltage-clamping and data acquisition were controlled 
using PatchMaster/FitMaster software (HEKA Elektronik, Lambrecht, Germany) running 
on an Apple iMac. Current was low-pass-filtered at 10 kHz. Leak subtraction was 
performed automatically by software using a P/4 procedure following the test pulse. Giga-
ohm seals were allowed to stabilize in the on-cell configuration for 1 min prior to 
establishing the whole-cell configuration. Series resistance was less than 5 MΩ for all 
recordings. Series resistance compensation up to 80% was used when necessary. All 
data were acquired at least 1 min after attaining the whole-cell configuration. Before each 
protocol, the membrane potential was hyperpolarized to −130 mV to ensure complete 
removal of both fast inactivation and slow-inactivation. All experiments were conducted at 
22 ± 2 ˚C. Analysis and graphing were done using FitMaster software (HEKA Elektronik) 
and Igor Pro (Wavemetrics, Lake Oswego, OR, USA). All data acquisition and analysis 
programs were run on an Apple iMac (Apple Computer).  
 Some cDNA constructs produced small ionic currents. To ensure, the recorded 
currents were indeed construct-produced currents and not endogenous background 
currents, untransfected cells were patched and compared to transfected cells. The 
untransfected CHOK1 cells, which were exclusively used for cDNA expression, produced 
no endogenous sodium currents.  
4.3.10. Activation protocol 
To determine the voltage-dependence of activation, we measured the peak current 
amplitude at test pulse potentials ranging from −100 mV to +80 mV in increments of +10 
mV for 20 ms. Channel conductance (G) was calculated from peak INa: 
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GNa=INa/V−ENa (Eq. 3) 
where GNa is conductance, INa is peak sodium current in response to the command 
potential V, and ENa is the Nernst equilibrium potential. Calculated values for conductance 
were fit with the Boltzmann equation: 
G/Gmax=1/(1+exp[−ze0[Vm−V1/2]/kT]) (Eq. 4) 
where G/Gmax is normalized conductance amplitude, Vm is the command potential, z is the 
apparent valence, e0 is the elementary charge, V1/2 is the midpoint voltage, k is the 
Boltzmann constant, and T is temperature in K. 
4.3.11. Steady-state fast inactivation protocol 
The voltage-dependence of fast inactivation was measured by preconditioning the 
channels to a hyperpolarizing potential of −130 mV and then eliciting pre-pulse potentials 
that ranged from −170 to +10 mV in increments of 10 mV for 500 ms, followed by a 10 
ms test pulse during which the voltage was stepped to 0 mV. Normalized current 
amplitudes from the test pulse were fit as a function of voltage using the Boltzmann 
equation: 
I/Imax=1/(1+exp(−ze0(VM−V1/2)/kT) (Eq. 5) 
where Imax is the maximum test pulse current amplitude. 
4.3.12. Persistent currents protocol 
Persistent current was measured between 145 and 150 ms during a 200 ms 
depolarizing pulse to 0 mV from a holding potential of -130 mV. Pulses were averaged to 
increase signal-to-noise ratio. 
4.3.13. Recovery from fast inactivation protocol 
Channels were fast inactivated during a 500 ms depolarizing step to 0 mV, and 
recovery was measured during a 19 ms test pulse to 0 mV following a −130 mV recovery 
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pulse for durations between 0 and 4 s. Time constants of fast inactivation recovery showed 
two components and were fit using a double exponential equation: 
I=Iss+α1exp(−t/τ1)+α2exp(−t/τ2) (Eq. 6) 
where I is current amplitude, Iss is the plateau amplitude, α1 and α2 are the amplitudes at 
time 0 for time constants τ1 and τ2, and t is time. 
4.3.14. Isothermal titration calorimetry 
The peptide with the following sequence: SYIIISFLIVVNM (from Nav1.4 DIV-S6, 
residues 1580-1592) was synthesized by GenScript. It was solubilized in DMSO and 
diluted to a final concentration of 1 mM with the final buffer containing by percentage: 10% 
DMSO, 60% acetonitrile, 30% ITC buffer. Acetonitrile was required to solubilize the 
peptide. The ITC buffer contained 50 mM HEPES pH7.2 and 150 mM KCl. CBD and 
Lidocaine were each solubilized in DMSO and diluted to a final concentration of 40 mM 
and 100 mM, respectively in the same final buffer as the peptide. Each titrant was injected 
into the peptide containing sample cell 13 times each with a volume of 3 µM with the 
exception of the first injection which was 0.4 µM. Stirring speed was set at 750 rpm.   
4.3.15. Action potential modeling  
Skeletal AP modeling was based on a model developed by Cannon et al., (1993). 
All APs were programmed and run using Python. The modified parameters were based 
on electrophysiological results obtained from whole-cell patch-clamp experiments 
(Cannon et al., 1993). The model accounted for activation voltage-dependence, SSFI 
voltage-dependence, and persistent INa. The WT pH7.4 model uses the original 
parameters from the model. P1158S models were programmed by shifting parameters 
from the original Cannon model by the difference between the values in P1158S 
experiments at a given pH/CBD (Cannon et al., 1993; Ghovanloo et al., 2018a).  
4.3.16. Statistics  
A one-factor analysis of variance (ANOVA) was used to compare the mean 
89 
responses. Post-hoc tests using the Tukey Kramer adjustment compared the mean 
responses between channel variants across conditions. A level of significance α=0.05 was 
used in all overall post-hoc tests, and effects with p-values less than 0.05 were considered 
to be statistically significant. All values are reported as means ± standard error of means 
(SEM) for n recordings/samples. Power analysis with α=0.05 was performed to yield 
sufficient n size for each experiment. Analysis was performed in JMP version 14. 
4.4. Results 
4.4.1. Molecular dynamics (MD) simulations predict CBD accumulates 
in the hydrophobic region of phospholipid bilayers 
We previously determined that CBD non-selectively inhibits voltage-dependent 
sodium and potassium currents with a steep average Hill-slope of ~3, which suggested 
multiple interactions. Contrary to what is expected for classic pseudo–second order 
bimolecular blocking schemes, we found CBD was fastest to equilibrate and most potent 
at lower temperatures (Ghovanloo et al., 2018c). These findings, together with CBD’s 
stabilizing effects on neuronal Nav inactivation and CBD’s high LogP of ~5.9, led us to 
explore whether CBD alters membrane elasticity, which indirectly could inhibit Nav 
currents (Ghovanloo et al., 2018c), similar to what has been suggested for amphiphilic 
compounds (Lundbæk et al., 2004; Lundbæk, 2005). To test this hypothesis, we 
performed MD simulations of CBD (in mM concentration in membrane) on 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POPC) lipid membranes in the hundreds of 
nanoseconds range (Figure 4-1A-E). MD results indicate that in both symmetrical (i.e. the 
same number of CBD molecules in both leaflets of the membrane) and asymmetrical (i.e. 
CBD in a single leaflet), there are no substantial changes in the area per lipid.  
Figure 4-1C shows CBD density estimates as a function of membrane leaflet 
coordinate, where the lipid bilayer is centered at 0 (membrane thickness of ~4 nm is 
unchanged across conditions). These results show, in symmetrical conditions, that there 
are two density peaks in both negative and positive coordinate ranges with an almost 
perfect overlap, and that CBD localizes in the area between the lipid headgroups and the 
membrane center, close to the lipid headgroup region. In the asymmetric condition, with 
3 CBD molecules initially placed in the leaflet to the right, there is only a single peak in the 
positive coordinate range. The MD results show that CBD molecules tend to reside in the 
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leaflet to which they originally were added, where they interact with, and detach rapidly 
from polar residues at the bilayer/solution interface and occasionally, move toward the 
water molecules outside the lipid. However, CBD then quickly moves back down into the 
lipid. This suggests, within the hundreds of nanoseconds timeframe of our simulations, 
that CBD does not diffuse across the two leaflets but, instead, tends to localize in the 
leaflet where it was initially placed. This could be a product of the oxygen atoms in CBD 
keeping it from diffusing across leaflets, and the CBD’s hydrophobic tail keeping it from 
getting too close to water molecules outside the membrane.  
91 
 






(A-B) The effects of CBD on POPC membrane area per lipid and lipid diffusion. System 0 is control, 
System 1 is 2 CBD molecules in symmetry (1 in each leaflet), System 2 is 3 CBD molecules in 
asymmetry (only in a single leaflet), System 3 is 6 CBD molecules in symmetry (3 in each leaflet) 
(at 300 K, 26.9 ˚C). (A) Area per lipid and (B) mean square displacement as a function of time are 
not affected by CBD. (C) Distribution of CBD into the membrane across a range of conditions. The 
distribution of phosphate groups is shown as solid lines, the distribution of CBD as dotted lines. 
The bilayer thickness remains ~4 nm in presence and absence of CBD. (D) Order parameter of 
lipid acyl chains estimated from the MD simulations. (E) Snapshot of a CBD molecule in the POPC 
leaflet extracted from the MD simulations. The zoomed-in image shows localization of CBD 
molecule below the leaflet headgroup. (F) NMR spectra collected at 20˚C. (G) De-packed traces. 
(H) Order parameter calculation from NMR. 
4.4.2. 2H NMR verifies the MD predictions regarding localization 
Next, we performed acyl chain order parameter calculations (from MD) which 
suggested that CBD causes a slight ordering of the membrane methylenes in the plateau 
region of the palmitoyl chain (C3-C8) (Figure 4-1D). Overall, the MD results suggest that 
CBD preferentially localizes under the phosphate heads, close to carbons 3-7 of the 
aliphatic chains of the POPC molecules (Figure 4-1E).   
We tested MD predictions regarding CBD localization using NMR(Lafleur et al., 
1989) with POPC-d31 and POPC-d31/CBD at a 4:1 ratio in deuterium depleted water at 
three different temperatures (20, 30, and 40˚C) (Figure 4-1F-H; Figure 4-2). The NMR 
results were in striking agreement with the MD predictions of the changes in acyl chain 
order parameters and suggested that CBD causes an ordering of the C2-C8 methylenes, 
and a slight disordering from C10-C15, in a temperature-dependent manner.  
 
Figure 4-2 2H NMR at different temperatures.  
(A-C) Order parameters associated with POPC membranes at 20, 30, and 40 ˚C.  
a b c
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4.4.3. CBD alters bilayer elasticity in gramicidin-based fluorescence 
assay (GFA) 
 To explore CBD’s possible effects on lipid bilayer properties (membrane elasticity) 
that were predicted from the MD and NMR experiments, we tested CBD’s effects on lipid 
bilayer properties at concentrations where CBD has acute effects on Nav channels using 
a gramicidin-based fluorescence assay (GFA) which takes advantage of the gramicidin 
channels’ unique sensitivity to changes in bilayer properties (Andersen & Koeppe, 2007). 
The GFA is based on the gramicidin channels’ permeability to Tl+, a quencher of the water-
soluble fluorophore 8-aminonaphthalene-1,3,6-trisulfonate (ANTS), which can be 
encapsulated in large unilamellar vesicles (LUVs) that have been doped with gramicidin. 
The rate of Tl+ influx, the rate of fluorescence quench, is a measure of the time-averaged 
number of gA channels in the LUV membrane (Ingólfsson et al., 2010). Molecules that 
alter the thickness and elasticity of the LUV membrane will alter the lipid bilayer 
contribution to the free energy of dimerization, and thus the free energy of dimerization: 
 ,   
which will produce a shift in the gramicidin monomer«dimer equilibrium (Figure 4-3A). 
Changes in this equilibrium will result in changes in the rate of Tl+ influx (fluorescence 
quench). CBD reduced the Tl+ influx rates in concentration-dependent manner (Figure 4-
3). For comparison, we also show results obtained with Triton X-100, from (Ingólfsson et 
al., 2010), which increased the quench rates demonstrating that these two molecules have 
opposite effects on the membrane, and we conclude that CBD increases bilayer stiffness 
or thickness, whereas Triton X-100 decreases bilayer stiffness or thickness. Given that 
CBD has minimal effects in bilayer thickness (Figure 4-1), we conclude that CBD indeed 



















Figure 4-3 CBD alters lipid bilayer properties in gramicidin-based fluorescence 
assay (GFA).  
(A) Cartoon representation of gramicidin monomers in each leaflet coming together (dimerizing) to 
form cationic channels. The dimerization of the gramicidin channels is directly related to membrane 
elasticity. These properties are used to assay compound (e.g. CBD) effects on membrane elasticity. 
(B) Fluorescence quench traces showing Tl+ quench of ANTS fluorescence in gramicidin-
containing DC22:1PC LUVs with no drug (control, black) and incubated with CBD for 10 min at the 
noted concentrations. The results for each drug represent 5 to 8 repeats (dots) and their averages 
(solid white lines). (C) Single repeats (dots) with stretched exponential fits (red solid lines). (D) 
Florescence quench rates determined from the stretched exponential fits at varying concentrations 
of CBD (red) and TX100 (purple, from (Ingólfsson et al., 2010)) normalized to quench rates in the 
absence of drug. Mean ± SD, n = 2 (for CBD). 
4.4.4. CBD interacts with the Nav local-anesthetic site 
 We previously found that CBD displays an approximately 10-fold state-
dependence in Nav inhibition, a property similar to classic pore-blockers (Bean et al., 
1983; Kuo & Bean, 1994; Ghovanloo et al., 2018c), which has also been observed with 
bilayer-modifying molecules (Lundbæk, 2005). Therefore, we tested CBD inhibition from 
the inactivated-state in a Nav1.1 pore-mutant (F1763A–LA mutant) (Ghovanloo et al., 
2018c) and the results suggested a relatively small ~2.5-fold drop in potency (Ghovanloo 
et al., 2018c). To further explore possible CBD interactions at the pore, we performed 
molecular docking using the human Nav1.4 cryo-EM structure (Pan et al., 2018). Figure 
4-4A-B show CBD docked onto the Nav1.4 pore, supporting a possible interaction at the 



















To test the docking result, we mutated the LA Nav1.4 F1586 into alanine (A) and 
performed voltage-clamp. Figure 4-4C-F show biophysical characterization of F1586A 
compared with WT-Nav1.4. We found that both channels have similar biophysical 
properties and, most importantly, the inactivation voltage-dependences were almost 
identical (p>0.05) (Figure 4-4F), suggesting that at any given potential both F1586A and 
Nav1.4 would have the same availability; therefore, pharmacological experiments could 
be performed using the same voltage-protocols on both channels.  
In contrast to neuronal Navs that have inactivation midpoints (V1/2) of ~-65 mV in 
neurons with resting membrane potentials (RMP) that are also ~-65 mV, Nav1.4 has a V1/2 
of ~-67 mV in skeletal muscle fibers with an RMP of ~-90 mV. This indicates that, whereas 
neuronal Navs are half-inactivated at RMP, Nav1.4 is almost fully available at RMP. 
Therefore, we measured lidocaine (positive control) and CBD inhibition of Nav1.4 from 
rest (-110 mV holding-potential to 0 mV, test-pulse at 1 Hz) to be closer to physiological 
conditions (Figure 4-4G-H). Our results suggest that 1.1 mM (resting IC50 on Nav1.4 (Nuss 
et al., 1995)) lidocaine blocks ~60% of INa in WT, and ~20% in F1586A (p=0.020). 10 µM 
CBD blocks ~45% INa in WT and ~25% in F1586A (p=0.037). Hence, there is a 3-fold 
difference between lidocaine’s inhibition of WT vs. F1586A, and a smaller 1.5-fold 
difference for CBD inhibition. This suggests that while CBD may interact with the Nav pore 
similar to lidocaine, CBD’s interaction at the pore is likely not as critical a determinant of 
its INa inhibition compared with lidocaine. 
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(A) Side-view of CBD docked into the pore of the human Nav1.4 structure. The structure is coloured 
by domain. DIV is coloured in deep blue. (B) Zoomed-in side-view, F1586 is coloured in yellow. (C-
D) Representative families of macroscopic current traces from WT-Nav1.4 and F1586A. (E) 
Voltage-dependence of activation as normalized conductance plotted against membrane potential 
(Nav1.4: V1/2 = -19.9 ± 2.7 mV, z = 2.8 ± 0.3; F1586A: V1/2 = -22.4 ± 2.2 mV, z = 3.0 ± 0.3; n = 5-
7). (F) Voltage-dependence of SSFI as normalized current plotted against membrane potential 
(Nav1.4: V1/2 = -66.9 ± 2.8 mV, z = -2.6 ± 0.3; F1586A: V1/2 = -63.3 ± 3.0 mV, z = -3.5 ± 0.3; n = 8-
9). (G-H) Lidocaine/CBD inhibition of Nav1.4 and F1586A from -110 mV (rest) at 1 Hz (Lidocaine-
Nav1.4: Mean block = 60.6 ± 2.3%; Lidocaine-F1586A: Mean block = 24.6 ± 9.3%; CBD-Nav1.4: 
Mean block = 42.4 ± 6.4%; CBD-F1586A: Mean block = 25.3 ± 4.8%; n = 3-5). Sample traces 
before and after compound perfusion are shown. 
4.4.5. CBD interacts with DIV-S6  
 Because CBD’s INa inhibition was less dependent on interactions in the LA site than 
a well-established pore-blocker like lidocaine, we investigated whether CBD interacts with 
the DIV-S6 (which includes F1586) or if it is inert, using isothermal titration calorimetry. 
We then compared CBD interactions to lidocaine. We found that both lidocaine and CBD 
appear to interact with the protein segment, though the nature of this interaction seems to 
differ (Figure 4-5). Figures 4.5A-B show sample ITC heat traces. Our results suggested 
that in the presence of protein, lidocaine titration causes an endothermic interaction. 
However, when the protein is absent, lidocaine titration into blank buffer causes 
exothermicity. In contrast, CBD titration in both blank buffer and in the presence of protein 
resulted in endothermicity. Interestingly, the magnitude of CBD’s heats of interaction were 
~4-fold larger in the protein condition compared to the blank condition. This was in contrast 
to lidocaine that showed comparable heats of interaction magnitudes in both conditions, 
but in different directions. To quantify interactions of both lidocaine and CBD, we 
subtracted the heats from runs with both protein and ligand subtracted from only ligand 
(blank). The subtracted heats show a similar trend between lidocaine and CBD (Figure 4-
5C-D). These results suggest that both lidocaine and CBD interact with the protein 




Figure 4-5 CBD interactions with DIV-S6, using isothermal titration calorimetry 
(ITC). 
(A) Representative ITC traces for titration of 100 mM lidocaine into 1 mM peptide or blank buffer. 
The heat signal, once the binding is saturated is the same as the blank if the blank was only 
measuring the interaction if lidocaine with the solution. The blank measures 3 interactions, 
interactions between solute molecules, solute and lidocaine and lidocaine and lidocaine. As more 
lidocaine is added with each injection the solution is changed. This makes the heat of interaction 
with in-blank trace different from beginning to end. This change is due to a change in amount of 
lidocaine in the solution. Because this change is progressive with each injection and that the 
injections into the peptide are the same volume, subtraction was used as a means to quantify 
lidocaine peptide interaction. The purpose of this experiment was to visualize heats of interaction 
between the protein and ligand, not binding of protein with ligand, in which case protein 
configuration becomes important. (B) Representative ITC traces for titration of 40 mM CBD into 1 
mM peptide or blank buffer. (C) The blank condition subtracted heat of titration in protein condition 
is shown for lidocaine, and (D) CBD. A peak heat of 968.0 ± 23.4 kcal*mol-1 was seen for lidocaine 
titration and a peak heat of 1022.2 ± 160.6 kcal*mol-1 was seen for the CBD titration (n = 3-4). 
4.4.6. CBD may penetrate into the pore through fenestrations 
LAs block bacterial Navs in their resting-state by entering the pore through 
fenestrations in a size-dependent manner (i.e. smaller LAs get through more readily) 
(Gamal El-Din et al., 2018). Here, we sought to determine whether it is possible to block 
CBD’s access to the human Nav1.4 pore from the lipid phase of the membrane by 
occluding fenestrations. We previously found that CBD is highly lipid-bound (99.6%) 
(Ghovanloo et al., 2018c), and our MD results show that it preferentially localized in the 
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reasoned that once CBD partitions into the membrane, it will have access to the Nav pore 
through the intramembrane fenestrations. To test this idea, we scrutinized the docking 
pose of CBD in the human Nav1.4 and observed its localization close to the fenestrations 
(Figure 4-6A; Figure 4-7A-D).  
Next, we identified 4 residues (DI-F432, DII-V787, DIII-I1280, and DIV-I1583) that 
partially or fully occluded the fenestrations when mutated to tryptophan (W), as predicted 
by computational mutagenesis and structural minimization (partial versus full occlusion is 
due to structural asymmetry of mammalian Navs) (Figure 4-6B-C).  
We measured resting-state block of 1.1 mM lidocaine, 350 µM flecainide, and 10 
µM CBD from -110 mV on our WWWW construct. Our results suggest that lidocaine 
(p>0.05) and flecainide (p>0.05), but not CBD (p<0.05) blocked the WWWW mutant the 
same as WT (after compound has reached equilibrium) (Figure 4-6D). This is an 
interesting result considering that CBD is larger than lidocaine, but slightly smaller than 
flecainide. CBD was inert with respect to block of WWWW, relative to WT-Nav1.4, which 
suggests that CBD interacts with Nav1.4 via the fenestrations. 
To visualize the possible pathway CBD follows through Nav1.4 fenestrations and 
into the pore at an atomistic resolution, we performed MD simulations in which we 
encouraged CBD to detach from its binding-site (see Methods, Figure 4-6E-G; Figure 4-
7E). These results demonstrate that CBD can enter its binding-site in the pore through the 
fenestration without major reorganization of the channel structure.  
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(A) Side-view of CBD docked into the human Nav1.4 structure. The structure is coloured by domain 
(matched color to domain is shown in panel (F)), CBD is represented in purple. (B) Side-view of all 
four sides of human Nav1.4 (coloured by domain). Nav1.4 fenestrations are highlighted in red, 
along with the position of respective residues that were mutated into tryptophans (W). (C) 
Computational mutagenesis of fenestrations results 2 full and 2 partial occlusions (paralleled 
domains). (D) Lidocaine (1.1 mM) inhibition of Nav1.4 and WWWW from -110 mV (rest) at 1 Hz 
(Nav1.4: Mean block = 60.6 ± 2.3%; WWWW: Mean block = 53.6 ± 11.7%), flecainide (350 µM) 
inhibition (Nav1.4: Mean block = 64.6 ± 6.0%; WWWW: Mean block = 76.4 ± 11.3%), and CBD (10 
µM) inhibition (Nav1.4: Mean block = 42.4 ± 6.4%; WWWW: Mean block = 6.4 ± 1.3%; n = 3-5 
panel-wide). Traces before and after compound perfusion are shown. (E) CBD pathway through 
the Nav1.4 fenestration from side view, as predicted by MD simulations, red and blue correlate to 
CBD being inside and outside the fenestration, respectively. (F) CBD pathway from top view of the 





Figure 4-7 Nav1.4 fenestration interactions with CBD. 
CBD in hNav1.4 (PDB ID – 6AGF) in the best position energy wise (-7.9 kcal/mol)






(A-D) Shows CBD posed in the human Nav1.4 structure using molecular docking. (E) RMSD of the 
fenestration residues as a function of time in the absence (black) and the presence of CBD passing 
through the fenestration (red and green, two different simulation parameter sets). The similar 
RMSD profiles show that CBD’s passage does not distort the structural integrity of the fenestration.  
4.4.7. CBD does not affect Nav1.4 activation but stabilizes the 
inactivated state 
 We previously characterized the effects of CBD on Nav1.1 gating (Ghovanloo et 
al., 2018c). We found that CBD at ~IC50 reduced channel conductance, did not change 
the voltage-dependence of activation, but produced a hyperpolarizing shift in steady-state 
fast inactivation (SSFI), and slowed recovery from fast (300 ms) and slow (10 s) 
inactivation (Ghovanloo et al., 2018c). Together with CBD’s inhibition of resurgent sodium 
currents (Patel et al., 2016; Ghovanloo et al., 2018c), these results suggested that CBD 
prevents the opening of Navs, but the channels that can open, activate with unchanged 
voltage-dependence and are more likely to inactivate. The overall effect is a reduction in 
excitability (Ghovanloo et al., 2018c). Here, we hypothesized that CBD’s non-selectivity in 
INa inhibition suggests non-selectivity in modulating Nav gating (i.e. CBD imparts similar 
gating modulation across Nav subtypes). To test this idea, we assessed Nav1.4 activation 
in presence and absence of 1 µM CBD by measuring peak channel conductance at 
membrane potentials between −100 and +80 mV (Figure 4-8A). CBD did not significantly 
alter V1/2 or apparent valence (z) of activation (p>0.05). Normalized Nav1.4 currents as 
function of membrane potential are shown in Figure 4-8B. These results indicate that, as 
with Nav1.1, CBD does not alter Nav1.4 activation.  
 Next, we examined the voltage-dependence of SSFI using a standard 200 ms pre-
pulse voltage protocol. Normalized current amplitudes were plotted as a function of pre-
pulse voltage (Figure 4-8C). These results mimicked our previous observations in Nav1.1 
(Ghovanloo et al., 2018c), in that CBD left-shifted the Nav1.4 inactivation curve (p<0.05). 
To measure recovery from inactivation, we held Nav1.4 at -130 mV to ensure that 
the channels were fully available, then pulsed the channels to 0 mV for 500 ms and 
allowed different time intervals at -130 mV to measure recovery as a function of time. As 
previously observed in Nav1.1, CBD slowed the Nav1.4 recovery from inactivation 
(p<0.05), suggesting that it takes longer for CBD to come off the channels than the time it 
takes the channels to recover from inactivation (Figure 4-8D). Collectively, these results 
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support our hypothesis that CBD non-selectively modulates Nav gating, and further 
suggests how CBD may reduce Nav1.4 excitability.  
 
Figure 4-8 Effects of CBD (1 µM) on Nav1.4 gating.  
(A-B) Voltage-dependence of activation as normalized conductance plotted against membrane 
potential (Control: V1/2 = -19.9 ± 4.2 mV, z = 2.8 ± 0.3; CBD: V1/2 = -14.3 ± 4.2 mV, z = 2.8 ± 0.3; n 
= 5) and normalized activating currents as a function of potential. (C) Voltage-dependence of SSFI 
plotted against membrane potential (Control: V1/2 = -64.1 ± 2.4 mV, z = -2.7 ± 0.3; CBD: V1/2 = -
72.7 ± 3.0 mV, z = -2.8 ± 0.4; n = 5-8). (D) Recovery from fast inactivation at: 500 ms (Control: 𝞃Fast 
= 0.0025 ± 0.00069 s, 𝞃Slow = 0.224 ± 0.046 s; CBD: 𝞃Fast = 0.0048 ± 0.00081 s; 𝞃Slow = 0.677 ± 
0.054 s; n = 5-7).  
4.4.8. CBD hyperpolarizes SSFI in Nav1.4-WWWW 
To determine a possible association between membrane elasticity and stabilized 
inactivation, we measured effects of CBD before and after compound perfusion in the 
WWWW mutant, in a matched-pair manner. Although CBD did not inhibit peak INa, it 
hyperpolarized the SSFI curve (p<0.05), suggesting CBD’s modulation of membrane 
elasticity is at least in part responsible for stabilizing Nav inactivation (Figure 4-9). This is 
an interesting finding because our GFA results suggest that CBD increases bilayer 
stiffness or thickness, and previous studies suggest that compounds such as Triton X-100 
that reduce this stiffness or thickness also hyperpolarize the Nav SSFI curve (Lundbæk et 
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Figure 4-9 CBD stabilizes inactivation in the fenestration-occluded construct. 
(A-B) Show voltage-dependence of SSFI before and after (A) control (extracellular (ECS) solution) 
and (B) CBD (10 µM) in WWWW construct (Before control: V1/2 = -54.7 ± 5.1 mV, After control: V1/2 
= -54.2 ± 5.4 mV, Before CBD: V1/2 = -48.8 ± 8.8 mV, After CBD: V1/2 = -72.7 ± 5.7 mV, n = 3-6). 
The ECS experiment was performed to ensure that hyperpolarization shifts in the CBD condition 
are not due to possible confounding effects associated with fluoride in the internal (CsF) solutions. 
(C-D) Show representative families of inactivating currents before and after perfusion. CBD does 
not block peak currents but shifts the SSFI curve to the left. (D) Show averaged shift in the midpoint 
of SSFI before and after perfusion.  
4.4.9. CBD effects on a pH-sensitive mixed myotonia/hypoPP Nav1.4-
mutant, P1158S (DIII-S4-S5) 
Because CBD is therapeutic against seizure disorders (Devinsky et al., 2017), 
typically considered neuronal GOF conditions, we examined whether CBD may similarly 
ameliorate a skeletal muscle GOF condition (Cannon, 2015). We recently discovered that 
the P1158S mutation in Nav1.4 increases the channel’s pH-sensitivity (Ghovanloo et al., 
2018a). The P1158S gating displays pH-dependent shifts that, using AP modeling, are 
predicted to correlate with the phenotypes associated with this variant. Therefore, the 
relationship between pH and P1158S could be used as an in-vitro/in-silico assay of Nav1.4 
hyperexcitability (to model moderate to severe GOF). Here, we used this assay to 
investigate CBD’s effects on skeletal muscle hyperexcitability. We tested effects of 1 µM 
CBD (pKa=9.64) on P1158S at pH6.4 (myotonia-triggering) and pH7.4 (hypoPP-































the lack of selectivity in CBD gating modulation by CBD also exists in P1158S at both pHs. 
CBD did not change activation (p>0.05), but hyperpolarized inactivation (p<0.05) and 
slowed recovery from inactivation (p<0.05) (Figure 4-10A-F). Consistent with previous 
results where CBD inhibited persistent INa (Patel et al., 2016; Ghovanloo et al., 2018c), 
CBD also reduced the exacerbated persistent INa associated with P1158S at pH7.4 
(p<0.05) (Figure 4-10G). Persistent INa reduction could not be detected at pH6.4 (p>0.05) 
(Figure 4-10H) because both low pH (Peters et al., 2018; Ghovanloo et al., 2018a, 2018b) 
and CBD reduce current amplitudes to levels where differences in amplitudes could not 

























































Figure 4-10 Effects of CBD (1 µM) on the gating of a mixed mutant, P1158S, in 
pH7.4 and 6.4. 
(A-B) Voltage-dependence of activation as normalized conductance plotted against membrane 
potential, at pH7.4 (Control: V1/2 = -30.0 ± 3.3 mV, z = 3.1 ± 0.2; CBD: V1/2 = -32.7 ± 3.6 mV, z = 
2.9 ± 0.2; n = 7-8) and pH6.4 (Control: V1/2 = -23.0 ± 3.3 mV, z = 2.9 ± 0.2; CBD: V1/2 = -21.1 ± 3.3 
mV, z = 2.5 ± 0.2; n = 8). (C-D) Voltage-dependence of SSFI plotted against membrane potential 
at pH7.4 (Control: V1/2 = -73.2 ± 2.6 mV, z = 2.9 ± 0.2; CBD: V1/2 = -83.0 ± 2.6 mV, z = 3.0 ± 0.3; n 
= 7) and pH6.4 (Control: V1/2 = -68.4 ± 3.0 mV, z = 2.7 ± 0.4; CBD: V1/2 = -81.7 ± 2.3 mV, z = 2.7 ± 
0.3; n = 5-9). (E-F) Recovery from fast-inactivation at 500 ms at pH7.3 (Control: 𝞃Fast = 0.0018 ± 
0.006 s, 𝞃Slow = 0.15 ± 0.6 s; CBD: 𝞃Fast = 0.24 ± 0.07s; 𝞃Slow = 2.5 ± 0.6 s; n = 6-7) and pH6.4 
(Control: 𝞃Fast = 0.065 ± 0.04 s, 𝞃Slow = 0.75 ± 0.4 s; CBD: 𝞃Fast = 0.13 ± 0.07 s; 𝞃Slow = 0.62 ± 0.1 s; 
n = 4-7). (G-H) Persistent currents measured from a 200 ms depolarizing pulse to 0 mV from a 
holding potential of -130 mV at pH7.4 (Control: Percentage = 4.4 ± 1.2%; CBD: Percentage = 1.0 
± 0.2%; n = 4) and pH6.4 (Control: Percentage = 4.4 ± 2.1%; CBD: Percentage = 5.4 ± 1.2%; n = 
5-6). 
4.4.10. AP model predicts CBD reduces myotonia, but not hypoPP 
in the P1158S-pH assay 
We modeled the gating changes from the patch-clamp experiments with WT and 
P1158S (both control and CBD) into the Cannon AP model (Cannon et al., 1993). We ran 
the simulations using a 50 µA/cm2 stimulus. The simulation pulse started at 50 ms and 
stopped at 350 ms (Figure 4-11). During this pulse, the WT channels activated at 50 ms 
and fired a single AP. The channels remained inactivated until the stimulus was removed 
at 350 ms, and then the potential recovered back to RMP (Figure 4-11A). As expected, 
CBD reduced the AP amplitude (Figure 4-11B), similar to CBD effects observed in 
different neuron types (Khan et al., 2018; Ghovanloo et al., 2018c). At pH6.4, P1158S 
displayed a continuous train of APs for the entire stimulation period. After the stimulus was 
removed, P1158S showed a progressive series of after-depolarizations of the membrane 
potential, characteristic of a myotonic burst (Figure 4-11C) (Cannon, 2015). Interestingly, 
the CBD-mediated shifts at pH6.4 in P1158S reduced the simulated AP amplitudes for the 
entirety of the pulse duration (and delayed onset of first AP, consistent with CBD 
preventing Nav opening) and abolished the post-pulse myotonic after-depolarizations 
(Figure 4-11D). At pH7.4, P1158S fired a single AP, followed by a period where 
membrane potential remained depolarized around −35 mV, even post-stimulus 
termination (Figure 4-11E). This inability to repolarize holds the Nav channels in an 
inactivated state, and is consistent with the periodic paralysis phenotype (Cannon, 2015). 
In contrast to the myotonic phenotype, CBD did not alleviate the hypoPP phenotype in our 
P1158S-pH in-vitro/in-silico assay (Figure 4-11F), consistent with its slowing of recovery 
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Figure 4-11 AP simulations of skeletal muscles in presence and absence of CBD, 
based on voltage-clamp. 
Top of the figure show pulse protocol used for simulations, and a cartoon representation of P1158S-
pH in-vitro/in-silico assay, where pH can be used to control the P1158S phenotype. (A-B) Show 
simulations in WT-Nav1.4 in presence and absence of CBD. (C-D) Show simulations of P1158S at 
pH6.4. (E-F) Show results from pH7.4.  
4.4.11. CBD reduces rat diaphragm muscle contraction 
To survey and determine whether CBD reduces skeletal muscle contractions, we 
surgically removed rat diaphragm muscles and measured muscle contractions evoked by 
phrenic nerve stimulation. In Figure 4-12A-B, we show images of the diaphragm, cut into 
a hemi-diaphragm. We used electrodes to stimulate the phrenic nerve and measured the 
muscle contraction using a force transducer, at a saturating concentration of 100 µM of 
CBD, reasoning that if CBD reduces muscle contraction, a saturating concentration should 
provide a large enough response to detect any potential reduction in contraction. Our 
results suggested that CBD reduces the contraction amplitude to ~60% of control (p<0.05) 
(Figure 4-12C). Next, we sought to determine whether a selective block of Nav channels 
also reduces skeletal muscle contraction using 300 nM tetrodotoxin (TTX), a saturating 
concentration of this potent blocker of selected Nav channels (IC50 ~10-30 nM on TTX-
sensitive channels (Hille, 2001)). TTX also reduced contraction to ~20% of control 
(p<0.05) (Figure 4-12C). The remaining ~20% contraction could be due to stimulation of 
voltage-gated calcium channels in transverse membranes that directly interact with 
ryanodine-sensitive calcium release in the SR that can initiate contraction (Catterall, 1991, 
2011; TANABE et al., 1993). Representative traces of muscle contraction in control, CBD, 
and TTX are shown in Figure 4-12D-F. These results show that a selective inhibition of 
Nav reduces skeletal muscle contraction, suggesting that CBD’s reduction of muscular 
contraction could be due, at least in part, to its effect on Nav (Ghovanloo et al., 2018c). 




Figure 4-12 Effects of CBD on rat diaphragm contraction.  
(A) Image of dissected rat diaphragm muscle. (B) Image of rat diaphragm cut into a hemi-
diaphragm, which was placed between electric plates that were used for electric stimulation. The 
subsequent muscle contractions were measured using a force transducer. (C) Quantification of 
normalized of muscle contractions in CBD and TTX (Percentage of normalized contraction: Control 
= 100 ± 5.3%; CBD = 60.6 ± 3.5%; TTX = 28.9 ± 5.3%; n = 6-9). (D-F) Sample contraction traces 
across all three conditions. 
4.5. Discussion 
4.5.1. Pathway and mechanism of Nav1.4 inhibition by CBD 
Although CBD holds therapeutic promise (Ross et al., 2008; Patel et al., 2016; 
Devinsky et al., 2017; Kaplan et al., 2017; Ghovanloo et al., 2018c; Pumroy et al., 2019; 
Fouda et al., 2020) and has been approved for two seizure disorders, its mechanisms of 
action remain largely unknown. We previously described the effects of CBD on Nav, which 
are among its proposed targets (Ghovanloo et al., 2018c). CBD’s effects on neuronal Nav 
resemble the properties described for both amphiphilic compounds and traditional pore-
blockers. That study provided foundational hypotheses about CBD’s mechanism of action 
on Nav. Here, we tested those ideas using a combination of ex-vivo, in-vitro, and in-silico 
techniques.  
Amphiphiles, those molecules possessing both lipophilic and hydrophilic  
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(Lundbæk et al., 2004; Lundbæk, 2005; Kapoor et al., 2019). The apparent diversity of 
targets is a by-product of amphiphiles modulating membrane elasticity (Lundbæk et al., 
2004; Lundbæk, 2005; Kapoor et al., 2019). This modification is achieved by amphiphiles 
localizing at the solution–bilayer interface, which is made possible by having the 
compound’s polar group residing at the interface with the hydrophobic region, which then 
gets inserted into the bilayer core. This partitioning into the lipid bilayer alters membrane 
elasticity, and changes phase preference and curvature (Lundbæk et al., 2004; Lundbæk, 
2005; Kapoor et al., 2019). The net effect of these alterations to the membrane for the 
bilayer-embedded Nav channel is a stabilized inactivated state (Lundbæk et al., 2004; 
Lundbæk, 2005; Kapoor et al., 2019).  
We used MD simulations to ‘visualize’ CBD localization and its effects on 
membrane elasticity. Interestingly, the MD prediction regarding localization, independently 
confirmed by NMR measurements of CBD in lipid vesicles, suggested CBD positioning 
between C8-C10. Our gramicidin-based functional assay suggested that CBD slightly 
changes membrane elasticity. This result is consistent with our previous findings, including 
CBD’s temperature-dependence (CBD effects were enhanced at lower temperatures), 
stabilized Nav inactivation, and non-selectivity (Ghovanloo et al., 2018c). Together, these 
findings suggest that CBD inhibition of Nav currents (and possibly other ionic currents) is, 
at least in part, mediated through changing lipid bilayer elasticity.  
In this study, we further found that CBD had the opposite effect to Triton X-100 in 
GFA. Also, the magnitude change of quench rate was different between the two 
compounds at a given concentration; however, both compounds similarly hyperpolarized 
the Nav inactivation. These findings suggest that there could be at least two, maybe three 
mechanisms involved. The exact mechanisms through which CBD’s presence alter the 
lipid/Nav interactions should be further investigated in future studies.  
The modulated receptor hypothesis suggests that resting-state block occurs when 
a compound enters from the lipid phase of the membrane into the LA binding site, whereas 
rapid open-state block happens when a compound enters the open pore from the cytosol 
(Hille, 1977a; Hondeghem & Katzung, 1984). Pore-blockers can reach their binding site 
from the cytosolic side when the activation gate is open. A recent study showed that 
compounds can have direct access from the membrane phase to the LA site through 
channel fenestrations, culminating in resting-state block (Gamal El-Din et al., 2018).  
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We previously found that some characteristics of CBD inhibition of Nav are similar 
to classic pore-blockers (Ghovanloo et al., 2018c; Fouda et al., 2020). Here, we tested 
CBD interactions inside the Nav1.4 LA site at rest. Destabilizing the LA site by the F1586A 
mutation, reduced CBD block of Nav1.4. This result is particularly notable since the LA 
site becomes a more favourable interaction site when the channel adopts a more 
inactivated state (a key reason for LAs’ strong state-dependence) (Ghovanloo & Ruben, 
2020). Therefore, CBD’s reduced block in F1586A at rest could support the idea that CBD 
interacts with Nav at the pore. However, this does not indicate that the pore is the primary 
determinant of CBD inhibition, especially when CBD is compared to a traditional blocker 
like lidocaine, which is more affected by the F1586A mutation.  
Next, we reasoned that, if CBD blocks the pore, a likely path to reach the pore from 
the lipid phase would be through the Nav fenestrations (based on MD results, high LogP, 
and high lipid binding partitioning). We found that our fenestration-occluded Nav1.4-
WWWW construct abolished resting-state block by CBD but not lidocaine or flecainide. 
This could be a consequence of the differences in hydrophobicity (and size/shape) 
between these three compounds. Because CBD is several orders of magnitude more 
hydrophobic than either lidocaine or flecainide, it may preferentially reach the pore through 
the fenestrations, whereas lidocaine and flecainide can reach the pore also from the 
cytoplasmic phase even if access through the fenestrations is blocked. This interpretation 
is consistent with the modulated receptor hypothesis (Figure 4-13). 
Finally, we determined that, while CBD’s INa block occurs through its interactions 
inside the Nav1.4 pore, its stabilization of inactivation at least in part arises from 
modulating membrane elasticity. Both mechanisms contribute to CBD’s overall inhibition 
of Nav currents.  
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Figure 4-13 Comparison between some of the relevant physicochemical 
properties of the compounds used in this study. 
(A) Chemical structures of the compounds used in this study. (B) Three dimensional structures of 
the compounds. (C) Volume (Å3) and area (Å2) for each compound was calculated using UCSF 
Chimera. LogP values are obtained from ChEMBL database. CBD, lidocaine, and flecainide all 
interact with the LA site inside the Nav pore. TTX interacts with the outer selectivity filter of the Nav 
pore. CBD is several times more hydrophobic than the other compounds. CBD is larger than 
lidocaine and slightly smaller than flecainide.  
4.5.2. Possible applications for CBD for skeletal muscle 
Skeletal muscle hyperexcitability disorders have historically received less attention 
than disorders in other tissues, including the brain. Drugs most commonly used for 
myotonia include compounds developed for other conditions, such as anti-convulsants 
and anti-arrhythmics (Alfonsi et al., 2007; Trip et al., 2008), which may cause unwanted, 
off-target side-effects. Hence, another therapeutic approach has been lifestyle 
modifications. For instance, myotonic patients may modify their lifestyles to avoid triggers 
like potassium ingestion or cold temperatures. Treatment of hypoPP is usually achieved 
using oral potassium ingestion and by avoiding dietary carbohydrates and sodium. During 
hypokalemia, increasing K+ levels may reduce membrane depolarization and shift the 
resting potential to more negative potentials. Acetazolamide or dichlorphenamide may be 
useful; however, these compounds can exacerbate symptoms (Torres et al., 1981; Tawil 
et al., 2000; Sternberg et al., 2001; Venance et al., 2004). There is a need for new 












































Cannabinoids have long been used to alleviate muscular problems (Baker et al., 
2000; Borgelt et al., 2013). In this study, we show CBD reduces skeletal contraction in rat 
diaphragm muscle. As CBD is a poly-pharmacology compound, we cannot state with 
certainty that the observed contraction reduction is due to INa inhibition alone, but as 
demonstrated with the TTX results, INa block is sufficient to reduce contraction, meaning 
that CBD’s activity at Nav1.4 could be a part of the mechanism in this reduction. Another 
caveat is that we cannot exclude the possibility of a phrenic nerve independent (i.e. direct 
muscle) stimulation resulting in muscle contraction in our myography experiments. The 
overall mechanism suggested by our results is summarized in Figure 4-14. 
To explore a possible use for CBD in myotonia and hypoPP, we tested it in an in-
vitro/in-silico assay. Our results suggest that CBD may alleviate the myotonic but not the 
hypoPP phenotype. One caveat is that these predictions are based in part on computer 
simulations. However, from a theoretical perspective, most Nav1.4 mutations that cause 
myotonia do so by changing conventional channel gating (e.g. activation, inactivation, 
persistent currents); hypoPP mutants are due to pathogenic gating pore currents 
associated with the VSD, so it is conceivable for a compound like CBD to alleviate 
myotonic behavior, but not hypoPP.  
In conclusion, our results suggest that CBD inhibition of Nav has at least two 
components: altered membrane elasticity and pore block. Nav1.4 inhibition could 
contribute to CBD reducing skeletal muscle contractions and may have potential 
therapeutic value against myotonia (Figure 4-14). From a broader perspective, our 
proposed mechanism may hold true for other compounds that are similar to CBD in 
modulating Navs or other channels with similar structures.  
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Figure 4-14 Pathway of skeletal muscle inhibition via Nav1.4. 
This is a cartoon representation of the mechanism and pathway through which CBD inhibits Nav1.4. 
Once CBD is exposed to the skeletal muscle, given its high lipophilicity, the majority of it gets inside 
the sarcolemma. Upon entering the sarcolemma, it localizes in the middle regions of the leaflet, 
and travels through the Nav1.4 fenestrations into the pore. Inside the pore mutation of the LA 
F1586A reduces CBD inhibition. CBD also alters the membrane elasticity, which promotes the 
inactivated state of the Nav channel, which adds to the overall CBD inhibitory effects. The net result 
is a reduced electrical excitability of the skeletal muscle, which - at least in part - contributes to a 
reduction in muscle contraction.  
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Chapter 5. Cannabidiol interactions with voltage-
gated sodium channels 
This chapter describes work submitted for publication. A purely structural version 
of this work is posted as a pre-print (Sait et al., 2020). My contributions to this work were 
added after the pre-print posting. This chapter presents a modified version of this study, 
with a focus on key structural findings and my own electrophysiological contributions.  
5.1. Abstract 
Voltage-gated sodium (Nav) channels are targets for a range of pharmaceutical 
drugs developed for treatment of various conditions. Cannabidiol (CBD), the non-
psychoactive compound isolated from cannabis plants, was recently approved for 
treatment of two types of epilepsy associated with sodium channel mutations. In this study, 
we first used high resolution X-ray crystallography to demonstrate the detailed nature of 
the interactions of CBD inside the bacterial NavMs. Our results show CBD binds at a novel 
site at the interface of the fenestrations and the central hydrophobic cavity of the channel. 
Binding at this site blocks the transmembrane-spanning sodium ion translocation pathway, 
providing a molecular mechanism for channel inhibition. Next, we performed 
electrophysiological studies on NavMs that show CBD blocks this channel, similar to other 
Nav channels tested previously. In summary, this study provides new insight into a 
possible mechanism for CBD with Nav channels. 
5.2. Introduction 
Nav channels are responsible for the upstroke of action potentials in excitable 
tissues. The members of the human Nav channels are predominantly expressed in a 
tissue-specific manner and share many functional characteristics. Mutations in these 
channels are responsible for a variety of different conditions (Catterall et al., 2005; 
Catterall, 2014).  
CBD is a highly hydrophobic compound that is recently shown to be a Nav inhibitor. 
Furthermore, in addition to Nav channels, CBD is suggested to target a variety of different 
targets (Ross et al., 2008; Patel et al., 2016; Kaplan et al., 2017; Ghovanloo et al., 2018c; 
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Fouda et al., 2020). We previously characterized the effects of CBD on human Nav 
channels (Ghovanloo et al., 2018c). Our findings in that study suggested that one of the 
CBD pathways of Nav inhibition is via interactions inside the Nav pore. We also recently 
showed that CBD’s mechanism of Nav inhibition has at least two components, lipid 
membrane modulation and direct pore block. The Nav subtype that we described these 
mechanisms in was the skeletal muscle variant, Nav1.4. In that study, we used extensive 
functional and simulations to show CBD movement through Nav1.4 fenestrations and into 
the pore (Ghovanloo et al., 2020b).  
In the present study, we sought to structurally show CBD interactions inside the 
Nav pore. This was to gain additional insights into CBD’s binding pose inside the pore. To 
do this, we performed X-ray crystallography of the prokaryotic NavMs with CBD. We 
provide a crystal structure of CBD-NavMs (Bagnéris et al., 2014; Naylor et al., 2016; Sula 
& Wallace, 2017) at 2.25 Å. The high-resolution crystallography provides a means of 
understanding the CBD interactions with Nav channels.  
5.3. Methods 
5.3.1. Protein expression and purification 
The NavMs (Uniprot ID: A0L5S6) and NavMs proteins were expressed and purified 
as previously described (Sula & Wallace, 2017), with the following modifications: the 
bound protein was eluted in a buffer containing 20 mM Tris, pH 7.5, 300 mM NaCl, 0.5 M 
imidazole and 0.52% Hega10. The Histag was removed by thrombin cleavage overnight 
at 4° C. The protein sample was loaded onto a Superdex 200 column and eluted with 20 
mM Tris, pH 7.5, 300 mM NaCl, and 0.52% Hega10 buffer. Protein samples were pooled 
and concentrated to 10 mg/ml using a 100 kDa cut-off Amicon concentrator and stored at 
a concentration of 10 mg/ml at -80 oC. 
5.3.2. Crystallisation, data collection, and structure determination 
1 µl of CBD (100 mM) in 100% DMSO was added to 50 µl of the purified protein 
solution to produce a final protein concentration of ~10 mg/ml containing 2 mM CBD and 
2.5% v/v DMSO. The best crystals were grown at 4 °C via the sitting drop vapour diffusion 
method using a 2:1 ratio of the protein and reservoir solutions containing 0.1 M lithium 
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sulphate, 0.1 M HEPES, pH 7, and 40% v/v PEG200. The apo NavMs crystals were grown 
under the same condition as the crystals of the CBD complex, but without the DMSO and 
drug. Crystals were flash-frozen, with the PEG200 acting as the cryo-protectant. 
Data were collected on beamline P13 at the Electron Synchrotron (DESY, 
Germany); on beamline Proxima1 at the Soleil Synchrotron (France), and on beamlines 
IO3, IO4, and I24 at the Diamond Light Source (UK). Hundreds of crystals were screened, 
and full data sets were collected from more than 40 crystals. Diffraction images were 
integrated and scaled using XDS (Kabsch et al., 2010) and then merged with Aimless 
(Evans & Murshudov, 2013) using the CCP4 suite of programmes (Winn et al., 2011). The 
structure was determined from the crystals which diffracted to the highest resolution (2.20 
Å for the apo protein, and 2.25 Å for the CBD complex). Because of the small but 
significant variations in the unit cell dimensions and resolution between different crystals 
of the same type produced under the same conditions, as we have seen previously (Naylor 
et al., 2016; Sula & Wallace, 2017), datasets from different crystals were not merged. 
The structure determinations by molecular replacement were as previously 
described using Phaser with the full-length wildtype NavMs structure (PDB 5HVX) as the 
search model (McCoy et al., 2007; Sula & Wallace, 2017). Model building was carried out 
using Coot (Emsley et al., 2010). Refinement was done using REFMACS. The structure 
quality was checked using PROCHECK and MolProbity, which indicated that 99.2% of the 
residues were in allowed conformations. Figures were created in CCP4mg, unless 
otherwise noted (Laskowski et al., 1993; Chen et al., 2010; McNicholas et al., 2011). 
5.3.3. Electrophysiology compound preparation 
Powdered CBD (Toronto Research Chemicals) was dissolved in 100% DMSO to 
create stock. The stock was used to prepare drug solutions in extracellular solutions at 
different concentrations with no more than 0.5% total DMSO content. 
5.3.4. Cell culture 
Chinese Hamster Ovary (CHOK1) cells were transiently co-transfected with cDNA 
encoding eGFP, the β1-subunit, and NavMs α-subunit 
(https://www.addgene.org/100004/). Transfection was done according to the PolyFect 
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transfection protocol. After each set of transfections, a minimum of 8-hour incubation was 
allowed before plating on sterile coverslips. All cells were incubated at 37 °C/5% CO2. 
5.3.5. Electrophysiology 
Whole-cell patch-clamp recordings were performed in an extracellular solution 
containing (in mM): 140 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES (pH 7.4). Solutions 
were adjusted to pH7.4 with CsOH. Pipettes were filled with intracellular solution, 
containing (in mM): 120 CsF, 20 CsCl, 10 NaCl, 10 HEPES. All recordings were made 
using an EPC-9 patch-clamp amplifier (HEKA Elektronik, Lambrecht, Germany) digitized 
at 20 kHz via an ITC-16 interface (Instrutech, Great Neck, NY, USA). Voltage-clamping 
and data acquisition were controlled using PatchMaster software (HEKA Elektronik, 
Lambrecht, Germany) running on an Apple iMac. Current was low-pass-filtered at 10 kHz. 
Leak subtraction was performed automatically by software using a P/N procedure 
following the test pulse. Gigaohm seals were allowed to stabilize in the on-cell 
configuration for 1 min prior to establishing the whole-cell configuration. Series resistance 
was less than 5 MΩ for all recordings. Series resistance compensation up to 80% was 
used when necessary. All data were acquired at least 1 min after attaining the whole-cell 
configuration. Before each protocol, the membrane potential was hyperpolarized to −180 
mV to ensure complete removal of inactivation. All experiments were conducted at 22 ± 2 
˚C. Analysis and graphing were done using FitMaster software (HEKA Elektronik) and Igor 
Pro (Wavemetrics, Lake Oswego, OR, USA). All data acquisition and analysis programs 
were run on an Apple iMac (Apple Computer). 
5.3.6. Statistics 
Variables are presented as means ± standard error and were normally distributed. 
T-test was used to compare the responses. A level of significance α = 0.05 was used in 




5.4.1. CBD binding site in sodium channels 
The key reason for using NavMs for this study is that they provide, to date, the 
highest resolution (~2.2-2.5 Å) views of any Nav channel (Naylor et al., 2016; Sula & 
Wallace, 2017), especially of the transmembrane and drug binding regions. This feature 
results in obtaining detailed views of the protein molecular structures with drugs bound to 
them.  
We found that the CBD binding site is located in a hydrophobic pocket present in 
each subunit that runs perpendicular to the channel direction (Figure 5-1A-B). These 
features are known as fenestrations and located in the transmembrane segments (Figure 
5-1C). These fenestrations are located just below the selectivity filter, which are the 
features originally proposed by (Hille, 1977b) as sites for ingress of hydrophobic drugs in 
the channel interior. CBD is located at the end of the fenestrations that lies closest to the 
central pore and protrudes into (and blocks) the central pore cavity. This site is in 
agreement with the MD simulations showing CBD pathway into the Nav1.4 cavity 
(Ghovanloo et al., 2020b). Inside the NavMs pore, there is enough room for 4 CBD 
molecules, but 1 CBD molecule is sufficient to block sodium conduction. The CBD 
interaction site is very close to the locations of the binding sites that have been identified 
for other analgesics and hydrophobic compounds in both NavMs and NavAb (Sula & 
Wallace, 2017; Gamal El-Din et al., 2018).  
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Figure 5-1 The NavMs channel/CBD crystal structure. 
(A) The crystal structure (2.25 Å resolution) of the NavMs sodium channel (in coral coloured ribbon 
depiction) with one CBD molecule (in green space-filing depiction), showing its location within the 
hydrophobic cavity of the channels located within the fenestration. Three sodium ions are shown 
as grey spheres in the selectivity filter. The view on the right side is rotated 90 degrees from the 
view on the left. (B) As in (A) but showing 4 CBD molecules in the stick depiction) (C) (left) Surface 
view of space filling structure of NavMs with CBD (in green) present. The orientation is the same 
as in the left panel of part A. The CBD is just visible through the fenestration hole. (right) As in left 
panel, but sliced through the space filling model (and through the middle of the fenestration) with 2 
CBD molecules present, showing where the drug lies along the fenestration and ion pathway. 
5.4.2. Functional CBD inhibition of NavMs 
To investigate whether CBD functionally inhibits NavMs, we performed whole-cell 
voltage-clamp of transiently transfected cells. We previously determined that CBD imparts 
little selectivity in inhibiting various voltage-dependent sodium (inhibition of human 
channels from inactivated-state range: ~2–4 µM) and potassium currents, including the 
bacterial sodium channel NaChBac. We also found that CBD inhibition of Nav channels 
has a steep Hill-slope (~2) from both resting- and inactivated-states, indicating that 
relatively small magnitude fold differences in CBD potency are a product of the slope 
(Ghovanloo et al., 2018c). Here, we found that CBD inhibits NavMs less potently and with 
slightly shallower Hill slope than other Nav channels previously studied (Ghovanloo et al., 
2018c; Fouda et al., 2020) (Figure 5-2). The moderate variation in CBD inhibition potency 
between human Navs and NavMs is consistent with previous reports using other Nav 
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blockers (Bagnéris et al., 2014). Overall, these results show that CBD inhibits NavMs 
similarly to other Nav channel and, thus, the proposed interaction inside the pore from the 
NavMs X-ray structure is functionally relevant.  
 
Figure 5-2 CBD inhibition of NavMs. 
(A) Block was measured after ~6 minutes wash and incubation in CBD. IC50 measurement was 
done from CBD inhibition data obtained from whole cell voltage-clamp recordings and fit with the 
Hill Langmuir equation. The IC50 for CBD’s inhibition of NavMs is 19.4 ± 3.1 µM with a Hill slope of 
1.5 ± 0.4 (the S.E. values quoted are errors of the fit, n = 7 panel-wide). (B) Sample traces before 
and after 10 µM CBD perfusion are shown. (C) Bar graphs showing percentage of peak sodium 




























This study has demonstrated the structural nature of the interactions of CBD and 
a Nav channel, showing that CBD binding blocks the transmembrane pathway for sodium 
ion translocation through the membrane (Naylor et al., 2016), and hence provides a 
potential mechanism for the functioning of CBD in Nav channels. This further suggests a 
possible molecular basis for the medicinal effects of CBD in the treatment of epilepsies, 
as Nav channels have been shown to be causally related to various types of human 
epilepsy, with disease-related mutations interfering with sodium ion transmembrane flux. 
The CBD binding site is a novel site, near to, but not coincident with, known analgesic 
binding sites in sodium channels; binding at this site would effectively block Nav channel 
functioning. This binding site is located at the pore end of the transmembrane 
fenestrations which enable the ingress of hydrophobic molecules into the channel lumen, 
hence indicating this may also provide the pathway for CBD to enter and block the 
channels. 
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Chapter 6. General discussion 
6.1. Key findings, conclusions, and implications 
The overall goal of this thesis was to gain additional knowledge about how 
hyperexcitability is imparted upon Nav channels and to find new ways of 
pharmacologically targeting this hyperexcitability.  
6.1.1. Aim 1 
Skeletal muscle hyperexcitability can impose serious limitations on a patient’s 
quality of life. Mutations that cause hyperexcitability in Nav1.4 are plentiful, and their 
biophysical consequences are complex. Although a given mutation may alter only single 
component of the channel gating, many clinically relevant mutations tend to alter multiple 
aspects of channel biophysics (Ghovanloo et al., 2016b). For instance, a single missense 
mutation may right-shift activation (LOF) and also exacerbate persistent currents (GOF). 
The overall channotype (channel sequence variation profile) is a mixture of both defects 
(Klassen et al., 2011). The most intriguing aspect of P1158S is that its channotype 
culminates in multiple degrees of hyperexcitability. 
The results from aim 1 describe how P1158S increases the pH-sensitivity of 
Nav1.4. These results are particularly notable in that P1158S is located on the intracellular 
side of the channel, and the interactions between protons and Nav seem to be 
predominantly confined to the extracellular side of the channel. This suggests that the 
P1158S effect on pH-sensitivity is likely indirect in nature. This observation is further 
supported by the patch-clamp experiments with reduced intracellular pH showing no pH-
mediated shifts in the P1158S gating.  
Aim 1 highlights the complexity of pH-Nav interactions and also illuminates the 
importance of investigating residues that could both directly (directly get protonated) or in 
directly (alter gating, potentially exposing secondary residues to protons) mediate pH-
sensitivity. Additionally, aim 1 introduces an in-vitro/in-silico hyperexcitability assay of 
Nav1.4 which is a useful tool to investigate potential therapeutics against myotonia and 
periodic paralysis (Chapter 2).   
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6.1.2. Aim 2 
CBD is a highly hydrophobic compound with a very complex profile. Numerous 
studies from researchers across scientific disciplines suggest a wide range of molecular 
targets for CBD. The diversity of targets has suggested potential therapeutic value against 
a variety of disorders, many of which seem unrelated to one another. For instance, in 
addition to the noted hyperexcitability disorders, CBD has also been suggested to possess 
antibiotic properties (van Klingeren & ten Ham, 1976; Kosgodage et al., 2019). This has 
created a reputation in which CBD is perceived as both a panacea and somewhat of a 
‘snake oil’.  
This CBD reputation has at least two possible explanations. First, CBD indeed 
interacts with the diverse molecular targets suggested by the existing literature. Second, 
the experimental assays in use are inadequate to investigate CBD effects; therefore, any 
given proposed molecular target could be a false positive.  
One way to rectify this apparent is to investigate CBD interactions with a molecular 
target that is involved in seemingly different disorders. The Nav superfamily fits this 
description given that, depending on the tissue, Navs underlie a broad range of disorders. 
In aim 2, the main goal was to determine the effects of CBD on different Navs, 
determine whether CBD has any selectivity, and discover how CBD modulates Nav gating. 
The results in aim 2 provide the first in-depth description of CBD effects on voltage-
dependent sodium currents. The lack of selectivity, high hydrophobicity, high lipid 
partitioning, and increased apparent potency at lower temperatures (along with faster 
kinetics; this indicates that the CBD effects would be less pronounced at higher 
temperatures, such as regular body temperature compared to the lower temperatures in 
in-vitro experiments) resulted in concluding that CBD likely affects the membrane as much 
as it likely modulates the Nav gating directly (Chapter 3). These conclusions laid the 
foundation for a series of hypothesis regarding CBD mechanisms of action.  
6.1.3. Aim 3 
The hypotheses generated in aim 2 were tested in aim 3. The extensive mutational 
work and MD simulations suggested that CBD both directly interacts inside the Nav pore 
to physically block sodium conduction, and also alters the cell membrane elasticity to 
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stabilize the Nav inactivated state. Aim 3 also describes the pathway of CBD passage 
through the intralipid Nav fenestrations into the LA site, inside the pore (Chapter 4). We 
recently further verified this pathway with our collaborators using X-ray crystallography 
(Chapter 5), showing the CBD pose crystallized inside the pore of the bacterial NavMs 
(Sait et al., 2020).  
From a broader perspective and beyond CBD’s inhibition of Navs, the mechanisms 
presented in aim 3 could hold true for a variety of membrane-bound protein targets (Ibeas 
Bih et al., 2015; Ghovanloo et al., 2018c; Fouda et al., 2020). For instance, CBD’s 
modulation of membrane elasticity would conceivably alter the biophysical properties of 
any given ion channel or receptor. Furthermore, the presence of intralipid fenestrations or 
fenestration-like structures in a given protein target could mediate CBD passage into the 
heart of the target, altering the protein’s normal function. Although these predictions 
should be tested on a case by case basis, the results from aim 3 provide a theory that 
could, at least in part, explain the diversity of CBD targets proposed in the literature.  
From a pharmacological perspective, the CBD results presented in aims 2 and 3 
are the first (to our knowledge) detailed mechanistic description of how a 
superhydrophobic compound inhibits Navs. In aim 2, we discovered that CBD does not 
affect Nav open-state inactivation. The results in both aims 2 and 3 also suggest that CBD 
prevents Navs from opening. These results, along with the finding that occluding the 
fenestrations abolishes block, prompts us to propose that CBD does not interact with the 
open-state of the channel. This prediction is consistent with the overall trend that has been 
proposed for LAs that are charged or neutral with low LogDs (Hille, 2001; Ghovanloo et 
al., 2018c) and suggests that, as the drug becomes more hydrophobic, it tends to interact 
more with resting- and inactivated-states (Figure 6-1). One caveat to the scheme 
proposed in (Figure 6-1) is that it is based on a single ultra-hydrophobic compound. To 
determine whether this scheme holds true for other compounds with similar 
physicochemical properties to CBD, other compounds must be tested. 
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Figure 6-1 Proposed channel blocking scheme for a superhydrophobic 
compound. 
Hypothesis for block by LAs, based on: (Hille, 1977b, 2001; Hondeghem & Katzung, 1977). (A-B) 
The first two models are based on previous studies. (A) Nav states and transitions with charged 
drug moelcules. Charged (hydrophilic) drug may come and go only while the gate is open. (B) 
Neutral (hydrophobic) drug can bind and unbind even if when the gate is closed. Therefore, two 
pathways exist for drug to reach its receptor in the pore. The hydrophilic pathway is closed when 
the gate is closed. (C) The third model is based on our results from our studies on CBD and Nav 
channels. The star indicates drug. We propose as the drug becomes more hydrophobic, its 
interaction with the channel transitions from only the open-state (O) to only interactions with rest- 
(R) and inactivated-states (I). 
From a clinical perspective, in aim 3 (Chapter 4), we showed that CBD reduces 
skeletal muscle contraction. Furthermore, CBD may hold therapeutic value against 
myotonia, as suggested by the in-vitro/in-silico hyperexcitability assay of Nav1.4. This 
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prediction must be further validated and tested in future studies using animals-based and 
clinical assays.  
6.2. Potential limitations 
One of the primary limitations of these studies is that the majority of experiments 
were performed using heterologous expression systems: CHOK1 and HEK-293 cells. 
CHO cells have small background currents and are good for studying channels with 
smaller currents, while HEK cells typically last longer and are more durable during 
experiments. Navs are typically modulated by many proteins and accessory subunits 
which could be missing in heterologous systems. However, despite their limitations, 
heterologous systems work like blank canvases that are excellent for purely biophysical 
studies such as those presented here.  
To verify the CBD effects observed in heterologous systems in a more 
physiologically relevant system, human iPSC-derived neurons were used in aim 2 to 
reproduce CBD inhibition of both sodium and potassium currents. Although iPSC cells are 
generally considered more physiological than either CHO or HEK cells, they do not fully 
recapitulate intact human cells. For instance, iPSC-derived cells are often immature and 
lack various structures. Furthermore, these cells are inadequate for studying the 
biophysical properties of a given channel. This is particularly evident when studying 
neuronal Navs. To determine which Nav isoform is predominantly (or solely) expressed in 
a given iPSC-derived in neuron is rather challenging without the aid of highly selective 
Nav modulators. Therefore, even with extensive pharmacological tools, experiments with 
these cells require elaborate pharmacological cocktails which may introduce confounding 
effects.  
The nature of patch-clamp experiments is also a limitation. A typical patch-clamp 
experiment involves the overexpression of a given ion channel to many times greater than 
physiological levels. This overexpression is often done using transient transfections. This 
process involves co-transfection of 2-3 cDNAs. In these experiments, α subunit, β subunit 
(to boost expression and make gating more physiological), and eGFP (reporter) were 
used. Because only fluorescent cells were patched, both α subunit and eGFP were 
successfully co-transfected in all of the presented data; however, it was not possible to be 
sure the β subunit was also present in all cells. Stably transfected cells reduce some of 
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these limitations. However, perhaps the biggest limitation to whole-cell patch-clamp is that, 
upon rupturing the contact point between the tip of the pipette and cell membrane, all of 
the intracellular components of the cell are dialyzed out.  
Another caveat to these studies is that many conclusions are based on computer 
simulations. In the case of AP modeling, all of the simulations were based on functional 
data, and the MD simulations were performed according to well-established 
parameterizations and protocols. To ensure that simulation-based limitations are minimal, 
all simulations were either intertwined with functional data (e.g. in-vitro/in-silico 
hyperexcitability assay of Nav1.4) or were functionally tested (e.g. fenestration and lipid 
NMR experiments). 
6.3. Final remarks 
The structural similarities in the Nav family is a major challenge in developing 
selective Nav-targeting therapeutics. Most small molecules that inhibit Nav channels are 
non-selective in nature, a function of the binding site in the pore of the channel in which 
key residues are conserved across the orthologues. Despite this lack of selectivity, these 
molecules have found wide ranging clinical efficacy in disorders of excitability. However, 
these compounds typically have a narrow therapeutic index, presumably due to their non-
selective inhibition. The results described in this thesis suggest that CBD, as a Nav 
inhibitor would suffer from the same limitations as traditional Nav blockers. Furthermore, 
because of its hydrophobicity, it modulates a wider range of targets than traditional Nav 
blockers. These properties could cause enough off-target effects to render CBD useless 
against Nav hyperexcitable conditions, including the conditions associated with the 
skeletal muscle. However, the strongest argument for CBD as a Nav-related therapeutic 
is its clinically proven efficacy in Dravet Syndrome. This efficacy is likely the result of CBD 
modulating multiple targets, and not just one particular set of Nav channels.  
In conclusion, the work presented in this thesis describes a new pathway of pH-
sensitivity, a novel assay to investigate drug effects against Nav1.4 hyperexcitability, CBD 
effects and mechanism of action on Nav and membrane, and implicates CBD as a possible 
therapeutic for myotonia. Finally, this work could be a first steppingstone into determining 
whether CBD or other similar compounds could develop or contribute to the development 
of other promising therapeutics.  
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